TMF-13817737  CONFIDENTIAL   
GlaxoSmithKline group of companies   212390  
 1 
 TITLE PAGE  
Protocol Title: A Phase III, Randomized, Multicenter, Parallel -Group, Double -Blind, 
Double -Dummy Study in Adolescent and Adult Female Participants Comparing the 
Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated 
Urinary Tract Infection (Acute Cystitis)  
Protocol Number:  212390 / Amendment 3  
Compound 
Number:  [COMPANY_004]2140944  
Study Phase:  Phase III   
Short Title:  Phase III, Double -Blind, Parallel -Group, Comparator -Controlled, Efficacy  
and Safety Study of Gepotidacin in the Treatment of Uncomplicated Urinary Tract 
Infection (Acute Cystitis); Efficacy of Antibacterial Gepotidacin Evaluated (EAGLE -3) 
Sponsor Name [CONTACT_29560]:  
GlaxoSmithKline Research & Development Limited  
[ADDRESS_1042131]  
Middlesex, TW8 9GS  
[LOCATION_006] 
Sponsor Name [CONTACT_29560]:  
GlaxoSmithKline  
[ADDRESS_1042132] information  can be found in the Study Reference 
Manual   
Regulatory  Agency Identifying Number:  
IND: [ADDRESS_1042133]: 2020 -000553 -27 
Protocol Amendment Number:   3 
Approval Date:  03-NOV -2021   
Copyright 2021 the GlaxoSmithKline group of companies. All  rights reserved. 
Unauthorized copying or use of this information is prohibited.  
 
TMF-13817737  CONFIDENTIAL   
  212390  
 2 
 SPONSOR SIGNATORY:  
Protocol Title: A Phase III, Randomized, Multicenter, Parallel -Group, Double -Blind, 
Double -Dummy Study in Adolescent and Adult Female Participants Comparing the 
Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated 
Urinary Tract Infection (Acute Cystit is) 
Protocol Number:  212390 / Amendment 3  
Compound 
Number:  [COMPANY_004]2140944  
 
 
 
 
Salim Janmohamed, BSc, MBBS (Hons), FRCP, FACE  
Senior Director , Clinical Sciences ( Infectious Diseases )  
GlaxoSmithKline  
Pharmaceutical Research and Development   Date  
The signed page is a separate document.  
 
 
 
 
Medical Monitor Name [CONTACT_9352] [CONTACT_126701] . 
 
 
TMF-13817737  CONFIDENTIAL   
  212390  
 3 
 PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  
DOCUMENT HISTORY  
Document  Date  DNG Number  
Amendment 3  03-NOV -2021  TMF-13817737  
Amendment 2  14-APR-2021  TMF-12037491  
Amendment 1  14-NOV -2019  2019N407320_01  
Original Protocol  31-JUL-2019  2019N407320_00  
 
Amendment 3   03-NOV -2021  
This global amendment is  considered to be substantial.  
Overall Rationale for the Amendment:   This global amendment added details for an 
interim analysis to be conducted and managed by [CONTACT_760986]. The primary 
analysis method was updated from Cochran -Mantel -Haenszel to Miettinen and 
Nurminen. Other revisions include increasing the inclusion window for the onset of acute 
cystitis clinical signs and symptoms from ≤72 hours to <96 hours , minor revision s to 
2 exclusion criteria were made, prescreening activities for consent and urine pregnancy 
testing were clarified , the potential for home healthcare visits w as added, minor revisions 
were made to allow more site and participant flexibility at the  Baseline Visit , and minor 
updates were made to the Schedule of Events table for the interactive response 
technology . The amendment also includes additional minor administrative and wording 
edits.  
TMF-13817737  CONFIDENTIAL   
  212390  
 4 
 Section # and Name  [CONTACT_42407]  
4.2 Scientific 
Rationale for Study 
Design  
6.3. Measures to 
Minimize  Bias: 
Randomization and 
Blinding  
9.[ADDRESS_1042134]  
10.3.5 Committee 
Structure  
Throughout  Added interim analysis and 
Independent Data Monitoring 
Committee details, including 
updates to the number of 
evaluable participants needed and 
sample size determination 
revisions , as well as applicable 
revisions to section numbers and 
content (i.e. additions and 
deletions) in the statistical section  To allow interim statistical 
evaluation for efficacy and futility  
Synopsis  
3 Objectives and 
Estimands/Endpoints  Revised the secondary 
therapeutic response objective  Consistency between primary and 
secondary endpoint  
Synopsis  
9.1 Statistical 
Hypotheses  
9.2 Sample Size 
Determination  
9.5 Interim Analys is  Revised description of the number 
of participants  in the primary 
analysis population based on 
interim analysis considerations 
and clarified that the number of 
randomized participants may vary 
based on evaluability rate and 
review of qualifying uropathogens  Updated for clarification related to 
the interi m analysis on the primary 
analysis population  
1.3 Schedule of 
Activities  Divided the “Interactive response 
technology” row in to 2 separate 
rows specific for the screening 
and randomization modules  To align with how the interactive 
response is being used at study 
sites and to more closely follow 
the expected order of procedures  
TMF-13817737  CONFIDENTIAL   
  212390  
 5 
 Section # and Name  [CONTACT_11029]  
1.3 Schedule of 
Activities  
8 Study Assessments 
and Procedures  Clarified prescreening activities 
that may occur  Consistency with the Study 
Reference Manual  
1.3 Schedule of 
Activities  
4.1 Overall Design  
10.5.2 Study 
Procedures During 
the COVID -19 
Pandemic  Added text to allow potential home 
healthcare visits. Such visits will 
be limited to where applicable 
regulations and infrastructure 
allow  To support study feasibility  
2.3.1 Risk 
Assessment  Minor text clarifications for clinical 
QTc effects and added relevant 
exposures for nonclinical 
embryofetal effects  Consistency with currently known 
safety data  
5.1 Inclusion Criteria 
#2 Revised the criterion to allow the 
onset of clinic al signs and 
symptoms of acute cystitis within 
≤96 hours prior to study entry  To support study enrollment  
5.2 Exclusion Criteria 
#2 Edited to include “uncontrolled” 
before high blood pressure  Text clarification  
5.2 Exclusion Criteria 
#30 Revised wording to support a “no” 
response , which is in line with this 
being an exclusion criterion  Text clarification  
8 Study Assessments 
and Procedures  Remove d the requirement for 
participants to remain at the site 
for approximately 1 to 2 hours  
after dosing at  the Baseline Visit; 
however, retained text indicating 
that posttreatment assessments 
still need to be completed  To support site flexibility for study 
conduct  
8 Study Assessments 
and Procedures  Removed topi[INVESTIGATOR_760962], participants may be 
treated with either topi[INVESTIGATOR_760963]-13817737  CONFIDENTIAL   
  212390  
 6 
 Section # and Name  [CONTACT_11029]  
[IP_ADDRESS] 
Microbiological 
Outcome and 
Response  
[IP_ADDRESS].  Clinical Signs 
and Symptom Scores, 
Clinical Outcomes, 
and Clinical 
Response  Removed footnote from tables 
with regard to comparing the date 
and time of other systemic 
antimicrobials received with the 
date and time of On -therapy Visit  Updated as “time” will not be used  
9.[ADDRESS_1042135] not been 
summarized  
 
TMF-13817737  CONFIDENTIAL   
  212390  
 7 
 TABLE OF CONTENTS  
PAGE  
TITLE PAGE  ................................ ................................ ................................ ...................  1 
SPONSOR SIGNATORY:  ................................ ................................ ...............................  2 
PROTOCOL AMENDME NT SUMMARY OF CHANGE S TABLE  ................................ ..... 3 
1. PROTOCOL SUMMARY  ................................ ................................ ........................  10 
1.1. Synopsis  ................................ ................................ ................................ ..... 10 
1.2. Schema  ................................ ................................ ................................ ...... 15 
1.3. Schedule of Activ ities (SoA)  ................................ ................................ ........  16 
2. INTRODUCTION  ................................ ................................ ................................ .... 19 
2.1. Study Rationale  ................................ ................................ ..........................  19 
2.2. Backgro und ................................ ................................ ................................  20 
2.3. Benefit/Risk Assessment  ................................ ................................ ............  21 
2.3.1.  Risk Assessment  ................................ ................................ .........  22 
2.3.2.  Benefit Assessment  ................................ ................................ ..... 29 
2.3.3.  Overall Benefit: Risk Conclusion  ................................ ..................  29 
3. OBJECTIVES AND ESTIMANDS/ENDPOI NTS ................................ .....................  30 
4. STUDY DESIGN  ................................ ................................ ................................ .... 36 
4.1. Overall Design  ................................ ................................ ............................  36 
4.2. Scientific Rationale for Study Design  ................................ ..........................  37 
4.3. Justification for Dose  ................................ ................................ ..................  38 
4.4. End-of-Study Definition  ................................ ................................ ...............  41 
5. STUDY POPULATION  ................................ ................................ ...........................  41 
5.1. Inclusion Criteria  ................................ ................................ .........................  41 
5.2. Exclu sion Criteria  ................................ ................................ ........................  42 
5.3. Lifestyle Considerations  ................................ ................................ ..............  45 
5.3.1.  Meals and Dietary Restrictions  ................................ ....................  45 
5.4. Screen Failures ................................ ................................ ...........................  45 
6. STUDY TREATMENT  ................................ ................................ ............................  46 
6.1. Study Tre atments Administered  ................................ ................................ .. 46 
6.2. Preparation/Handling/Storage/Accountability  ................................ ..............  48 
6.3. Measures to Minimize Bias: Randomization and Blinding  ...........................  48 
6.4. Study Treatment Compliance  ................................ ................................ ...... 49 
6.5. Concomitant Therapy ................................ ................................ ..................  50 
6.5.1.  Permitted Medications and Nondrug Therapi[INVESTIGATOR_014]  ...........................  50 
6.5.2.  Prohibited Medications and Nondrug Therapi[INVESTIGATOR_014] ...........................  50 
6.6. Dose Modification  ................................ ................................ .......................  51 
6.7. Treatment after the End of the Study  ................................ ..........................  51 
7. DISCONTINUATION OF S TUDY TREATMENT AND P ARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ..... [ADDRESS_1042136] o p pi n g Crit eri a  ................................ ................................ ..  5 4  
7. 1. 3.  R e c h all e n g e  ................................ ................................ .................  5 5  
7. 1. 4.  G a str oi nt e sti n al E v al u ati o n Crit eri a  ................................ ..............  5 5  
7. 2.  P arti ci p a nt Di s c o nti n u ati o n/ Wit h dr a w al fr o m t h e St u d y  ...............................  [ADDRESS_1042137] ati sti c al A n al y s e s  ................................ ................................ .....................  7 9  
9. 4. 1.  G e n er al C o n si d er ati o n s  ................................ ...............................  7 9  
9. 4. 2.  Effi c a c y A n al y s e s  ................................ ................................ .........  8 0  
9. 4. 3.  S af et y A n al y s e s  ................................ ................................ ...........  8 3  
9. 5.  I nt er i m A n al y si s  ................................ ................................ ..........................  8 4  
9. 6.  D at a M o nit ori n g C o m mitt e e or Ot h er R e vi e w B o ar d  ................................ ...  8 5  
1 0.  S U P P O R TI N G D O C U M E N T A TI O N A N D O P E R A TI O N A L  
C O N SI D E R A TI O N S  ................................ ................................ ...............................  8 6  
1 0. 1.  A p p e n di x 1: Cl o stri di u m Diffi cil e  T e sti n g Pr o c e d ur e a n d Al g orit h m  .............  8 6  
1 0. 2.  A p p e n di x 2: C o ntr a c e pti v e G ui d a n c e a n d C oll e cti o n of Pr e g n a n c y 
I nf or m ati o n  ................................ ................................ ................................ ..  8 7  
1 0. 2. 1.  D efi niti o n s:  ................................ ................................ ...................  8 7  C CI 
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 9 
 1 0. 2. 2.  C o nt r a c e pti o n G ui d a n c e:  ................................ .............................  8 8  
1 0. 2. 3.  C oll e cti o n of Pr e g n a n c y I nf or m ati o n:  ................................ ...........  8 9  
1 0. 3.  A p p e n di x 3: R e g ul at or y, Et hi c al, a n d St u d y O v er si g ht 
C o n si d er ati o n s  ................................ ................................ ............................  9 0  
1 0. 3. 1.  R e g ul at or y a n d Et hi c al C o n si d er ati o n s  ................................ ........  9 0  
1 0. 3. 2.  Fi n a n ci al Di s cl o s ur e  ................................ ................................ .....  9 0  
1 0. 3. 3.  I nf or m e d C o n s e nt/ A s s e nt Pr o c e s s  ................................ ...............  [ADDRESS_1042138] art a n d Cl o s ur e  ................................ .................  9 4  
1 0. 3. 1 0.  P u bli c ati o n P oli c y  ................................ ................................ .........  9 4  
1 0. 4.  A p p e n di x 4: Al g orit h m f or D et er mi ni n g Q u alif yi n g Ur o p at h o g e n s  ................  9 5  
1 0. 5.  A p p e n di x 5: C O VI D -[ADDRESS_1042139] u d y Pr o c e d ur e s D uri n g t h e C O VI D -1 9 P a n d e mi c  .....................  9 6  
1 0. 6.  A p p e n di x  6: Cli ni c al Si g n s a n d S y m pt o m s S c or e f or A c ut e C y stiti s  ............  9 8  
1 0. 8.  A p p e n di x 8: Cli ni c al L a b or at or y T e st s  ................................ .......................  1 0 1  
1 0. 9.  A p p e n di x  9: A d diti o n al G ui d a n c e o n P er mitt e d a n d Pr o hi bit e d 
M e di c ati o n s a n d Cr e di bl e m e d s. or g  ................................ ...........................  1 0 4  
1 0. 1 0.  A p p e n di x 1 0: Li v er S af et y: R e q uir e d A cti o n s a n d F oll o w -u p 
A s s e s s m e nt s  ................................ ................................ ............................  1 0 7  
1 0. 1 1.  A p p e n di x 1 1: A d v er s e E v e nt s: D efi niti o n s a n d Pr o c e d ur e s f or 
R e c or di n g, E v al u ati n g, F oll o w -u p, a n d R e p orti n g  ................................ .....  [ADDRESS_1042140] a n d 
C a s e s of Cl o stri di u m Diffi cil e  ................................ .....................  1 1 3  
1 0. 1 1. 4.  R e c or di n g a n d F oll o w -U p of A E a n d S A E  ................................ ..  1 1 4  
1 0. 1 1. 5.  R e p orti n g of S A E t o G S K/ P P D  ................................ ..................  1 1 5  
1 0. 1 2.  A p p e n di x 1 2: G e n eti c s  ................................ ................................ ..............  1 1 7  
1 0. 1 3.  A p p e n di x  1 3: Di vi si o n of Mi cr o bi ol o g y a n d I nf e cti o u s Di s e a s e s A d ult 
T o xi cit y T a bl e s f or A d v er s e E v e nt A s s e s s m e nt ................................ .........  1 1 8  
1 0. 1 4.  A p p e n di x 1 4: A b br e vi ati o n s a n d Tr a d e m ar k s  ................................ ............  1 2 5  
1 0. 1 5.  A p p e n di x 1 5: Pr ot o c ol A m e n d m e nt Hi st or y  ................................ ...............  1 2 7  
1 1.  R E F E R E N C E S  ................................ ................................ ................................ .....  1 3 4  
 C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 10 
 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title:  A Phase III, Randomized, Multicenter, Parallel -Group, Double -Blind, 
Double -Dummy Study in Adolescent and Adult Female Participants Comparing the 
Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated 
Urinary Tract Infection  (Acute Cystitis)  
Short Title:  Phase III, Double -Blind, Parallel -Group, Comparator -Controlled, Efficacy 
and Safety Study of Gepotidacin in the Treatment of Uncomplicated Urinary Tract 
Infection (Acute Cystitis); Efficacy of Antibacterial Gepotidacin Evalua ted (EAGLE -3) 
Rationale:  
Urinary tract infections (UTIs; acute cystitis) are very common, with approximately 11% 
of women (greater than 18  years of age) reporting at least [ADDRESS_1042141] of all female adolescen ts and women experience more than 
1 epi[INVESTIGATOR_126647], requiring antimicrobial therapy, by [CONTACT_14898] 24  years. The 
predominant uropathogen isolated in community -acquired UTIs is Escherichia coli  (75% 
to 90%) followed by [CONTACT_760987] s (5% to 15%). Multidrug resistance, 
which is typi[INVESTIGATOR_126648], has now emerged at the 
community level and has made treatment approaches for UTIs more difficult. 
Gepotidacin is a first -in-class, novel triazaacenaphthylene bac terial type II topoisomerase 
inhibitor. The microbiological spectrum of activity of gepotidacin includes E. coli , 
S. saprophyticus , and Enterococcus faecalis . This Phase III study aims to evaluate the 
therapeutic response (combined microbiological and clin ical efficacy per participant) of 
oral gepotidacin compared to oral nitrofurantoin for acute cystitis in adolescent and adult 
female participants.  
Objectives and Estimands/Endpoints:  
Objectives  Endpoints  
Primary  
• To assess the combined clinical 
and microbiological efficacy of 
gepotidacin compared to 
nitrofurantoin, at the 
Test-of-Cure (TOC) Visit, in 
female participants with acute 
cystitis with qualifying bacterial 
uropathogen(s) at Baseline that 
all are susceptible to 
nitrofurantoin  • Therapeutic resp onse (combined per -participant 
microbiological and clinical response) at the TOC 
Visit 
TMF-13817737  CONFIDENTIAL   
  212390  
 11 
 Objectives  Endpoints  
Secondary  
• To assess the clinical efficacy of 
gepotidacin compared to 
nitrofurantoin, at the TOC and 
Follow -up Visits, in female 
participants with acute cystitis  • Clinical outcome and response at the TOC and 
Follow -up Visits  
• To assess the clinical efficacy of 
gepotidacin compared to 
nitrofurantoin, at the TOC and 
Follow -up Visits, in female 
participants with acute cystitis 
with qualifying bacterial 
uropathogen(s) a t Baseline that 
all are susceptible to 
nitrofurantoin  • Clinical outcome and response at the TOC and 
Follow -up Visits  
• To assess the microbiological 
efficacy of gepotidacin 
compared to nitrofurantoin, at 
the TOC and Follow -up Visits, in 
female participants with acute 
cystitis with qualifying bacterial 
uropathogen(s) at Baseline that 
all are susceptible to 
nitrofurantoin  • Microbiological outcome and response at the TOC 
and Follow -up Visits  
• To assess the combined clinical 
and microbiological efficacy of 
gepoti dacin compared to 
nitrofurantoin, at the Follow -up 
Visit, in female participants with 
acute cystitis with qualifying 
bacterial uropathogen(s) at 
Baseline that all are susceptible 
to nitrofurantoin  • Therapeutic response (combined per -participant 
microbiological and clinical response) at the 
Follow -up Visit  
• To assess the safety and 
tolerability of gepotidacin 
compared to nitrofurantoin in 
female participants with acute 
cystitis  • Treatment -emergent adverse events and serious 
adverse events and chang e from baseline results 
for clinical laboratory tests, electrocardiograms, 
and vital sign measurements  
Note: Exploratory objectives are described in the main protocol text.  
TMF-[ADDRESS_1042142] is: What is the treatment effect on the 
therapeutic response after 5 days of treatment with gepotidacin 1500 mg twice daily 
compared to 5 days of treatment with nitrofurantoin 100 mg twice daily in participants 
with acute cystitis with qualifying bacterial uropathogen(s) at Baseline that all are 
susceptible to nitrofurantoin, regardless of treatment discontinuation for any reason. 
Receipt of systemic antimicrobials will impact the endpoint definition (see 
Section  [IP_ADDRESS]  and Section [IP_ADDRESS] ). 
The primary estimand is described by [CONTACT_6570]:  
• Population: Female participants with acute cystitis with qualifying bacterial 
uropathogen(s) at Baseline that all are susceptible to nitrofurantoin.  
• Treatment condition: Gepotidacin 1500 mg twice daily for 5 days versus 
nitrofurantoin 100 mg twice daily for 5 days, regardless of adherence.  
• Variable : Therapeutic response (combined per -participant microbiological and 
clinical response) at the TOC Visit. Microbiological success is defined as 
eradication (i.e., reduction) of all qualifying bacterial uropathogens recovered at 
baseline to <103 colony -form ing units/mL (CFU/mL) as observed on quantitative 
urine culture without the participant receiving other systemic antimicrobials. 
Clinical success is defined as resolution of signs and symptoms of acute cystitis 
present at Baseline (and no new signs and sym ptoms) without the participant 
receiving other systemic antimicrobials.  
• Summary measure: Absolute difference in the therapeutic success rate in the 
gepotidacin and nitrofurantoin treatment groups.  
• Intercurrent events (ICEs):  
• Study treatment discontinuatio n (due to any reason) – treatment policy 
strategy (interest is in the treatment effect regardless of study treatment 
discontinuation).  
• Use of systemic antimicrobials – composite strategy. This ICE is captured 
through the definitions of microbiological and clinical response (see 
Section  [IP_ADDRESS]  and Section [IP_ADDRESS] ) and will be counted as therapeutic 
failures.  
Rationale for Estimand:  
Interest lies in the treatment effect regardless of whether the full course of 5 days of 
treatment was taken or not, which reflects how patients may be treated in clinical 
practice. Hence, a treatmen t policy strategy is appropriate for treatment withdrawal 
before completing 5 days of treatment. Use of other systemic antimicrobials may 
confound the bacterial culture results; thus, the microbiological response will be 
considered failure. For clinical da ta, the use of a systemic antimicrobial for acute cystitis 
is a sign of treatment failure and use of a systemic antimicrobial for another infection 
cannot be considered a success as it confounds the assessment of efficacy. Therefore, the 
definition of a su ccessful therapeutic response precludes the use of other systemic 
antimicrobials.  
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 1 3  
 Sec o n dar y Esti ma n ds:  
T he sec o n d ar y cli nical q uesti o ns of i nterest are: W hat is t he treat me nt effect o n eac h of 
t he sec o n dar y efficac y e n d p oi nts after 5 da ys of treat me nt wit h ge p oti daci n 1 5 0 0 m g 
t wice dail y c o m pare d t o 5 da ys of treat me nt wit h nitr of ura nt oi n 1 0 0 m g t wice dail y  i n 
partici pa nts wit h ac ute c ystitis (cli nical e n d p oi nts) a n d i n partici pa nts wit h ac ute c ystitis 
wit h q ualif yi n g bacterial ur o pat h o ge n(s) at Baseli ne t hat all are s us ce pti ble t o 
nitr of ura nt oi n (t hera pe uti c, cli nical, a n d micr o bi ol o gic al e n d p oi nts), re gar d less of 
treat me nt disc o nti n uati o n f or a n y reas o n. Recei pt of s yste mic a nti micr o bials i m pacts t he 
e n d p oi nt defi niti o n (see Secti o n 8. 1. 2. 1  a n d Secti o n 8. 1. 3. 1 ).  
F or eac h of t h e sec o n d ar y e n d p oi nts t he esti ma n d will f oll o w a si milar a p pr oac h t o t he 
esti ma n d f or t he pri mar y e n d p oi nt a n d will use t he sa me strate gies f or t he I C Es. T he 
e x ce pti o n is t he s u m mar y me as ure f or t he o utc o m e e n d p oi nts. T hese e n d p oi nts are 
descri pti vel y s u m mariz e d; t heref ore, t he s u m mar y me as ure will be t he p erce nta ge i n eac h 
cli nical a n d micr o bi ol o gical o utc o me cate g or y i n t he ge p oti daci n a n d nitr of ura nt oi n ar ms  
se parat el y (as n o direct c o m paris o n bet wee n tr eat me nt gr o u ps will be ma d e) (see 
Secti o n  8. 1. 2. 1  a n d Secti o n 8. 1. 3. 1  f or e n d p oi nt d efi niti o ns).  
T he safet y e n d p oi nt will use a treat me nt p olic y str ate g y of t he I C E of wit h dra wal fr o m 
treat me nt as t he safet y will be assesse d at all p ost b aseli ne assess me nts irres pecti ve of 
w het her t he p artici pa nt c o m plete d t he treat me nt.  
See Ta ble 1 f or t he c o m p o ne nts of esti ma n d f or t h e sec o n dar y e n d p oi nts.  
O ver all Desi g n:  
• St u d y [ADDRESS_1042143] u d y i n 
a d olesce nt a n d a d ult fe m ale partici pa nts c o m p ari n g t he effic ac y a n d safet y of oral 
ge p oti daci n t o oral nitr of ura nt oi n i n t he treat me nt of u nc o m plicate d U TI  (ac ute 
c ystitis).  
• Partici pa nts will be stratifie d b y a ge cate g or y a n d ac ute c ystitis rec urre n ce a n d 
will be ra n d o ml y assi g n e d i n a 1: 1 rati o t o recei ve eit her oral ge p oti daci n or oral 
nitr of ura nt oi n.  
• A p pr o priate s afet y, effic ac y, a n d micr o bi ol o gic al asse ss me nts will be c o n d ucte d 
at t he Bas eli ne ( Da y 1) Visit a n d re peate d at t he O n -t hera p y ( Da y 2 t o 4), T O C 
( Da y 1 0 t o  1 3), a n d F oll o w -u p ( Da y 2 8 ± 3) Visits.  
 
 
 
• F or t he pri mar y efficac y e n d p oi nt of t hera p e utic res p o nse (c o m bi ne d 
per -partici pa nt micr o bi ol o gic al a n d cli nical r es p o nse), t hera p e utic s uccess refers 
t o partic i pa nts w h o ha ve bee n dee me d b ot h a micr o bi ol o gical s uc cess (re d u cti o n 
of all q ualif yi n g b acterial ur o pat h o ge ns [ e. g., 1 0 5 c ol o n y -f or mi n g u nits/ m L 
( C F U/ m L)] rec o v ere d at Baseli ne t o < 1 0 3 C F U/ m L as o bs er ve d o n q u a ntitati ve 
uri ne c ult ure wit h o ut t he partici p a nt recei vi n g ot her s yste mic a nti micr o bials) a n d C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 14 
 a clinical success (resolution of signs and symptoms of acute cystitis present at 
Baseline [and no new signs and symptoms] without the participant receiving other 
systemic antimicrobials) at the TOC Visit in  the Microbiological Intent -to-Treat 
Nitrofurantoin -Susceptible (micro -ITT NTF -S) Population, regardless of 
treatment discontinuation.  
Disclosure Statement : This is a parallel -group treatment study with 2 arms that is 
participant, care provider, investigator, and outcomes assessor blinded.  
Number of Participants:  
The study is planned to enroll approximately 2500  participants to fulfill the maximum 
target sample size of approximately 884 participants in the primary analysis micro -ITT 
NTF -S Population. The final number of randomized participants may vary based on the 
evaluability rate  and review of qualifying uropathogens by [CONTACT_760988] . 
Treatment Groups and Duration:  
• Participants will receive 1 of the following treatments:  
• Gepotidacin: 1500 mg administered orally twice daily for 5 days (Note: Each 
dose should be taken after food consumption and with water to assist with 
tolerability.)  
• Nitrofurantoin: 100 mg administered orally twice daily for 5 days (Note: Each 
dose should be taken after food consumption and with water.)  
• The duration of study participation is approximately 28 days with 4 planned study 
visits:  
• Baseline (Day 1) Visit  
• On-therapy (Day 2 to 4) Visit  
• TOC (Day 10 to 13) Visit  
• Follow -up (Day 28±3) Visit  
Data Monitoring or Other Committee:  Yes; this study will include an Independent 
Data Monitoring Committee for interim analysis purposes, a GlaxoSmithKline Safety 
Review  Team will monitor blinded safety data, and a Microbiology Review Team will 
monitor blinded microbiological data  instream .  
 
TMF-13817737  CONFIDENTIAL   
  212390  
 15 
 1.2. Schema  
Figure 1 Study Design Schematic  
 
 
BID=twice daily; HPF=high -power field; TOC=Test -of-Cure; WBC=white blood cell.  
a. There will be central randomization with stratification by [CONTACT_67579] (<18 years, ≥18 to 50 years, or >50 years) and acute cystitis recurrence (no nrecurrent infection or recurrent 
infection, defined as a confirmed infection [not including the current infection in the calculation] with at least [ADDRESS_1042144] 12 months before study entry).  
b. Study treatment will be administered under double -blind, double -dummy conditions. Each dose should be taken after food consumption and with water.  

T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 1 6  
 1. 3.  S c h e d ul e of A cti viti e s ( S o A)  
Vi sit a B a s eli n e  O n -T h er a p y b T O C b F oll o w -u p  E arl y 
Wit h dra w al  
St u d y D a y  1 
2 t o 4  1 0 t o 1 3  2 8 ± [ADDRESS_1042145] d o s e  
Writt e n i nf or m e d c o ns e nt/ ass e nt  X      
I R T – Scr e e ni n g m o d ul e  X      
I ncl usi o n a n d excl usi o n crit eri a  X      
P artici p a nt d e m o gr a p hy  X      
P hysic al ex a mi n ati o n (i ncl u di n g h ei g ht a n d w ei g ht at B as eli n e o nly)  X   Xc   
R ec or d ac ut e cystitis si g ns a n d sy m pt o ms d X  X X X X 
M e dic al/s ur gic al hist ory  X      
Di a g n osis of pr es u m ptiv e ac ut e cystitis f X      
B act eri ol o gy s a m pl es g X  Xh X X X 
R a n d o miz ati o n  X      
1 2 -l e a d E C G i X  Xi    
Vit al si g n m e as ur e m e nts j X  X X   
H e m at ol o gy, c h e mistry, a n d uri n alysis  X  X X   
S er ol o gy ( h e p atitis B a n d C a n d HI V) k X      
Uri n e pr e g n a ncy t est l Xl  Xl X  X 
Dr u g a n d alc o h ol scr e e n  X      
I R T – R a n d o miz ati o n m o d ul e  X      
A d mi nist er or al d os e of st u dy tr e at m e nt n  X Xi,o     
S eri o us a dv ers e ev e nts p X X X X X X 
A dv ers e ev e nts q  X X X X X 
C o nc o mit a nt m e dic ati o n r evi e w  X X X X X X 
St u dy tr e at m e nt c o m pli a nc e r   X X   
Sc h e d ul e n ext visit  Xs  Xt Xt Xt  
G e n etic s a m pl e u X      
E C G = el ectr oc ar di o gr a m; HI V = h u m a n i m m u n o d efici e ncy vir us; H P F = hi g h -p o w er fi el d; I R T =i nt er activ e r es p o ns e t ec h n ol o gy; N A = n ot a p plic a bl e; T O C = T est -of -C ur e; U TI = uri n ary 
tr act i nf ecti o n; W B C = w hit e bl o o d c ell.  C CI 
C CI 
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 1 7  
 N ot e:  T o r e d uc e p artici p a nt o n -sit e visits or if u nf or es e e n iss u es i m p act cli nic visits, a n d p artici p a nts ar e u n a bl e t o att e n d a sit e visit, h o m e h e alt hc ar e ( h o m e visits a n d t el e m e dici n e 
visits) m ay b e us e d t o c o n d uct pr oc e d ur es as d et ail e d i n t h e St u dy R ef er e nc e M a n u al. H o m e h e alt hc ar e will o nly b e utili z e d w h er e a p plic a bl e c o u ntry a n d l oc al r e g ul ati o ns a n d 
i nfr astr uct ur e all o w.  
a.  F or all st u dy visits, t o mi ni miz e t h e a m o u nt of ti m e t h at p artici p a nts s p e n d at t h e cli nic, e C o ns e nt m ay b e utiliz e d a n d r e m o t e c oll ecti o n of st u dy -r el at e d d at a m ay b e o bt ai n e d  
as d escri b e d i n t h e St u dy R ef er e nc e M a n u al. T h us, s o m e visit d at a m ay b e c oll ect e d t hr o u g h a c o m bi n ati o n of t el e m e dici n e a n d o n -sit e visits. C oll ecti o n of i nf or m ati o n vi a 
t el e m e dici n e will b e p erf or m e d o nly w h er e l oc al r e g ul ati o ns p er mit. Pr escr e e ni n g act iviti es m ay als o b e c o n d uct e d, i ncl u di n g a pr escr e e ni n g i nf or m e d c o ns e nt a n d uri n e t esti n g, 
as d et ail e d i n S ecti o n [ADDRESS_1042146] u dy R ef er e nc e M a n u al.  
b.  F or t h e O n -t h er a py ( D ay 2 t o 4) Visit: P artici p a nts will b e i nstr uct e d t o r et ur n t o t h e st u dy sit e wit hi n [ADDRESS_1042147] u dy R ef er e nc e M a n u al. F or t h e T O C ( D ay 1 0 t o 1 3) Visit: P artici p a nts will b e i nstr uct e d t o 
r et ur n t o t h e st u dy sit e [ADDRESS_1042148] u dy p hysici a n or ot h er wis e a p pr o pri at ely m e dic ally tr ai n e d s t aff w h o p erf or m e d t h e cli nic al sc ori n g ass ess m e nt.  
f.  B as e d o n c o nfir m ati o n of nitrit e or py uri a ( > 1 5 W B C/ H P F or t h e pr es e nc e of 3 +/l ar g e l e uk ocyt e est er as e) fr o m a pr etr e at m e nt c l e a n -catc h mi dstr e a m uri n e s a m pl e p er l oc al 
l a b or at ory pr oc e d ur es.  
g.  P artici p a nts will pr ovi d e a cl e a n -c atc h mi dstr e a m uri n e s a m pl e at e ac h visit f or Gr a m st ai n, q u a ntit ativ e b act eri ol o gy c ult ur e, a n d i n vitr o a nti micr o bi al s usc e pti bility t esti n g by a 
d esi g n at e d c e ntr al l a b or at ory(i es). R ef er t o t h e l a b or at ory m a n u al.  
h.  A b act eri ol o gy uri n e s a m pl e will b e c oll ect e d at t h e O n -t h er a py Visit, as f urt h er d et ail e d i n t h e St u dy R ef er e nc e M a n u al.  
i.  S e e S ecti o n 5. 2  f or E C G excl usi o n crit eri o n f or p artici p a nts a g e d ≥ 1 2 t o < [ADDRESS_1042149] d os e (i. e., ex p ect e d ti m e of m axi m u m c o nc e ntr ati o n; E C G c oll ecti o n s h o ul d i d e ally b e wit hi n a p pr oxi m at ely 1. [ADDRESS_1042150] d os e). 
Aft er t h e first a p pr oxi m at ely [ADDRESS_1042151] u dy sit e d uri n g 
t h e B as eli n e Visit; p artici p a nts will s elf -a d mi nist er  as o ut p ati e nts t h er e aft er, b e gi n ni n g wit h t h e s ec o n d d os e. E ac h d os e s h o ul d b e t ak e n aft er f o o d c o ns u m pti o n a n d wit h w at er. 
T h e d at e a n d ti m e of e ac h d os e a d mi nist er e d at t h e st u dy sit e will b e r ec or d e d i n t h e s o urc e d oc u m e nts.  C CI 
C CI 
TMF-[ADDRESS_1042152] resul ts are confirmed. Note:  The On -therapy Visit should be scheduled to support 
completion of the postdose ECG within the protocol -defined window. Also, in a woman of childbearing potential, the high sensitivity pregnancy test must be performed and 
show negat ive results at the latest before Dose [ADDRESS_1042153] serious adverse events from the time of consent/assent in order to fulfill international regulatory requirements.  
q. Record adverse events from the time of the first dose of stu dy treatment.  
r. Determine study treatment compliance by [CONTACT_170491][INVESTIGATOR_692].  
s. Confirm return day/time for the On -therapy, TOC, and Follow -up Visits.  
t. Previsit reminder: Study site staff will contact [CONTACT_2299] 24±[ADDRESS_1042154] sample only if the participant has a signed consent/assent specific for this purpose. The Baseline Visit is the recom mended time to collect the sample, but it can be 
collected at any time during the study.  
 
 
TMF-13817737  CONFIDENTIAL   
  212390  
 19 
 2. INTRODUCTION  
Gepotidacin ([COMPANY_004]2140944), a novel triazaacenaphthylene bacterial type  II 
topoisomerase inhibitor, is being developed for the treatment of uncomplicated urinary 
tract infections (UTIs; acute cystitis). Gepotidacin has activity versus key pathogens, 
including drug -resistant strains associated with a range of conventional and biothreat 
infections. The microbiological spectrum of activity of gepotidacin includes Esch erichia 
coli, the key causative pathogen of acute cystitis, Staphylococcus saprophyticus , and 
Enterococcus faecalis .  
Gepotidacin selectively inhibits bacterial DNA replication by [CONTACT_126705] a unique way 
on the GyrA subunit of bacterial DNA gyrase and the ParC subunit of bacterial 
topoisomerase IV. This interaction appears to be highly specific to bacterial 
topoisomerases as evidenced by [CONTACT_126706] , 
supporting the selective activity of gepotidacin against the bac terial target. The novel 
mode of action of this new class antibacterial affords in vitro activity against most target 
pathogens resistant to established antibacterials, including fluoroquinolones.  
2.1. Study Rationale  
This study is being conducted based on the need to identify new and effective oral 
antibiotic treatment options for acute cystitis, as such therapi[INVESTIGATOR_126649] -resistant (MDR) pathogens and extended -spectrum 
-lactamase (ESBL) -producing Enterobacterales p athogens, which are impacting the 
efficacy of currently available oral antibacterial treatment options (see Section  2.2). 
Two Phase II studies have been conducted and  the results demonstrated that gepotidacin 
was efficacious in the treatment of uncomplicated urogenital gonorrhea and acute 
bacterial skin and skin structure infections (ABSSSIs) (see Section 5.3.3 in the 
investigator’s brochure [IB] for details). In addit ion, a Phase IIa pharmacokinetic (PK) 
study (206899) was conducted in 22 female participants with acute cystitis that also 
included exploratory clinical and microbiological efficacy objectives. All 22  participants 
were evaluable for PK and clinical efficac y analysis. Of the 22  participants, 19 
participants (86%) and 18 participants (82%) achieved symptom resolution at the Test -of-
Cure (TOC) and Follow -up Visits, respectively. Eight of 22  participants (36%) who 
received at least 1  dose of gepotidacin had a q ualifying baseline uropathogen (5 with E. 
coli isolates, 1  with a S. saprophyticus  isolate, 1 with a Klebsiella pneumoniae  isolate , 
and 1 with a  Citrobacter koseri  isolate). Of these 8 participants, 7  participants (88%) and 
6 participants (75%) had a micro biological response of microbiological success 
(<103 colony -forming units/mL [ CFU/mL]) at the TOC and Follow -up Visits, 
respectively. Furthermore, of these 8  participants, 6 participants (75%) and 5 participants 
(63%) had a therapeutic response (combined per -participant microbiological and clinical 
response) of success at the TOC and Follow -up Visits, respectively. Refer to the IB for 
PK, safety, and additional efficacy results.  
This study (212390) aims to evaluate the therapeutic response (combined microbiological 
and clinical efficacy per participant) of oral gepotidacin compared to oral n itrofurantoin 
for acute cystitis in adolescent and adult female participants.  
TMF-[ADDRESS_1042155] infections are very common, with approximately 11% of women >[ADDRESS_1042156] 1 epi[INVESTIGATOR_126650] [ Foxman , 2000]. Of these, 
half will experience more than 1 recurrent epi[INVESTIGATOR_126651] [ Foxman , 2000]. 
The peak incidence of acute cystitis occurs in young, sexually active women ages 18 to 
29 years [ Fihn, 2003]. The predominant uropathogens isolated in community -acquired  
UTIs are E. coli  (75% to 90%) followed by S. saprophyticus  (5% to 15%) [ Stamm , 1993; 
Talan , 2000; Foxman , 2010]. Klebsiella , Enterobacter , Proteus  species, and enterococci 
are observed in only 5% to 10% of acute cystitis [ Stamm , 1993; Talan , 2000; Foxman , 
2010].  
Multidrug resistance, which is typi[INVESTIGATOR_126648], has now 
emerged at the community level and has made treatment approaches for UTIs more 
difficult [ Hooton , 2012; Flamm , 2014; Sanchez, 2016] . This has led to increasing patient 
morbidity, increasing costs due to reassessment and retreatment, higher rates of 
hospi[INVESTIGATOR_059], and increased use of broad -spectrum antibiotics [ Foxman , 2002; Gupta, 
2011a; Hooton , 2012]. Furthermore, ESBL -producing Enterobacteriaceae (now 
recognized as Enterobacterales),  which includes E. coli , is recognized as a serious threat 
by [CONTACT_7698] (CDC) [ CDC , 2019] and 
drug-resistant Enterobacteriaceae  is a critical priority pathogen for the World Health 
Organization (WHO) [ WHO , 2017]. One reason for this serious threat level is the 
growing rise in the MDR  E. coli sequence type (ST) -131 clone [ Johnson , 2012; Nicolas -
Chanoine , 2014]. Spread of this ST -[ADDRESS_1042157] E. coli  worldwide [ Peirano , 2010]. The availability of oral 
antimicrobials that are effective against ESBLs is limited and, for some outpatient 
infections, no oral options remain.  
An in vitro evaluation of antimicrobial resistance of urinary E. coli  isolates 
(n=12,253,679) among US outpatients between 2000 and 2010 was conducted using 
The Surveillance Network and found significant increases in the percentage of E. coli  that 
were resis tant to ciprofloxacin (3% to 17.1%) and trimethoprim -sulfamethoxazole 
(TMP -SXT) (17.9% to 24.2%), whereas there were minimal changes in the percentage of 
resistance to nitrofurantoin (0.8% to 1.6%) and ceftriaxone (0.2% to 2.3%) over time 
[Sanchez , 2012]. Another surveillance study, which looked at US susceptibility patterns 
and ESBL rates of E. coli  from UTIs, showed an increase in ESBL rates from 7.8% t o 
18.3% (p<0.0001) from 2010 to 2014 [ Lob, 2016]. The expansion of ESBL -producing 
E. coli, which are usually co -resistant to TMP -SXT and fluoroquinolones, is of  urgent 
concern globally as well [ Oteo , 2010]. Recent global surveillance data of E. coli  showed 
high resistance rates to third -generation cephalosporins and flu oroquinolones in all 
6 WHO regions [ WHO , 2014]. An evaluation of the prevalence and susceptibility of 
acute cystitis pathogens in 9  European countries and Brazi l from 2003 to 2006 showed 
that >10% of E. coli  strains were MDR and 1.7% were ESBL producers [ Schito , 2009]. A 
separate study in Brazil reported a prevale nce of 7.6% ESBL -producing Enterobacterales 
among pathogens from community -acquired UTIs [ Abreu , 2013]. In China, the 
prevalence of ESBLs in urinary E. coli  in women ranged from 5% to 10.6% depending 
on the age group [ Ho, 2007].  
TMF-[ADDRESS_1042158] a concerning 
allergy history or tolerance issues [ Gupta , 2011b]. Trimethoprim -sulfamethoxazole 
should not be used as a first -line treatment if the prevalence of resistance exceeds the 
20% threshold or if TMP -SXT was used for treatment of a UTI in the previous [ADDRESS_1042159] uropathogens including E. coli  (see Section  [IP_ADDRESS] 
of the IB for details) and provides high and sustained urine concentrations for the 
treatment of UTIs. With its unique ability to selectively inhibit bacterial DNA replication 
by a means not utilized by [CONTACT_760989], gepotidacin 
warrants further study as a potential opportunity to address an unmet medical need by 
[CONTACT_1541] a new and effective oral treatment option for acute cystitis.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of 
gepotidacin is provided in the IB. Details on the active comparator in this study, 
nitrofurantoin, may be found in the locally approved prescribing information.  
2.3. Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and 
reasonably expected adverse events (AEs) of gepotidacin and nitrofurantoin may be 
found in the IB and the locally approved prescribing information, respectively.  
TMF-13817737  CONFIDENTIAL   
  212390  
22 
 2.3.1.  Risk Assessment  
Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk   Mitigation Strategy  
Gepotidacin ([COMPANY_004]2140944)  
Cardiovascular Effects  
Based on nonclinical data, cardiovascular 
effects were reversible increase in heart rate 
and blood pressure (dog and monkey); 
reversible 10 to 21  msec (4% to 9%) increase 
in QTc (monkey); and at the highest dose, a 
reversible 2 to 3 msec (6% to 8%) increase in 
QRS (monkey).  
Based on a thorough QTc clinical study, 
gepotidacin may cause mild, reversible heart 
rate effects and QT prolongation.  In a thorough QTc study, infusion of gepotidacin 
at doses of [ADDRESS_1042160] of 
approximately 6  to 10 bpm and QT prolongation 
measured as ∆∆QTcF of 12 to 22  msec. The QT 
prolongation evolved during the infusion and was 
quickly reversed over 2  hours after the end of the 
infusion (see Section 5.2.6 and Section 6 of the 
IB). 
In Phase I and II studies, 
concentration -dependent QT prolongation has 
been observed during clinical t rials with 
gepotidacin; however, this increase has not 
translated into clinically significant QTc values or 
changes from baseline (change from baseline 
>60 msec or QTcF >500 msec) or cardiovascular 
AEs.  
In Phase I and II studies, gepotidacin did not have 
a clinically relevant effect on cardiac conduction 
(PR and QRS intervals).  See Section 5.2 for excluded cardiac 
conditions. Close monitoring of clinical 
parameters a nd AEs (Section  1.3) will be 
conducted, and treatment monitoring and 
evaluation criteria (Section  7.1.2 ) will be 
utilized to mitigate cardiovascular effects.  
Participants taking medications known to 
increase QT or potent CYP3A4 inhibitors will 
be excluded (see Section  6.5.2 ). 
See also the Renal and Hepatic sections within 
this table below.  
TMF-13817737  CONFIDENTIAL   
  212390  
23 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk   Mitigation Strategy  
Gastrointestinal Effects  
Based on nonclinical data, gastrointestinal 
effects were mild ulceration of the nonglandular 
mucos a and minimal erosion and/or mural 
inflammation of the glandular mucosa in 
stomach (rat, oral study); moderate cecal 
ulceration and minimal colonic erosion (rat, IV 
study); and vomiting (dog).  
Lower gastrointestinal effects (soft stools, 
flatulence, and di arrhea) are among the most 
common AEs reported in gepotidacin clinical 
studies. Nausea and vomiting AEs have also 
been commonly observed in gepotidacin 
clinical studies.  See also the Acetylcholinesterase Inhibition 
section within this table below.  
Clostrid ium difficile -associated diarrhea has been 
observed in clinical trials with gepotidacin.  See Section  5.2 for excluded medical 
conditions. Close monitoring of clinical 
parameters and AEs (Section  1.3) will be 
conducted to mitigate and assess 
gastrointestinal effects.  
Suspected C. difficile  infection will be managed 
according to a pres pecified algorithm provided 
in Appendix 1 . 
TMF-13817737  CONFIDENTIAL   
  212390  
24 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk   Mitigation Strategy  
Acetylcholinesterase Inhibition  
In vitro testing showed gepotidacin to be a 
rapi[INVESTIGATOR_760964].  
Based on clinical data, caution should be used 
in participants who have a condition requiring 
treatment with anticholinergic medications or 
who have certain medical conditions that may 
be exa cerbated by [CONTACT_760990].  Increased cholinergic effects can potentially be 
associated with more severe symptoms including 
atrioventricular block, seizure/convulsions, 
bronchospasm, and vasovagal syncope. No 
causal relationship between these events and the 
use of gepotidacin has been established during 
clinical trials to date.  
Adverse events consistent with 
acetylcholinesterase inhibition, including diarrhea, 
nausea, vomiting, gastrointestinal crampi[INVESTIGATOR_126653],  dyspnea, bradycardia, lacrimation, 
salivation, and diaphoresis/sweating have been 
reported during clinical trials with gepotidacin.  
Mild and transient non -gastrointestinal AEs have 
been associated with Cmax levels higher than this 
dosing regimen.  Partici pants who have medical conditions or 
require medications that may be impacted by 
[CONTACT_126710]. See 
Section 5.2 for excluded medical conditions 
and Section 6.5.2 , Prohibited Medications and 
Nondrug Therapi[INVESTIGATOR_014], for prohibited medications.  
Close monitoring of clinical parameters and 
AEs will be conducted to assess effects 
potentially related to acetylcholi nesterase 
inhibition (Section 1.3). 
 
Hepatic Effects  
In preclinical studies, increases in ALT, GLDH, 
alkaline phosphatase, and total bilirubin were 
observed in some r at studies of varying 
exposure.  Elevations in ALT have occurred in a few 
participants with pre -existing hepatitis C infection, 
but none were felt related to study treatment. The 
type and pattern of elevation in liver 
transaminases observed has not been su ggestive 
of an adverse effect of gepotidacin and none were 
considered related to study treatment.  
A substantial increase in Cmax and AUC and 
decrease in clearance was observed in volunteer 
participants with severe hepatic impairment.  Participants with severe hepatic impairment are 
excluded from Phase III trials. See Section  5.[ADDRESS_1042161] been 
implemented.  
TMF-13817737  CONFIDENTIAL   
  212390  
25 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk   Mitigation Strategy  
Renal Effects  
In preclinical trials, mild to moderate tubular 
degeneration was noted in the rat and 
proteinuria in the dog. Proteinuria was also 
observed in humans.  No clinical evidence of renal toxicity has been 
seen in clinical trials to da te. 
A substantial increase in Cmax and AUC and 
decrease in clearance was observed in severe 
renal impairment/ESRD participants not on 
hemodialysis and in ESRD participants requiring 
hemodialysis (note: gepotidacin may have been 
administered at any time oth er than when 
receiving dialysis).  Participants with severe renal 
impairment/ESRD (including those who may 
require dialysis) are excluded from Phase III 
trials. See Section  5.[ADDRESS_1042162] been 
implemented.  
TMF-13817737  CONFIDENTIAL   
  212390  
26 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk   Mitigation Strategy  
Reproductive System Effects  
Preclinical studies demonstrated that 
gepotidacin was not genotoxic and no 
drug-related malformations were observed. 
Although positive in vitro findings for 
clastogenicity, consistent with a mechanism 
related to mammalian topoisomerase II 
inhibition were found, in vivo data from rat 
micronucleus and COMET assays suggest that 
gepotidacin does not pose a genotoxic hazard 
to humans.  
Gepotidacin  effects on embryofetal 
development were limited to decreased fetal 
weights for male and female fetuses in rats and 
decreased fetal weights and increased fetal 
resorptions (fetal deaths) in mice, both at 
maternally toxic doses. These occurred at 
clinically  relevant exposures (65  µg.h/mL in rat 
and 35 µg.h/mL in mouse).  There are no data on the use of gepotidacin  in 
pregnant women.  Gepotidacin is contraindicated in pregnant or 
nursing mothers and women of childbearing 
potential who are not employing adequate 
contraceptive measures. See Appendix 2  for 
contraceptive measures and Appendix 8  for 
required pregnancy testing.  
TMF-13817737  CONFIDENTIAL   
  212390  
27 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk   Mitigation Strategy  
Other  
Nitrofurantoin  The most frequent AEs possibly or probably 
related to oral nitrofurantoin treatment are nausea 
(8%), headache (6%), and flatulence (1.5%). As 
with gepotidacin, there is also a need to monitor 
for C. difficile -associated diarrhea during 
nitrofurantoin treat ment.  
Nitrofurantoin is contraindicated for patients with 
anuria, oliguria, or significant impairment of renal 
function; pregnant patients at term (38 to 
42 weeks’ gestation), during labor and delivery, or 
when the onset of labor is imminent; neonates 
under 1 month of age; and patients with a 
previous history of cholestatic jaundice/hepatic 
dysfunction associated with nitrofurantoin.  
Rare adverse reactions that generally occur in 
patients receiving treatment for 6 months or 
longer are acute, subacute, or c hronic pulmonary 
reactions, with potential insidious development of 
chronic pulmonary reactions (diffuse interstitial 
pneumonitis or pulmonary fibrosis, or both).  
Peripheral neuropathy has occurred, which may 
be enhanced for patients with anemia, diabetes  
mellitus, electrolyte imbalance, vitamin B 
deficiency, and debilitating disease.  
Nitrofurantoin has induced the occurrence of 
hemolytic anemia of the primaquine -sensitivity Close monitoring of clinical parameters and 
AEs (Section  1.3) will be conducted, and 
treatment monitoring and evaluation criteria 
(Section 7.1.1 ) will be utilized to mitigate 
hepatic effects.  
Because planned treatment in this study is only 
5 days, the probability for adverse reactions 
associated with long -term use is low.  
The exclusion criteria for this study include 
contraindications to nitrofurantoin use and 
exclude participants at risk for nitrofurantoin 
adverse reactions, including acute porphyria as 
an example of a rare genetic risk (see 
Section 5.2).  
Participants with a history of sensitivity to 
nitrofurantoin, or components thereof, will not 
be allowed to enroll in the study (Section 5.2). 
Participant’s medical history will be carefully 
evaluated for history of hypersensitivity.  
Participants must agree not to use antacid 
preparations containing magnesium trisilicat e 
or uricosuric drugs during study treatment (see 
Section 5.2). 
TMF-13817737  CONFIDENTIAL   
  212390  
28 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk   Mitigation Strategy  
type, which appear to be linked to a 
glucose -6-phosphate dehydrogenase deficiency 
in the red blood cells of the affected patients.  
Hepatic reactions, including hepatitis, cholestatic 
jaundice, chronic active hepatitis, and hepatic 
necrosis, occur rarely.  
Concomitant administration of nitrofurantoin with 
antacids containing magnesium tr isilicate reduces 
both the rate and extent of absorption, and 
uricosuric drugs, such as probenecid and 
sulfinpyrazone, can inhibit renal tubular secretion 
of nitrofurantoin.  
Refer to locally approved nitrofurantoin 
prescribing information for specific det ails relating 
to nitrofurantoin.  Suspected C. difficile  infection will be managed 
according to a prespecified algorithm provided 
in Appendix 1 . 
Precautions related to nitrofurantoin are 
summarized in detail in the Study Reference 
Manual.  
bpm=beats per minute; AE=adverse event; ALT=alanine aminotransferase; AUC=area under the drug concentration -time curve; Cmax=maximum concentration; 
CYP3A4=cytochrome P450 enzyme 3A4; ESRD=end -stage renal disease; GLDH=glutamate dehydrogenase; IB=investigator’s brochure; IV=intravenous; 
ΔΔQTcF=placebo -correc ted change from baseline in corrected QT interval using the Fridericia formula; QTc=corrected QT interval; QTcF=interval corr ected for heart rate according 
to Fridericia’s formula.  
 
TMF-[ADDRESS_1042163] common indications for which antimicrobials are 
prescribed for otherwise healthy women [ Gupta , 2011b]. The increase in antimicrobial 
resistance among pathogens causing community -acquired UTIs over the past [ADDRESS_1042164] 
isolates resistant to other antibacterial treatments. Given gepotidacin’s spectrum of 
activity against E. coli , S. saprophyticus , and E. faecalis , as we ll as human safety data 
and the PK profile, it is anticipated that gepotidacin will benefit participants with acute 
cystitis.  
The active comparator in this study is nitrofurantoin, a marketed antibiotic for the 
treatment acute uncomplicated UTIs (acute cys titis) caused by [CONTACT_126711] 
E. coli or S. saprophyticus  (refer to locally approved nitrofurantoin prescribing 
information). Participants randomly assigned to this treatment group are also expected to 
experience treatment benefits. It is expecte d that gepotidacin will have a similar efficacy 
profile to nitrofurantoin.  
Overall, all participants in this study will not only receive routine medical monitoring 
appropriate for acute cystitis, but they will also receive heightened monitoring to 
minimize  safety risks when participating in a clinical study.  
2.3.3.  Overall Benefit: Risk Conclusion  
Antimicrobial resistance among uropathogens causing acute cystitis has increased in the 
past decades [ Gupta , 2011b; Sanchez, 2016]. However, even in the face of increasing 
drug resistance to existing agents, few new antibiotics with novel  mechanisms of action 
are being developed. Gepotidacin selectively inhibits bacterial DNA replication by a 
means not utilized by [CONTACT_126708]. Based on the 
known preclinical data for gepotidacin against E. coli , S. saproph yticus , and E. faecalis , 
the Phase II results showing the efficacious treatment of uncomplicated urogenital 
gonorrhea and ABSSSIs, Phase IIa results indicating efficacy in acute cystitis, and the 
cumulative safety results from Phase I and Phase II studies with oral gepotidacin 
treatment, this study will test whether gepotidacin is noninferior to [ADDRESS_1042165] 
participant safety and to better characterize the safety profile of the study treatments 
(Section 2.3.1 ). Furthermore, a GlaxoSmithKline ([COMPANY_004]) Safety Review Team (SRT) will 
monitor blinded safety data instream (see Appendix 3 ). Careful safety monitoring should 
also identify any emerging safety issues for gepotidacin and contribute to the benefit -risk 
profile of nitrofurantoin.  
The investiga tor may also, at his or her discretion, discontinue the participant from study 
treatment at any time and initiate appropriate alternative therapy.  
TMF-13817737  CONFIDENTIAL   
  212390  
 30 
 Taking into account the measures taken to minimize risk to participants participating in 
this study, the pote ntial risks identified in association with gepotidacin and nitrofurantoin 
are justified by [CONTACT_760991].  
3. OBJECTIVES AND ESTIM ANDS/ENDPOINTS  
Objectives  Endpoints  
Primary  
• To assess the combined clinical and 
microbiological efficacy of gepotidacin 
compared to nitrofurantoin, at the TOC 
Visit, in female participants with acute 
cystitis with qualifying bacterial 
uropathogen(s) at Baseline that all are 
susceptible to nitrofuran toin  • Therapeutic response (combined 
per-participant microbiological and clinical 
response) at the TOC Visit  
Secondary  
• To assess the clinical efficacy of 
gepotidacin compared to nitrofurantoin, at 
the TOC and Follow -up Visits, in female 
participants with acute cystitis  • Clinical outcome and response at the 
TOC and Follow -up Visits  
• To assess the clinical efficacy of 
gepotidacin compared to nitrofurantoin, at 
the TOC and Follow -up Visits, in female 
participants with acute cystitis with 
qualifying bacterial uropathogen(s) at 
Baseline that all are susceptible to 
nitrofurantoin  • Clinical outcome and response at the 
TOC and Follow -up Visits  
• To assess the microbiological efficacy of 
gepotidacin compared to nitrofurantoin, at 
the TOC and Follow -up Visits, in femal e 
participants with acute cystitis with 
qualifying bacterial uropathogen(s) at 
Baseline that all are susceptible to 
nitrofurantoin  • Microbiological outcome and response at 
the TOC and Follow -up Visits  
• To assess the combined clinical and 
microbiological eff icacy of gepotidacin 
compared to nitrofurantoin, at the 
Follow -up Visit, in female participants with 
acute cystitis with qualifying bacterial 
uropathogen(s) at Baseline that all are 
susceptible to nitrofurantoin  • Therapeutic response (combined 
per-participa nt microbiological and clinical 
response) at the Follow -up Visit  
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 3 1  
 O bj e cti ve s  E n d p oi nt s  
S e c o n d ary c o nti n u e d  
• T o ass ess t h e s afety an d toler a bility of 
g e poti d aci n c o m par e d to nitr of ur a ntoi n i n 
f e m al e partici p a nts wit h ac ut e cystitis   
• Tr e at m e nt -e m erg e nt A Es an d s eri ous 
A Es ( S A Es) a n d c h an ge fr o m b as eli n e 
r es ults f or cli nic al l ab or atory t ests, 
el ectr oc ar di ogr a ms ( E C Gs), a n d vit al si g n 
m e as ur e m e nts  
C CI 
T M F -[ADDRESS_1042166] is: W hat is t he treat me nt effect o n t he 
t hera pe utic res p o nse after 5 da ys of treat me nt wit h ge p oti daci n 1 5 0 0 m g t wice dail y 
c o m pare d t o 5 da ys of treat me nt wit h nitr of ura nt oi n 1 0 0 m g t wice d ail y i n p artici pa nts 
wit h ac ute c ystitis wit h q ualif yi n g bacterial ur o pat h o ge n(s) at Bas eli ne t hat all are 
s usce pti ble t o nitr of ura nt oi n, re gar dless of treat me nt disc o nti n uati o n f or a n y reas o n. 
Recei pt of s yste mic a nti micr o bials will i m pact t he e n d p oi nt defi niti o n (see 
Secti o n  8. 1. 2. 1  a n d Secti o n 8. 1. 3. 1 ).  
T he pri mar y esti ma n d is descri be d b y t he f oll o wi n g attri b utes:  
• P o p ulati o n: Fe male parti ci pa nts wit h ac ute c ystitis wit h q ualif yi n g bacterial 
ur o pat h o ge n(s) at Baseli ne t hat all are s us ce pti ble t o nitr of ura nt oi n.  
• Treat me nt c o n diti o n: Ge p oti daci n 1 5 0 0 m g t wic e dail y f or 5 da ys vers us 
nitr of ura nt oi n 1 0 0 m g t wice dail y f or 5 d a ys, re gar dless of a d here nce.  
• Varia ble: T h era p e utic res p o nse (c o m bi ne d per -partici pa nt micr o bi ol o gical a n d 
cli nical res p o nse) at t he T O C Visit. Micr o bi ol o gical s uccess is defi ne d as 
era dic ati o n (i.e., re d u cti o n) of all q ualif yi n g bact erial ur o pat h o ge ns rec o vere d at 
baseli ne t o < 1 0 3 c ol o n y -f or mi n g u nits/ m L ( C F U/ m L) as o bser v e d o n q ua ntitati ve 
uri ne c ult ure wit h o ut t he partici pa nt recei vi n g ot her s y ste mic a nti micr o bials. 
Cli nical s uccess is defi ne d as res ol uti o n of si g ns a n d s y m pt o ms of ac ute c ystitis 
prese nt at Baseli ne (a n d n o ne w si g ns a n d s y m pt o ms) wit h o ut t he partici pa nt 
recei vi n g ot her s yst e mic a nti micr o bials.  
• S u m mar y meas ure: A bs ol ute differe n ce i n t he t hera pe utic s uccess rat e i n t he 
ge p oti daci n a n d nitr of ura nt oi n treat me nt gr o u ps.  
• I nterc urre nt e v e nts (I C Es):  
• St u d y treat me nt disc o nti n uati o n ( d ue t o a n y reas o n) – treat me nt p olic y 
strate g y (i nterest is i n t he treat me nt effect r e gar dless of st u d y  treat me nt 
disc o nti n uati o n).  
• Use of s yste mic a nti micr o bials – c o m p osite strate g y. T his I C E is ca pt ur e d 
t hr o u g h t he d efi niti o ns of micr o bi ol o gical a n d cli nical res p o nse (see 
Secti o n  8. 1. 2. 1  a n d Secti o n 8. 1. 3. 1 ) a n d will be c o u nte d as t hera p e utic 
fail ures.  
Rati o nale f or Esti ma n d:  
I nterest lies i n t he treat me nt effect re gar dless of w h et her t he f ull c o urse of 5 da ys of 
treat me nt was ta k e n or n ot, w hic h reflects h o w patie nts ma y be tr eate d i n cli nical 
practice. He nce, a tr eat m e nt p olic y str ate g y is a p pr o priate f or treat me nt wit h dra wal 
bef ore c o m pleti n g 5 d a ys of treat me nt. Use of ot her s yste mic a nti micr o bials ma y C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 33 
 confound the bacterial culture results; thus, the microbiological response will be 
considered failure. For clinical data, the use of a systemic antimicrobial for acute cystitis 
is a sign of treatment failure and use of a systemic  antimicrobial for another infection 
cannot be considered a success as it confounds the assessment of efficacy. Therefore, the 
definition of a successful therapeutic response precludes the use of other systemic 
antimicrobials.  
Secondary Estimands:  
The seco ndary clinical questions of interest are: What is the treatment effect on each of 
the secondary efficacy endpoints after 5 days of treatment with gepotidacin 1500 mg 
twice daily compared to 5 days of treatment with nitrofurantoin 100 mg twice daily in 
participants with acute cystitis (clinical endpoints) and in participants with acute cystitis 
with qualifying bacterial uropathogen(s) at Baseline that all are susceptible to 
nitrofurantoin (therapeutic, clinical, and microbiological endpoints), regardless of 
treatment discontinuation for any reason. Receipt of systemic antimicrobials impacts the 
endpoint definition (see Section [IP_ADDRESS]  and Section [IP_ADDRESS] ). 
For each of the secondary endpoints the estimand will follow a similar approach to the 
estimand for the primary endpoint and will use the same strategies for the ICEs. The 
exception is the summary measure for the outcome endpoints. These endpoints are 
descriptively summarized; therefore, the summary measure will be the percentage in each 
clinical and microbiological outcome category in the gepotidacin and nitrofurantoin arms  
separately (as no direct comparison between treatment groups will be made) (see 
Section  [IP_ADDRESS]  and Section [IP_ADDRESS]  for endpoint definitions).  
The safety endpoint will use a treatment policy strategy of the ICE of withdrawal from 
treatment as the safety will be assessed at all postbaseline assessments irrespective of 
whether the p articipant completed the treatment.  
Components of estimand for all secondary endpoints are listed in Table 1. 
 
TMF-13817737  CONFIDENTIAL   
  212390  
 34 
 Table 1 Estimand for the Secondary Endpoints  
Secondary 
Endpoint  Population  Treatment Condition  Variable  Summary Measure  Intercurrent Event  
Clinical response at 
the TOC and 
Follow -up Visits  Female participants 
with acute cystitis  Gepotidacin 1500 mg 
BID for 5 days versus 
nitrofurantoin 100 mg 
BID for 5 days, 
regardless of 
adherence  See Table 10 and 
Table 11 Absolute difference in the 
clinical success rate in the 
gepotidacin and 
nitrofurantoin treatment 
groups  Study treatment discontinuation 
(due to any reason) – treatment 
policy  
Use of systemic antimicrobials – 
composite strategy  
Clinical outcome at 
the TOC and 
Follow -up Visits  Female participants 
with acute cystitis  Gepotidacin 1500 mg 
BID for 5 days versus 
nitrofurantoin 100 mg 
BID for 5 days, 
regardl ess of 
adherence  See Table 10 and 
Table 11 Percentage of participants in 
each outcome category in 
the gepotidacin and 
nitrofurantoin arms 
separately  Study treatment discontinuation 
(due to any reason) – treatment 
policy  
Use of systemic antimicrobials – 
composite strategy  
Clinical response at 
the T OC and 
Follow -up Visits  Female participants 
with acute cystitis with 
qualifying bacterial 
uropathogen(s) at 
Baseline that all are 
susceptible to 
nitrofurantoin  Gepotidacin 1500 mg 
BID for 5 days versus 
nitrofurantoin 100 mg 
BID for 5 days, 
regardless of 
adherence  See Table 5 Absolute difference in the 
clinical success rate in the 
gepotidacin and 
nitrofurantoin treatment 
groups  Study treatment discontinu ation 
(due to any reason) – treatment 
policy  
Use of systemic antimicrobials – 
composite strategy  
Clinical outcome at 
the TOC and 
Follow -up Visits  Female participants 
with acute cystitis with 
qualifying bacterial 
uropathogen(s) at 
baseline that all are 
susceptible to 
nitrofurantoin  Gepotidacin 1500 mg 
BID for 5 days versus 
nitrofurantoin 100 mg 
BID for 5 days, 
regardless of 
adherence  See Table 5 Percentage  of participants in 
each outcome category in 
the gepotidacin and 
nitrofurantoin arms 
separately  Study treatment discontinuation 
(due to any reason) – treatment 
policy  
Use of systemic antimicrobials – 
composite strategy  
TMF-13817737  CONFIDENTIAL   
  212390  
 35 
 Secondary 
Endpoint  Population  Treatment Condition  Variable  Summary Measure  Intercurrent Event  
Microbiological 
response at the 
TOC and Follow -up 
Visits  Female participants 
with acute cystitis with 
qualifying bacterial 
uropathogen(s) at 
Baseline that all are 
susceptible to 
nitrofurantoin  Gepotidacin 1500 mg 
BID for 5 days versus 
nitrofurantoin 100 mg 
BID for 5 days, 
regardless of 
adher ence  See Table 5 Absolute difference in the 
microbiological success rate 
in the gepotidacin and 
nitrofurantoin treatment 
groups  Study treatment discontinuation 
(due to any reason) – treatment 
policy  
Use of systemic antimicrobials – 
composite strategy  
Microbiological 
outcome at the 
Follow -up Visit  Female participants 
with acute cystitis with 
qualifying bacterial 
uropathogen(s) at 
Baseline that all  are 
susceptible to 
nitrofurantoin  Gepotidacin 1500 mg 
BID for 5 days versus 
nitrofurantoin 100 mg 
BID for 5 days, 
regardless of 
adherence  See Table 5 Percentage of participants in 
each outcome category in 
the gepotidacin and 
nitrofurantoin arms 
separately  Study treatment discontinuation 
(due to any reason) – treatment 
policy  
Use of systemic antimicrobials – 
composite strategy  
Therapeutic 
response at the 
Follow -up Visit  Female participants 
with acute cystitis with 
qualifying bacterial 
uropathogen(s) at 
Baseline that all are 
susceptible to 
nitrofurantoin  Gepotidacin 1500 mg 
BID for 5 days versus 
nitrofurantoin 100 mg 
BID for 5 days, 
regardless of 
adherence  See Table 5 and 
Table 11 Absolute difference i n the 
therapeutic success rate in 
the gepotidacin and 
nitrofurantoin treatment 
groups  Study treatment discontinuation 
(due to any reason) – treatment 
policy  
Use of systemic antimicrobials – 
composite strategy  
Safety  Female participants 
with acute cystitis 
infection  Gepotidacin 1500 mg 
BID for 5 days versus 
nitrofurantoin 100 mg 
BID for 5 days, 
regardless of 
adherence  TEAEs, SAEs, as 
well as change 
from baseline 
results for clinical 
laboratory tests, 
ECGs, and vital 
sign measurements  Summary statistics 
(appropriate for each type of 
endpoint) in the gepotidacin 
and nitrofurantoin arms 
separately  Study treatment discontinuation 
(due to any reason) – treatment 
policy  
BID=twice daily; EGG=electrocardiogram; SAE=serious adverse event; TEAE=treatment -emergent adverse event; TOC=Test -of-Cure.  
 
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 3 6  
 4.  S T U D Y D E SI G N  
4. 1.  O v er all D e si g n  
• St u d y [ADDRESS_1042167] u d y i n a d olesce nt a n d a d ult 
fe male partici pa nts c o m p ari n g t h e efficac y a n d safet y of oral ge p oti daci n t o oral 
nitr of ur a nt oi n i n t he treat me nt of u nc o m plicate d U TI (ac ut e c ystitis).  
• Partici pa nts will be stratifie d b y a ge cate g or y ( < 1 8 years, ≥ 1 8 t o 5 0 years, or 
> 5 0  years) a n d ac ute c ystitis rec urre n ce ( n o nrec urre nt i nfecti o n or rec urre nt 
i nfecti o n, defi ne d as a c o nfir me d i nfecti o n [ n ot i ncl u di n g t he c urre nt i nfecti o n i n t he 
calc ulati o n] wit h at least [ADDRESS_1042168] u d y e ntr y) a n d wil l be ra n d o ml y assi g ne d i n a 1: [ADDRESS_1042169] u d y treat me nts:  
• Ge p oti daci n: 1 5 0 0 m g a d mi nistere d orall y t wi ce d ail y ( BI D) f or 5 da ys ( N ote: 
Eac h d ose s h o ul d be ta k e n after f o o d c o ns u m pti o n a n d wit h water t o assist wit h 
t olera bilit y.)  
• Nitr of ura nt oi n: 1 0 0 m g a d mi nistere d orall y BI D f or 5 da ys ( N ote: E ac h d ose 
s h o ul d be ta ke n aft er f o o d c o ns u m pti o n a n d wit h water.)  
• A p pr o priate s afet y, effic ac y, a n d micr o bi ol o gic al assess me nts will be c o n d ucte d at 
t he Bas eli ne ( Da y 1) Visit a n d re peate d a t t he O n -t hera p y ( Da y 2 t o 4), T O C ( Da y 1 0 
t o  1 3), a n d F oll o w -u p ( Da y 2 8 ± 3) Visits.  
 
 Eac h tr eat me nt da y will be assesse d o ver 
[ADDRESS_1042170] u d y R efere nce Ma n ual ( S R M).  
• F or t he pri mar y efficac y e n d p oi nt of t hera p e utic res p o nse (c o m bi ne d p er -p artici pa nt 
micr o bi ol o gical a n d cli nical res p o nse), t hera pe utic s uccess r efers t o partici p a nts w h o 
ha ve bee n dee m e d b ot h a micr o bi ol o gical s u ccess (re d ucti o n of all q ualif yi n g 
bacterial ur o pat h o ge ns [ e. g., 1 0 5 C F U/ m L; d efi n e d i n A p pe n di x 4 ] rec o vere d at 
Baseli ne t o < 1 0 3 C F U/ m L as o bs er ve d o n q u a ntitati ve uri ne c ult ure wit h o ut t he 
partici pa nt recei vi n g ot her s yste mic a nti micr o bials) a n d a cli nic al s uccess (res ol uti o n 
of si g ns  a n d s y m pt o ms of ac ute c ystitis prese nt at Baseli ne [a n d n o ne w si g ns a n d 
s y m pt o ms] wit h o ut t he partici pa nt recei vi n g ot her s yste mic a nti micr o bials) at t he 
T O C Visit i n t he Micr o bi ol o gical I nt e nt -t o -Treat Nitr of ura nt oi n -S usce pti ble 
( micr o -I T T N T F -S) P o p ula ti o n, re gar dless of treat me nt disc o nti n uati o n. T he T O C 
Visit is [ADDRESS_1042171] u d y tr eat me nt.  
• Partici pa nts ma y ret ur n t o t he st u d y site at a n y ti me d ue t o A Es or if t he y are 
e x perie nci n g n e w or c o nti n ui n g si g ns a n d s y m pt o ms of ac ute c ystitis. Partici pa nts 
will be assesse d a n d tr eat e d per t he i n vesti gat or’s j u d ge m e nt. If a p artici pa nt is 
s witc he d t o a differe nt a nti bi otic bef ore or d uri n g t he T O C Visit, all T O C pr oce d ures 
s h o ul d be c o m plete d bef ore t he ot her a nti bi otic is starte d.  C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 37 
 • Participants with a concomitant fungal infection can only be treated with topi[INVESTIGATOR_760965].  
• Participants will return to the study site on Day 28 (±3) for a Follow -up Visit. 
Participant s experiencing signs and symptoms suggestive of infection recurrence or 
relapse will be assessed and treated per the investigator’s judgement.  
• The duration of study participation is approximately 28 days with 4 planned study 
visits (see Section  8 for study visit details):  
• Baseline (Day 1) Visit  
• On-therapy (Day 2 to 4) Visit  
• TOC (Day 10 to 13) Visit  
• Follow -up (Day 28±3) Visit  
A study design schematic is depi[INVESTIGATOR_6517] 1. The Schedule of Activities (SoA) is 
provided is Section  1.3. 
Refer to Appendix [ADDRESS_1042172] and/or 
monitoring due to coronavirus disease (COVID -19). For all study visits, to minimize the 
amount  of time that participants spend at the clinic, eConsent may be utilized and remote 
collection of study -related data may be obtained as described in the SRM. Thus, some 
visit data may be collected through a combination of telemedicine and on -site visits. 
Collection of information via telemedicine will be performed only where local 
regulations permit.  
Of note, t o reduce participant on -site visits or if unforeseen issues impact clinic visits, 
and participants are unable to attend a site visit, home healthcare  (home visits and 
telemedicine visits) may be used to conduct procedures as detailed in the Study 
Reference Manual. Home healthcare will only be utilized where applicable country and 
local regulations and infrastructure allow.  
4.2. Scientific Rationale for Stud y Design  
The study design is based on the Food and Drug Administration (FDA) guidance for 
industry for developi[INVESTIGATOR_760966] 
[DHHS , 2019; DHHS , 2018], the European Medicines Agency (EMA) addendum to the 
guideline on the evaluation of medicinal products indicated for treatment of bacteria l 
infections [ EMA , 2013], and feedback from the FDA and EMA. The primary efficacy 
endpoint will be the therapeutic response (combined per -participant microbiolo gical and 
clinical response) at the TOC Visit (i.e., 10 to 13  days after randomization, which is also 
5 to 8  days after completion of study treatment) in participants who have a qualifying 
bacterial uropathogen at Baseline. Although the guidances differ in  their criteria for 
defining qualifying uropathogens, this study has been designed with the qualifying 
uropathogen criteria defined in Appendix 4  and microbiolo gical success defined as 
reduction of all qualifying bacterial uropathogens recovered at Baseline to <103 CFU/mL 
as observed on quantitative urine culture without the participant receiving other systemic 
antimicrobials. Clinical success at the TOC Visit is  defined as the resolution of signs and 
symptoms of acute cystitis present at Baseline (and no new signs and symptoms) without 
T M F -[ADDRESS_1042173] e mic a nti micr o bials. T hera pe utic s u ccess refers t o 
partici pa nts w h o ha v e bee n dee me d b ot h a m icr o bi ol o gical s uc cess a n d a cli nical s uccess 
(i.e., res p o n ders).  
. 
Nitr of ura nt oi n has bee n s electe d as t he acti ve c o m parat or i n t his st u d y. Nitr of ura nt oi n is 
a n a p pr o ve d treat me nt t h at is i n dicate d f or t he tr eat me nt of ac ute u nc o m plic ate d U TI 
(ac ute c ystitis) ca use d b y s usce pt i ble strai ns of E. c oli  or S. s a pr o p hytic us  (refer t o l ocall y 
a p pr o ve d prescri bi n g i nf or mati o n). It is gl o ball y a vaila ble i n m ost re gi o ns a n d is a 
rec o m me n de d oral first -li ne treat me nt f or ac ut e c ystitis per c urre nt U S, U K, a n d 
E ur o pea n Ass o ciati o n of Ur ol o g y g ui d eli nes [ G u pta , 2 0 1 1 b; NI C E , 2 0 1 9; E A U , 2 0 1 9]. 
B ot h ge p oti daci n a n d nitr of ura nt oi n will be a d mi nistere d BI D f or a tr eat me nt d urati o n of 
[ADDRESS_1042174] e d t o pr o vi de effi caci o us treat me nt f or ac ut e c ystitis a n d is i n 
ali g n me nt wit h c urre nt cli nical practice. Ha vi n g t h e sa me d ose re gi me n will als o s u p p ort 
d o u ble -bli n d d ose a d mi nistrati o n.  A n o ni nferi orit y mar gi n of 1 0 % has b ee n selecte d f or 
t his st u d y [ D H H S , 2 0 1 9].  
B ot h a d ult a n d a d oles ce nt ( ≥ 1 2 t o < 1 8 years of a ge) eli gi ble fe mal e partici pa nts will be 
e nr oll e d i n t his d o u ble -bli n de d st u d y. T he st u d y is restricte d t o f e male partici pa nts per 
F D A g ui da n ce [ D H H S , 2 0 1 9]. A d olesce nt partici p a nts will o nl y b e e nr olle d a t st u d y sites 
w here i n vesti gat ors h a ve e x perie nce i n t his p o p ulati o n a n d if all o we d per t h e st u d y site’s 
i nstit uti o nal et hics c o m mittees a n d l ocal c o u ntr y/ n ati o nal re g ulat or y g ui deli nes a n d 
e nr oll me nt will be c o nti n ge nt u p o n s u c h a p pr o vals. A d olesce nt ass e nt f or ms a n d a d ult 
c o nse nt f or ms will be de vel o pe d wit h o versi g ht fr o m l ocal g o v er ni n g i nstit uti o nal re vie w 
b oar ds (I R Bs)/i n de pe n d e nt et hics c o m mittees (I E Cs) (see A p p e n di x 3 ). T here is n o u p per 
a ge li mit f or st u d y partici pa nts; h o we ver, partici pa nts are e x cl u de d if t he y resi de i n a 
n ursi n g h o me or de pe n d e nt care t y pe -facilit y, or if t he y h a ve a n y c o m or bi dities 
ass ociate d wit h c o m plicate d U TI. T h us, a n y p artici pa nts > [ADDRESS_1042175] erial ur o p at h o ge n at Baseli ne a n d t h e resista nce 
pr ofile of ur o p at h o ge ns. F or details o n t hese re vie w tea ms, refer t o A p p e n di x 3 . I n 
a d diti o n, a n I n d e pe n d e nt Data M o nit ori n g C o m mittee (I D M C) will ma na ge t he i nteri m 
a nal ysis (I A) as descri be d i n Secti o n  9. [ADDRESS_1042176] u d y is 1 5 0 0 m g BI D (t otal dail y d os e of 3 0 0 0 m g) f or 
[ADDRESS_1042177] erial treat me nt of u n c o m plicate d ac ute c ystitis i n w o me n, w hic h 
t y pi[INVESTIGATOR_1306] y ra n ges fr o m 3 t o 7  da ys [ G u pta , 2 0 1 1 b; NI C E , 2 0 1 9; E A U , 2 0 1 9]. T he safet y 
a n d t olera bilit y at t his or al d ose a n d d urati o n ha ve bee n e v al uate d i n P hase I st u dies a n d 
i n P hase II st u dies ( B T Z 1 1 6 7 0 4 a n d 2 0 6 8 9 9) (see Secti o n 5 of t he I B f or d etails). C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 39 
 Furthermore, high urine concentrations of gepotidacin are expected in this study based on 
a healthy volunteer Phase I study (BTZ117351) and a Phase IIa study in participants with 
acute cystitis (206899). In BTZ117351, approximately 287  mg of unchanged gepotidacin 
was excreted in urine after a single oral 1500 -mg (2  × 750-mg tablets) dose of 
gepotidacin (minimum ur ine area under drug concentration -time curve over 12  hours 
[AUC12h]=807  µg.h/mL). In the Phase IIa study, 206899, in participants with 
uncomplicated UTIs, approximately 460 mg of unchanged gepotidacin was excreted in 
urine over the steady -state dosing inte rval of 12 hours after repeat BID oral dosing of 
1500  mg (2  × 750-mg tablets) gepotidacin (minimum steady -state urine 
AUC12h=2256  µg.h/mL).  
The gepotidacin dose and duration for this study were selected based on in vitro and 
in vivo studies including exper imental animal pyelonephritis studies that simulated 
human PK exposures of gepotidacin to determine the efficacy of gepotidacin against 
isolates of E. coli , including MDR strains (see Section  4.2 of the IB for further details). 
Based on [COMPANY_004] assessment of the limitations of the current acute cystitis efficacy model 
in rodents, the pyelonephritis model is considered to allow evaluation of antibacterial 
efficacy in a more robust UTI.  
Additionally, an in vitro  study to determine the PK/pharmacodynamic (PD) 
characteristics of gepotidacin against E. coli (dose -fractionation and dose -ranging 
studies) indicate that AUC/MIC is the primary PK/PD index predictive of gepotidacin 
efficacy against E. coli . The magnitude of the ratio of free -drug AUC to MIC  over 
24 hours  (fAUC/MIC) required to achieve net bacterial stasis as well as 1 - and 2 -log 
reductions in bacterial burden from Baseline across multiple E. coli isolates with 
gepotidacin MIC values ranging from 1 to 4  µg/mL, were 34.5, 41.3, and 49.7, 
respectively.  
A set  of duplicate 10 -day hollow fiber infection model studies was also completed using 
E. coli isolate NCTC [ZIP_CODE] to determine the fAUC/MIC exposure of gepotidacin 
required to prevent the amplification of a resistant subpopulation. An inverted -U shaped 
functio n described the relationship between drug resistance amplification and fAUC, with 
fAUC values ≥549 preventing resistance amplification to gepotidacin for E. coli in the 
hollow fiber infection model for 10 days. This equates to an fAUC/MIC value ≥275 when 
applying the gepotidacin broth microdilution MIC of 2 µg/mL for E. coli  [ZIP_CODE], as 
determined in this study.  
When taking the fAUC/MIC target of 275 for resistance suppression into consideration 
with the concentrations of gepotidacin in human urine measured in BTZ117351 
(minimum urine AUC12h=807  µg.h/mL; thus, minimum urine AUC over 24 hours 
[AUC24h]=1614  µg.h/mL) and applying an MIC value of 4  µg/mL, the minimum human 
urine AUC/MIC achieved for the 1500 mg oral BID dose exceeds the fAUC/MIC 
resistance suppre ssion target of 275 by [CONTACT_3450] 1.5 -fold and 100% target 
attainment for a urine  AUC/MIC target of 275 would be expected for participants with 
E. coli isolates with gepotidacin MICs ≤4 µg/mL following 1500 mg BID oral dosing.   
When applying the higher concentrations of gepotidacin in human urine measured in the 
Phase IIa study (206899; minimum urine AUC12h=2256  µg.h/mL; thus, 
TMF-13817737  CONFIDENTIAL   
  212390  
 40 
 AUC24h=4512  µg.h/mL) and applying a MIC value of 4  µg/mL, the minimum human 
urine AUC/MIC achieved for the 1500 mg oral BID dose further exceeds the fAUC/MIC 
resistance suppression target of 275 by [CONTACT_3450] 4 -fold and 100% target attainment 
for a urine AUC/MIC target of 275 would also be expected for participants with E. coli 
isolates with gepotidacin MICs ≤4 µg/mL following 15 00 mg BID oral dosing.  
Additionally, in the Phase IIa study (206899), for 4 participants with available urine 
AUC24h steady -state PK parameters and qualifying Enterobacterales uropathogens who 
were microbiological successes at TOC, the plasma fAUC24h/MIC v alues ranged from 7 
to 90.5 and urine AUC24h/MIC ratios ranged from [ADDRESS_1042178] plasma fAUC/MIC (7.0) and urine AUC/MIC (1292) had a K. pneumoniae 
uropathogen with a gepotidacin MIC of 4  µg/mL . No participants had an ou tcome of 
microbiological persistence at TOC.  
In conclusion, minimum urine levels of gepotidacin are anticipated to be in excess of the 
fAUC/MIC target necessary for both efficacy and resistance suppression for E. coli as 
determined from the in vitro  PK/PD models. Given that the bladder is the primary site of 
infection in cystitis, the use of gepotidacin urine PK data, coupled with the robust in vivo  
efficacy demonstrated in the Phase IIa uncomplicated UTI study and human simulated 
PK pyelonephritis model, i s appropriate for selecting  the gepotidacin 1500 mg BID oral 
dose for 5 days for study in the treatment of participants with acute cystitis.  
In addition, a PK evaluation (Study 209611) in healthy adult and adolescent participants 
has been completed ( see Section  5 of the IB for further details). Overall, plasma Cmax 
values were 27% higher in adolescents; however, the range of Cmax values were similar, 
and AUC(0 -∞) values were similar for adults and adolescents following a [ADDRESS_1042179] of two 3000  mg gepotidacin doses 6  hours apart, 
Cmax values were 29% higher in adolescents; however, the ranges of Cmax values were 
similar, and following the second dose for adults and adolescents Cmax values were 
similar. The AUC(0 -τ) was approximately 35% higher in adolescents following both 
doses compared to adults. The total amount of gepotidacin excreted in urine was similar 
in adult and adolescent participants following a 1500 -mg single gepotidacin dose. 
Following two 3000 mg g epotidacin doses given 6 hours apart, the total amount excreted 
was approximately 35% higher in adolescents compared to adults. The maximum dose of 
gepotidacin evaluated in adolescents was 3000 mg given as 2 doses 6  hours apart. Across 
the age groups, the safety -risk profile was similar.  
The oral nitrofurantoin dose in this study is 100 mg BID (total daily dose of 200 mg) for 
5 days. This oral dose and duration of nitrofurantoin is within the prescribed labeling 
recommendations, which is 100 mg BID for up t o 7 days for adults and pediatric patients 
over 12 years of age (refer to locally approved prescribing information). The labeled 
7-day dosing duration of nitrofurantoin was based on clinical registration studies from 
several decades ago. More recently, a 5 -day dosing duration of nitrofurantoin was shown 
to be efficacious for the treatment of uncomplicated acute cystitis in women [ Gupta , 
2007] and a treatment duration of <7 da ys for nitrofurantoin is in alignment with current 
treatment guidelines [ Gupta , 2011b; NICE , 2019; EAU , 2019].  
TMF-[ADDRESS_1042180] participant in the 
study.  
5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
Otherwise healthy participants are eligible to be included in the study on ly if all of the 
following criteria apply:  
Age  
1. The participant is ≥12 years of age at the time of signing the informed consent/assent 
and has a body weight ≥40 kg.  
Note :  Although participants as young as [ADDRESS_1042181]  follow their institutional ethics committee and local country/national regulatory 
guidelines and enrollment will be contingent upon such approvals regarding the 
allowed lower age limit for clinical study participants.  
Type of Participant and Disease Char acteristics  
2. The participant has 2 or more of the following clinical signs and symptoms of acute 
cystitis with onset <96 hours prior to study entry: dysuria, frequency, urgency, or 
lower abdominal pain (see Appendix  6). 
3. The participant has nitrite or pyuria (>15 WBC/HPF or the presence of 3+/large 
leukocyte esterase) from a pretreatment clean -catch midstream urine sample based 
on local laboratory procedures.  
Sex 
4. The participant is female.  
Contraceptive use should be consistent with local regulations regarding the methods of 
contraception for those participating in clinical studies.  
• A female participant is eligible to participate if she is a woman of childbea ring 
potential (WOCBP) who is not pregnant as confirmed by a high sensitivity urine 
pregnancy test at Baseline (Day 1) regardless of current or prior contraception 
use or abstinence , is not breastfeeding, or is not a WOCBP.  
TMF-13817737  CONFIDENTIAL   
  212390  
 42 
 Note:   Pregnancy testing requir ements, contraceptive guidance, and WOCBP 
definitions are provided in Appendix 2  and requirements for pregnancy testing 
during and after stud y treatment are located in Appendix 8 . 
• Additional requirements for pregnancy testing during and after study treatment are 
located in Appendix 8 . 
• The investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.  
Informed  Consent  
5. The participant is capable of giving signed informed consent/assent as described in 
Appendix 3  which includes compliance with the requirements and restrictions listed 
in the informed consent form (ICF)/assent form and in this protocol.  
5.2. Exclusion Criteria  
Participants are excluded from t he study if any of the following criteria apply:  
Medical Conditions  
1. The participant resides in a nursing home or dependent care type -facility.  
2. The participant has a body mass index ≥40.0 kg/m2 or a body mass index 
≥35.0  kg/m2 and is experiencing obesity -related health conditions such as 
uncontrolled high blood pressure or uncontrolled diabetes.  
3. The participant has a history of sensitivity to the study treatments, or components 
thereof, or a history of a drug or other allergy that, in the opi[INVESTIGATOR_760967], contraindicates her participation.  
4. The participant is immunocompromised or has altered immune defenses that may 
predispose the participant to a higher risk of treatment failure and/or complications 
(e.g., uncontrolled diabete s, renal transplant recipi[INVESTIGATOR_840], participants with clinically 
significant persistent granulocytopenia [absolute neutrophil count <1000/µL], and 
participants receiving immunosuppressive therapy, including corticosteroid therapy 
[>40 mg/day prednisolone or eq uivalent for >1 week, ≥20  mg/day prednisolone or 
equivalent for >2 weeks, or prednisolone or equivalent ≥10 mg/day for >6  weeks]). 
Participants with a known CD4 count of <200 cells/mm3 should not be enrolled.  
5. The participant has any of the following:  
• Medic al condition that requires medication that may be impacted by 
[CONTACT_760992], such as:  
• Poorly controlled asthma or chronic obstructive pulmonary disease at 
Baseline and, in the opi[INVESTIGATOR_871], not stable on current 
therapy  
• Acute severe pain, uncontrolled with conventional medical management  
• Active peptic ulcer disease  
TMF-13817737  CONFIDENTIAL   
  212390  
 43 
 • Parkinson disease  
• Myasthenia gravis  
• A history of seizure disorder requiring medications for control (this does 
not include a history of childhood febrile seizu res) 
OR 
• Known acute porphyria  
• Any surgical or medical condition (active or chronic) that may interfere with 
drug absorption, distribution, metabolism, or excretion of the study treatment 
(e.g., ileostomy or malabsorption syndrome)  
6. The participant has a kno wn glucose -6-phosphate dehydrogenase deficiency.  
7. The participant, in the judgment of the investigator, would not be able or willing to 
comply with the protocol or complete study follow -up. 
8. The participant has a serious underlying disease that could be immi nently life -
threatening, or the participant is unlikely to survive for the duration of the study 
period.  
Urinary Tract Infection/Renal/Urogenital Exclusions  
9. The participant has acute cystitis that is known or suspected to be due to fungal, 
parasitic, or viral pathogens; or known or suspected to be due to Pseudomonas 
aeruginosa or Enterobacterales (other than E. coli ) as the contributing pathogen.  
10. The participa nt has symptoms known or suspected to be caused by [CONTACT_126714], such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, 
or chronic interstitial cystitis, that may interfere with the clinical efficacy 
assessments or preclude complete resolution of acute cystitis symptoms.  
11. The participant has an anatomical or physiological anomaly that predisposes the 
participant to UTIs or may be a source of persistent bacterial colonization, including 
calculi, obstruction or stricture of the urinary tract, primary renal disease (e.g., 
polycystic renal disease), or neurogenic bladder, or the participant has a history of 
anatomical or functional abnormalities of the urinary tract (e.g., chronic 
vesico -ureteral reflux, detrusor insufficiency).  
12. The participant has an indwelling catheter, nephrostomy, ureter stent, or other 
foreign material in the urinary tract.  
13. The participant who, in the opi[INVESTIGATOR_871], has an otherwise complicated 
UTI, an active upper UTI (e.g., pyelonephritis, urose psis), signs and symptom onset 
≥96 hours before study entry, or a temperature ≥101.4°F (≥38°C), flank pain, chills, 
or any other manifestations suggestive of upper UTI.  
14. The participant has known anuria, oliguria, or significant impairment of renal 
function  (creatinine clearance <60 mL/min or clinically significant elevated serum 
creatinine as determined by [CONTACT_093]).  
15. The participant presents with vaginal discharge at Baseline (e.g., suspected sexually 
transmitted disease).  
TMF-13817737  CONFIDENTIAL   
  212390  
 44 
 Cardiac Exclusions  
16. The par ticipant has congenital long QT syndrome or known prolongation of the 
corrected QT (QTc) interval.  
17. The participant has uncompensated heart failure.  
18. The participant has severe left ventricular hypertrophy.  
19. The participant has a family history of QT prolonga tion or sudden death.  
20. The participant has a recent history of vasovagal syncope or epi[INVESTIGATOR_760968] 12 months.  
21. The participant is taking QT -prolonging drugs or drugs known to increase the risk of 
torsa des de pointes (TdP) per the www.crediblemeds.org. “Known Risk of TdP” 
category at the time of her Baseline Visit, which cannot be safely discontinued from 
the Baseline Visit to the TOC Visit; or the participant is taking a strong 
cytochrome  P450 enzyme 3A 4 (CYP3A4) inhibitor.  
Cardiac ECG Exclusions  
22. For any participant ≥12 to <18 years of age, the participant has an abnormal ECG 
reading at Baseline or during the study treatment.  
23. The participant has a QTc >450 msec or a QTc >480 msec for participants with 
bundle -branch block.  
Note : 
• The QTc is the QT interval corrected for heart rate according to either 
Bazett’s formula (QTcB), or Fridericia’s (QTcF) formula, and/or another 
method. It is either machine read or manually overread.  
• The specific formula used t o determine eligibility and discontinuation for an 
individual participant should be determined prior to initiation of the study. In 
other words, several different formulas cannot be used to calculate the QTc 
for an individual participant and then the lowes t QTc value used to include or 
discontinue the participant from the trial.  
24. The participant has a documented or recent history of uncorrected hypokalemia 
within the past 3  months.  
Hepatic Exclusions  
25. The participant has a known alanine aminotransferase (ALT)  value >2 × upper limit 
of normal (ULN).  
26. The participant has a known bilirubin value >1.5 × ULN (isolated bilirubin >1.5 × 
ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).  
27. The participant has cirrhosis or current unstable liver or  biliary disease per 
investigator assessment defined by [CONTACT_31816], encephalopathy, 
coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent 
jaundice.  
TMF-13817737  CONFIDENTIAL   
  212390  
 45 
 Note :  Stable noncirrhotic chronic liver disease (including Gilbert’s syndrome, 
asymptomatic gallstones, and chronic stable hepatitis B or C [e.g., presence of 
hepatitis B surface antigen or positive hepatitis C antibody test result]) is acceptable 
if the participant otherwise meets entry criteria.  
28. The participant has a prev ious history of cholestatic jaundice/hepatic dysfunction 
associated with nitrofurantoin.  
Prior Antibiotic/Antifungal Use Exclusion  
29. The participant has received treatment with other systemic antimicrobials or 
systemic antifungals within 1 week before study entry.  
Concomitant Medication Use Exclusion  
30. The participant plans to use any of the prohibited medications or nondrug therapi[INVESTIGATOR_760969] 6.5.2 . 
Prior/Concurrent Clinical Study Experience  
31. The participant has been previously enrolled in this study or has previously been 
treated with gepotidacin.  
32. The participant has participated in a clinical trial and has received an investigational 
product within 30 days or 5 half -lives, whichever is longer.  
5.3. Lifestyle Considerations  
Participants will be requested to abstain from sexual activity from the Baseline Visit 
through the TOC Visit to prevent possible re -infection.  
5.3.1.  Meals and Dietary Restrictions  
Study treatment should be taken after food consumption (a meal or a snack) and with 
water (see Section 6.1). 
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study 
but are not subsequently randomized. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet th e 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes 
demography, screen failure details, eligibility criteria, any protocol deviations and any 
SAE s. 
Participants who are screen failures are allowed to be rescreened for the same infection 
epi[INVESTIGATOR_17114] a subsequent infection epi[INVESTIGATOR_760970].  
TMF-13817737  CONFIDENTIAL   
  212390  
 46 
 6. STUDY TREATMENT  
Study treatment is defined as any investigational treatment(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according 
to the study protocol.  
6.1. Study Treatments Administered  
All doses of study treatment should always be taken after food consumption and with 
water. Participants will receive oral study treatment (gepotidacin [2 tablets] + 
nitrofurantoin matching placebo [1 capsule] or nitrofurantoin [1  capsule] + gepotidacin 
matching placebo [2 tablets]) BID (approximately every 12 hours) for 5 days.  
• The first oral dose will be administered at the study site during the Baseline Visit; 
participants will self -administer subsequent doses as outpatients thereafter.  
• At the On -therapy Visit, whenever it is possible, the participa nt will have the 
pregnancy test performed at the study site. If the visit coincides with the 8th dose, the 
participant will take their next dose of study treatment at the study site after negative 
pregnancy test results are confirmed.  
• Before the On -therapy  Visit, if the requirement for the single pregnancy test to be 
done between dose [ADDRESS_1042182] is negative, those participants will be instructed to take their next dose 
of study treatment at home via text or by [CONTACT_760993] r On-therapy Visit.  
 
Note:   The On -therapy Visit should be scheduled to support completion of the postdose 
ECG within the protocol -defined window. Also, in WOCBP, the high sensitivity 
pregnancy test must be performed and show negative results at the latest  before  Dose 8 of 
study treatment is taken.  
TMF-13817737  CONFIDENTIAL   
  212390  
 47 
 Study 
Treatment 
Name:  [CONTACT_126747]  
(Matched to 
Nitrofurantoin ) Nitrofurantoin  Placebo  
(Matched to 
Gepotidacin)  
Type:  Drug  Drug  Drug  Drug  
Dose 
Formulation:  Tablets containing 
gepotidacin and 
inactive formulation 
excipi[INVESTIGATOR_126661] -encapsulated 
unit-dose 
nitrofurantoin 
placebo -to-match 
capsule  Over -encapsulated 
capsules containing 
nitrofurantoin (25  mg 
nitrofurantoin 
macrocrystals and 
75 mg nitrofurantoin 
monohydrate) and 
inactive formulation 
excipi[INVESTIGATOR_126662]-dose 
gepotidacin 
placebo -to-match 
tablet  
Unit-Dose 
Strengths/  
Dosage Levels:  2 x 750 -mg tablets  Not applicable  1 x 100 -mg capsule  Not applicable  
Route of 
Administration:  Oral Oral Oral Oral 
Dosing 
Instructions:  Administer twice daily 
for 5 days:  
1500  mg – 2 tablets  
(3000  mg total daily 
dose)  
Each dose should be 
taken after food 
consumption and 
with water.  Administer twice daily 
for 5 days:  
1 capsule  
Each dose should be 
taken after food 
consumption and 
with water.  Administer twice daily 
for 5 day s: 
100 mg – 1 capsule  
(200 mg total daily 
dose)  
Each dose should be 
taken after food 
consumption and 
with water.  Administer twice daily 
for 5 days:  
2 tablets  
Each dose should be 
taken after food 
consumption and 
with water.  
Packaging and 
Labeling:  Gepotidacin tablets 
will be provided in 
bottles. Each bottle 
will be labeled as 
required per country 
requirement.  Placebo -to-match 
nitrofurantoin 
capsules will be 
over-encapsulated 
and provided in 
bottles. Each bottle 
will be labeled as 
required per countr y 
requirement.  Nitrofurantoin 
capsules will be 
over-encapsulated 
and provided in 
bottles. Each bottle 
will be labeled as 
required per country 
requirement.  Placebo -to-match 
gepotidacin tablets 
will be provided in 
bottles. Each bottle 
will be labeled as 
required per country 
requirement.  
Manufacturer:  Patheon Canada  
(part of Thermo 
Fisher Scientific)  Almac, LTD  
(Over -encapsulation 
by [CONTACT_126715], LTD)  Alvogen  
(Over -encapsulation 
by [CONTACT_126715], LTD)  Patheon Canada  
(part of Thermo 
Fisher Scientific)  
TMF-13817737  CONFIDENTIAL   
  212390  
 48 
 6.2. Preparation/Handling/Storage/Accountability  
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study treatment received and any discrepancies 
are reported and resolved before use of the study treatment.  
2. Only participants enrolled in the study may receive study treatment and only 
authorized site staff may supply or administer study treatment. All study treatments 
must be stored in a secure, environmentally controlled, and monitored (manual  or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.  
3. The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for study treat ment accountability, reconciliation, and record 
maintenance (i.e., receipt, reconciliation, and final disposition records).  
4. Further guidance and information for the final disposition of unused study treatment 
are provided in the SRM.  
Under normal conditions of handling and administration, study treatment is not expected 
to pose significant safety risks to site staff . 
A Material Safety Data Sheet or equivalent document describing occupational hazards 
and recommended handling precautions either will be provided to the investigator, where 
this is required by [CONTACT_1207], or is available upon request from [COMPANY_004].  
6.3. Measures to Minimize Bias: Randomization and Blinding  
Participants will be stratified by [CONTACT_67579] (<18 years, ≥18 to 50 years, or >50 years) 
and acute cystitis recurrence (nonrecurrent infection or recurrent infection, defined as a 
confirmed infection [not including the current infection in the calculation] with at least 
[ADDRESS_1042183] 12 months before study entry). 
Participants will be centrally randomized in a 1:1 ratio to either gepotidacin + matching 
nitrofurantoin placebo or nitrofurantoin + matching gepotidacin placebo . All participants 
will be centrally randomized using interactive response technology (IRT). Before the 
study is initiated, information and directions for the IRT will be provided to each study 
site. 
Study treatment will be dispensed at the study visits su mmarized in Section  1.3. 
Returned study treatment should not be re -dispensed to other participants.  
This is a double -blind, double -dummy study. The study treatment tak en during the study 
will be double -blind. Neither the participant nor study personnel (i.e., investigators, [COMPANY_004], 
[COMPANY_003] [full service partner]) will know which study treatment a participant is receiving. In 
order to maintain study treatment blinding, particip ants will receive, in addition to their 
randomized active treatment (gepotidacin or nitrofurantoin), a matching placebo form of 
the active treatment to which they were not assigned. The matching placebos will look 
identical to the active form.  
TMF-13817737  CONFIDENTIAL   
  212390  
 49 
 The IRT will  be programmed with blind -breaking instructions. In case of an emergency, 
the investigator has the sole responsibility for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety must always be the first 
considera tion in making such a determination. If the investigator decides that unblinding 
is warranted, the investigator should make every effort to contact [CONTACT_23983]/[COMPANY_003] prior to 
unblinding a participant’s treatment assignment unless this could delay emergency 
treatment  of the participant. If a participant’s treatment assignment is unblinded 
[COMPANY_004]/[COMPANY_003] must be notified within [ADDRESS_1042184] be recorded in the source documentation and electronic 
case repo rt form ( eCRF), as applicable.  
A participant may continue in the study if that participant’s treatment is unblinded 
provided that there are no safety concerns for the participant per the investigator’s 
judgement.  
The [COMPANY_004] SRT, which will monitor safety data  instream, will remain blinded to 
participant treatment assignment throughout the study (see Appendix 3 ). A Microbiology 
Review Team will monitor blinde d pathogen identification and susceptibility data 
instream as well as the number of participants eligible for the micro -ITT Population. 
Blinded monitoring of pathogens will be conducted, to determine whether end -of-study 
targets are likely to be achieved. Provision will be made for a limited degree of 
unblinding of a minority of participant sample data should this be viewed as appropriate 
for planning closure of trial enrollment. Procedures will be described in a separate 
microbiology sample monitoring plan , and no impact on trial integrity is expected.  
The IDMC and Statistical Data Analysis Center (SDAC) will be unblinded for the IA 
(Section 9.5). The IDMC details wil l be described in a separate charter and analysis plan. 
The [COMPANY_004] and [COMPANY_003] study teams that are operating the study and conducting the final 
analysis will remain blinded.  
[COMPANY_004]’s Global Clinical Safety and Pharmacovigilance staff may unblind the treatment 
assig nment for any participant with an SAE. If the SAE requires that an expedited 
regulatory report be sent to one or more regulatory agencies, a copy of the report, 
identifying the participant’s treatment assignment, may be sent to investigators in 
accordance with local regulations and/or [COMPANY_004] policy.  
6.4. Study Treatment Compliance  
• When participants are dosed at the study site during the Baseline and On -therapy 
Visits, they will take their study treatment when directed by [CONTACT_170270], under medical supervision. The date and time of each dose administered at 
the study site will be recorded in the source documents. The dose of study treatment 
and study participant identification will be confirmed at the time of dosing by a 
member of the study site staf f other than the person administering the study treatment.  
• When participants self -administer study treatment as outpatients, compliance with 
gepotidacin, nitrofurantoin placebo, nitrofurantoin, and gepotidacin placebo will be 
assessed through querying the  participant during the study site visits and documented 
in the source documents and eCRF. A record of the number of gepotidacin and 
TMF-[ADDRESS_1042185] be maintained and reconciled with 
study treatment and compliance records. Study treatment start and stop dates, 
including dates for study treatment delays, will also be recorded in the eCRF.  
6.5. Concomitant Therapy  
Any medication or vaccine (includi ng over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving within [ADDRESS_1042186] be recorded in the 
eCRF along with the following:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage inform ation including dose and frequency  
The medical monitor should be contact[CONTACT_61519].  
6.5.1.  Permitted Medications and Nondrug Therapi[INVESTIGATOR_126663] H 1 antihistaminics not associated with QT prolongation is allowed (e.g., 
loratadine, cetirizine, ebastine, and fexofenadine). The use of topi[INVESTIGATOR_2855], nonsystemic 
antibacterials (e.g., topi[INVESTIGATOR_47288], neomycin, or polymyxin) and topi[INVESTIGATOR_2855], 
nonsystemic antifung als (e.g., topi[INVESTIGATOR_760971], tolnaftate, or ketoconazole) is allowed 
throughout the study. Please also refer to Appendix  9. 
Acetaminophen or paracetamol use is permitted throughout the study as it does not mask 
symptoms of the disease under study. A list of permitted medications commonly used for 
nausea, vomiting, pain, and diarrhea per investigator discretion is provided in 
Appendix  9. As described in Appendix  9, low -dose acetylsalicylic ac id (≤100 mg/day) is 
permitted for the prevention of cardiovascular (CV) disease events.  
A further detailed list of medications will be provided in the SRM.  
6.5.2.  Prohibited Medications and Nondrug Therapi[INVESTIGATOR_126664]/or during the study from  the Baseline Visit through the 
TOC Visit, the participant is prohibited from use of the following medications and 
nondrug therapi[INVESTIGATOR_014]:  
• An investigational product within 30 days or 5 half -lives, whichever is longer, of the 
Baseline Visit.  
• Treatment with othe r systemic antimicrobials (e.g., oral ciprofloxacin, 
amoxicillin/clavulanate, cephalexin, or doxycycline) or systemic antifungals (e.g., 
oral fluconazole, itraconazole, or terbinafine) within [ADDRESS_1042187] been completed.  
• Immunosuppressive therapy, including corticosteroid therapy (>40 mg/day 
prednisolone or equivalent for >1 week, ≥20 mg/day prednisol one or equivalent for 
>2 weeks, or prednisolone or equivalent ≥10 mg/day for >6 weeks).  
• QT-prolonging drugs or drugs with known TdP risk, per the www.crediblemeds.org 
“Known Risk of TdP” category, at the time of their Baseline Visit, which cannot be 
safely  discontinued from the Baseline Visit to the TOC Visit. Details regarding 
website access are provided in the SRM; additional guidance is provided in 
Appendix  9. Of note, ondansetron is not allowed from the Baseline Visit to the TOC 
Visit due to its known TdP risk. Alternative antiemetics that are permitted per 
investigator discretion are listed in Appendix  9.  
Note :  Crediblemeds.org categorizes drugs into 4 categories. The only category for 
exclusion in this study is the “Known Risk of TdP” category; participants taking 
drugs that meet criteria of other categories are N OT excluded from participation.  
• Strong CYP3A4 inhibitors (a list of strong CYP3A4 inhibitors is provided in the 
SRM) . 
• St John’s wort or other strong CYP3A4 inducers are not permitted from 14 days 
before study entry through the TOC Visit (a list is provided  in the SRM).  
• Prescription, nonprescription, or supplements that may impact UTI clinical or 
microbiological efficacy outcomes including, but not limited to, Uva ursi , 
D-mannose, cranberry tablets, phenazopyridine, nonsteroidal anti -inflammatory 
drugs inclu ding ibuprofen and cyclooxygenase -2 inhibitors, and uricosuric drugs 
(e.g., probenecid and sulfinpyrazone). As described in Appendix  9, acetylsalicylic 
acid (doses >100 mg/day) is not permitted.  
In addition, antacid preparations containing magnesium trisilicate are prohibited from the 
start of study treatment at the Base line Visit throughout the completion of the dosing 
period (i.e., until all [ADDRESS_1042188] been received).  
Due to the gepotidacin’s property of acetylcholinesterase inhibition, the concomitant use 
of succinylcholine or other nondepolarizin g paralytic agents is also prohibited. Caution 
should be used in participants who have a condition requiring medication that may 
exacerbate the inhibition of acetylcholinesterase, or neuromuscular blocking agents.  
6.6. Dose Modification  
The study design does no t allow for dose modifications.  
6.7. Treatment after the End of the Study  
Participants will not receive any additional treatment from [COMPANY_004] after they discontinue or 
complete the study (i.e., after the Follow -up Visit). Participants experiencing signs and 
symptom s suggestive of infection recurrence or relapse at the Follow -up Visit will be 
assessed and treated per the investigator’s judgement.  
TMF-13817737  CONFIDENTIAL   
  212390  
 52 
 7. DISCONTINUATION OF S TUDY TREATMENT AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Treatment  
In rare i nstances, it may be necessary for a participant to permanently discontinue 
(definitive discontinuation)  study treatment. If study treatment is definitively 
discontinued, the participant will remain in the study to be evaluated for safety and 
efficacy. See the SoA (Section  1.3) for data to be collected at the time of discontinuation 
of study treatment and follow -up and for any further evaluations that need to be 
completed . 
Participants may voluntarily discontinue study treatment at any time. The investigator 
may also, at his or her discretion, discontinue the participant from study treatment at any 
time and initiate appropriate alternative therapy.  
Reasons for study treatm ent discontinuation may include the following:  
• Adverse event  
• Protocol deviation  
• Termination of the study by [CONTACT_23983]  
• Investigator discretion  
• Lack of efficacy  
Note :  Pathogen identification or in vitro resistance of recovered uropathogens is not 
a reason for study treatment discontinuation.  
The reason for study treatment discontinuation will be recorded in the eCRF. Participants 
who discontinue study treatment for the reasons above will not be considered withdrawn 
from the study and should attend all subsequen t study visits (see Section  1.3). 
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_97175], and increased monitoring criteria  have been designed to 
assure participan t safety and evaluate liver event etiology.  
Discontinuation of study treatment for abnormal liver tests is required when:  
• a participant meets one of the conditions outlined in Algorithm A  or Algorithm B . 
• when in the presence of abnormal liver chemistries not meeting protocol -specifi ed 
stoppi[INVESTIGATOR_004], the investigator believes study treatment discontinuation is in the 
best interest of the participant.  
TMF-13817737  CONFIDENTIAL   
  212390  
 53 
 Algorithm A: Phase III Liver Chemistry Stoppi[INVESTIGATOR_760972]: ALT = alanine transaminase; INR = international normalized ratio; SAE = serious adverse event; ULN = 
upper limit of normal.  
Refer to Appendix 10  for required Liver Safety Actions and Follow -up Assess ments.  

TMF-13817737  CONFIDENTIAL   
  212390  
 54 
 Algorithm B: Phase III Liver Chemistry Increased Monitoring Algorithm with 
Continued Therapy for ALT 3 × ULN but <8 × ULN  
 
Abbreviations: ALT = alanine transaminase; bili = bilirubin; INR = international normalized ratio; SAE = serious adverse 
event; ULN = upper limit of normal.  
Refer to Appendix 10  for required Liver Safety Actions and Follow -up Assessments.  
7.1.2.  QTc Stoppi[INVESTIGATOR_2121]  
A participant who meets the bulleted criteria based on the average of triplicate ECG 
readings will be withdrawn from study treatment:  
• QTc >500 msec OR Uncorrected  QT >600 msec  
• Change from baseline of QTc >60 msec  
For patients with underlying bundle branch block, follow the discontinuation criteria 
listed below:  
Baseline QTc with Bundle 
Branch -Block  Discontinuation QTc with 
Bundle -Branch Block  
<450 msec  >500 msec  
450 to 480 msec  ≥530 msec  
 

TMF-13817737  CONFIDENTIAL   
  212390  
 55 
 • The same  QT correction formula must  be used for each individual pa rticipant  to 
determine eligibility for and discontinuation from the study. This formula may not be 
changed or substituted once the participant has been enrolled. (Note: Ideally, all 
ECGs for a participant should be performed with the same ECG machine.)  
• For example, if a participant is eligible for the protocol based on QTcB, then 
QTcB must be used for discontinuation of this individual participant as well.  
• Once the QT correction formula has been chosen for a participant’s eligibility, 
the same formula  must continue to be used for that participant for all QTc data 
being collected for data analysis . Safety ECGs and other nonprotocol -specified 
ECGs are an exception.  
• The QTc should be based on the average of triplicate ECG readings obtained over a 
brief ( e.g., 5 - to 10 -minute) recording period.  
7.1.3.  Rechallenge  
[IP_ADDRESS].  Study Treatment Restart or Rechallenge After Liver Stoppi[INVESTIGATOR_760973].  
7.1.4.  Gastrointestinal Evaluation Criteria  
If a participant meets the criteria in Appendix [ADDRESS_1042189] (Section  8.3.7 ). 
7.2. Participant Discontinuation/Withdrawal from the Study  
• A participant may withdraw from the study at any time at her own request or may be 
withdrawn at any time at the discretion of the investiga tor for safety, behavioral, 
compliance, or administrative reasons.  
• Reasons for study withdrawal include:  
• Participant lost to follow -up 
• Participant withdrew consent  
• Termination of the study by [CONTACT_23983]  
• Investigator discretion  
• If the participant withdraws consent  for disclosure of future information, the sponsor 
may retain and continue to use any data collected before such a withdrawal of 
consent.  
• If a participant withdraws from the study, she may request destruction of any 
samples taken and not tested, and the in vestigator must document this in the site 
study records.  
TMF-13817737  CONFIDENTIAL   
  212390  
 56 
 • At the time of discontinuing from the study, if possible, an early withdrawal visit 
should be conducted, as shown in the SoA (Section  1.3). See the SoA for data to be 
collected at the time of study discontinuation and follow -up and for any further 
evaluations that need to be completed.  
The reason for participant withdrawal will be recorded in the eCRF. Participants  who are 
withdrawn from the study should return to the study site and have the microbiological 
and clinical outcomes assessed at the time of withdrawal (see the SoA in Section  1.3), if 
data permit, and return all unused study treatment. Data from these participants will be 
considered evaluable up to the point at which they are withdrawn, using the same criteria 
for evaluability as for participants who complete the study . 
7.3. Lost to Follow -Up 
A participant  will be considered lost to follow -up if she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  
The following actions must be taken if a participant fails to return to the stud y site for a 
required study visit:  
• The study site must attempt to contact [CONTACT_126718]/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee 
must make every effort to regain contact [CONTACT_6635] (where possible, 
3 telephone calls and, if neces sary, a certified letter to the participant’s last 
known mailing address or local equivalent methods). These contact [CONTACT_78779]’s medical record.  
• Should the participant continue to be unreachable, she will be considere d to 
have withdrawn from the study with a primary reason of lost to follow -up.  
Discontinuation of specific sites or of the study as a whole are handled as part of 
Appendix 3 . 
8. STUDY ASSESSMENTS AN D PROCEDURES  
• Study procedures and their timing are summarized in the SoA (Section  1.3).  
• Protocol waivers or exemptions are not allowed.  
• Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the participant shoul d continue or 
discontinue study treatment.  
• Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.  
• All baseline screening evaluations must be completed and reviewed to confirm that 
potential participants meet all eligibility criteria. The investigator will maintain a 
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 5 7  
 scree ni n g l o g t o rec or d details of all partici pa nts s cree n e d a n d t o c o nfir m eli gi bilit y 
or rec or d reas o ns f or s cree ni n g fail ure, as a p plica ble.  
• Pr oce d ures c o n d ucte d as part  of t he partici pa nt’s r o uti ne cli nical ma na ge m e nt (e. g., 
bl o o d c o u nt) a n d o btai ne d bef ore si g ni n g of I C F ma y b e utilize d f or scree ni n g or 
baseli ne p ur p oses pr o vi de d t he pr oce d ure m et t he pr ot oc ol -s pecifi e d criteria a n d was 
perf or me d wit hi n t he ti me fra m e d efi ne d i n t he S o A.  
• Prescree ni n g acti vities ma y b e c o n d u cte d, i ncl u di n g a prescree ni n g i nf or me d c o nse nt 
a n d uri ne testi n g, as f urt h er detaile d i n t he S R M. T he re q uir e d baseli ne uri ne 
s peci me n ma y be c ollect e d as part of a n o pti o nal prescree ni n g pr ocess, if n ot alrea d y 
part of sta n dar d of care, a n d is f urt her detaile d i n t he S R M. T his s peci me n ca n be 
use d f or t he re q uire d b as eli ne pr oce d ures of t h e dia g n osis of pres u m pti ve ac ute 
c ystitis a n d pre g n a nc y testi n g.  
• T he ma xi m u m a m o u nt of bl o o d c ollecte d fr o m eac h p artici pa nt o ver t h e d urati o n of 
t he st u d y, i ncl u di n g a n y e xtra assess me nts t hat ma y b e re q uire d, will n ot e x cee d 
2 0 0  m L.  
• Re peat or u nsc h e d ule d sa m ples ma y be t a ke n f or s afet y reas o ns or f or tec h nical 
iss ues wit h t he sa m ples.  
• Partici pa nts ma y ret ur n t o t he st u d y site at a n y ti me d ue t o A Es or if t he y are 
e x perie nci n g n e w or c o nti n ui n g si g ns a n d s y m pt o ms of ac ute c ystitis. Partici pa nts 
will be assesse d a n d tr eat e d per t he i n vesti gat or’s j u d ge m e nt. If a p artici pa nt is 
s witc he d t o a differe nt a nti bi otic bef ore or d uri n g t he T O C Visit, all T O C pr oce d ures 
s h o ul d be c o m plete d bef ore t he ot her a nti bi otic is starte d.  
• Eac h treat me nt da y will be assesse d o v er [ADDRESS_1042190] u d y visits:  
N ote:  F or all st u d y visits, t o mi ni mize t he a m o u nt of ti me t hat partici pa nts s pe n d at 
t he cli nic, e C o nse nt ma y be utilize d a n d re m ote c ollecti o n of st u d y -relate d data ma y 
be o btai ne d as des cri be d i n t he S R M. T h us, s o me visit data ma y be c ollecte d t hr o u g h 
a c o m bi nati o n of tele me dici ne a n d o n -site visits. C ollecti o n of i nf or mati o n via 
tele me dici ne will be perf or me d o nl y w here l ocal r e g ul ati o ns per mit.  
• B aseli ne ( D a y 1) Visit : T he Baseli ne Visit will be perf or me d bef ore d osi n g o n 
Da y  1. Assess me nts will be perf or me d as s h o w n i n i n t he S o A ( Secti o n  1. 3 ), 
i ncl u di n g t he f oll o wi n g:  
• Pretreat me nt bas eli ne s peci me ns f or micr o bi ol o gic al testi n g will be c ollecte d, as 
descri be d i n Secti o n  8. 1. 1 . Cli nical si g ns a n d s y m pt o ms of ac ute c ystitis will be 
rec or de d, as des cri be d i n Secti o n  8. 1. 3. 1  a n d A p pe n di x  6.  
 
• F oll o wi n g c o m pleti o n of all pretreat me nt assess me nts, eli gi ble partici pa nts will 
be ra n d o ml y assi g ne d t o a st u d y tr eat me nt, a s des cri be d i n Secti o n 6. 3 . 
• T he first d ose of ra n d o ml y assi g ne d oral st u d y treat me nt  will be a d mi nistere d at 
t he st u d y site. After d ose a d mi nistrati o n, Da y [ADDRESS_1042191] u d y site, partici pa nts will self -a d mi nister d oses as o ut patie nts 
t hereafter, be gi n ni n g wit h t he sec o n d d ose. ( N ote: Eac h d ose s h o ul d be ta k e n 
after f o o d c o ns u m pti o n a n d wit h water.)  
• T he O n -t hera p y, T O C,  a n d F oll o w -u p Visits s h o ul d be sc he d ule d bef ore t h e 
partici pa nt lea v es t he st u d y site o n D a y 1 (as p er t he Sc he d ule of Acti vities 
Ta ble i n Secti o n  1. 3 ); t he pla n ne d ret ur n d a y/ti me s h o ul d be at t he c o n ve nie nce 
of t he partici pa nt a n d als o t he a vaila bilit y of t h e st u d y site staff.  
• O n -t her a p y ( D a y 2 t o 4) Visit : Partici pa nts will be i nstr ucte d t o ret ur n t o t he st u d y 
site [ADDRESS_1042192] u d y treat me nt  a d mi nistrati o n at Baseli ne i n or der t o 
c o m plete t he O n -t hera p y Visit. Assess me nts will be perf or me d as s h o w n i n t he S o A 
( Secti o n  1. 3 ), i ncl u di n g t he f oll o wi n g:  
• T he O n -t hera p y Visit will be prece de d b y a d o c u me nte d re mi n der c o ntact fr o m 
t he st u d y site t o t he parti ci pa nt 2 4  ± 4 h o urs bef ore t he sc he d ule d a p p oi nt me nt 
ti me per t he met h o d (e. g., te xt messa ge, tele p h o n e call, e -mail) c o nfir me d wit h 
t he st u d y site staff pri or t o de parti n g t he st u d y site o n Da y 1.  
• At t he O n -t hera p y Visit, w he ne ver it is p ossi ble, t he partici pa nt will ha ve t he 
pre g na nc y t est perf or me d at t he st u d y site. If t he visit c oi nci des wit h t he [ADDRESS_1042193] res ults are c o nfir me d.  
• Bef ore t he O n -t hera p y Visit, if t he re q uire me nt f or t he si n gle pre g na n c y test t o 
be d o ne bet w ee n d ose [ADDRESS_1042194] u d y site f or t h eir O n -t hera p y Visit.  
N ote:   T h e O n -t hera p y Visit s h o ul d be sc he d ule d t o s u p p ort c o m pleti o n  of t he 
p ost d ose E C G wit hi n t he pr ot oc ol -defi ne d wi n d o w. Als o, i n W O C B P, t he hi g h 
se nsiti vit y pre g na n c y test m ust be perf or me d a n d s h o w ne gati ve res ults at t he 
latest bef ore  D os e [ADDRESS_1042195] u d y treat me nt is ta ke n.  
• S peci me ns f or micr o bi ol o gic al testi n g will be c oll ecte d, as d escri be d i n 
Secti o n  8. 1 . Cli nical si g ns a n d s y m pt o ms of ac ute c ystitis will be rec or de d, as 
descri be d i n Secti o n  8. 1. 3. 1  a n d A p pe n di x  6.  
 
• Pre g n a nc y testi n g, as r e q uire d, after D ose 4 a n d b ef ore D ose 8. Refer t o 
A p pe n di x 8  f or details.  
• Partici pa nts will re mai n at t he st u d y site u ntil a p pr o xi mat el y [ADDRESS_1042196] d ose, as detaile d i n Secti o n 1. 3 . 
• T O C ( D a y 1 0 t o 1 3) Visit : Partici pa nts will be i nstr ucte d t o ret ur n t o t he st u d y site 
[ADDRESS_1042197] u d y tr eat me nt  i n or der t o c o m plete t h e T O C Visit. C CI 
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 5 9  
 Assess me nts will be perf or me d as s h o w n i n t he S o A ( Secti o n  1. 3 ), i ncl u di n g t he 
f oll o wi n g:  
• T he T O C Visit will be prece d e d b y a d oc u m e nte d re mi n der c o nt act fr o m t h e 
st u d y site t o t he partici pa nt 2 4  ± 4 h o urs bef ore t h e sc he d ule d a p p oi nt me nt ti me 
per t he met h o d (e. g., te xt messa ge, tele p h o n e call, e -mail) c o nfir me d wit h t he 
st u d y site staff pri or t o de parti n g t he st u d y site o n Da y 1.  
• S peci me ns f or micr o bi ol o gic al testi n g will be c oll ecte d, as d escri be d i n 
Secti o n  8. 1 . Cli nical si g ns a n d s y m pt o ms of ac ute c ystitis will be rec or de d, as 
descri be d i n Secti o n  8. 1. 3. 1  a n d A p pe n di x  6.  
 
 
• F oll o w -u p ( D a y 2 8 ± 3) Visit . Partici pa nts will be i nstr ucte d t o ret ur n t o t h e st u d y site 
2 8  ( ± 3)  da ys p ostra n d o miz ati o n i n or der t o c o m plete t he F oll o w -u p Visit. 
Assess me nts will be perf or me d as  s h o w n i n Secti o n  1. 3 , i ncl u di n g t he f oll o wi n g:  
• T he F oll o w -u p Visit will be prece de d b y a d oc u me nte d re mi n der c o ntact fr o m 
t he st u d y site t o t he parti c i pa nt 2 4  ± 4 h o urs bef ore t he sc he d ule d a p p oi nt me nt 
ti me per t he met h o d (e. g., te xt messa ge, tele p h o n e call, e -mail) c o nfir me d wit h 
t he st u d y site staff pri or t o de parti n g t he st u d y site o n Da y 1.  
• S peci me ns f or micr o bi ol o gic al testi n g will be c oll ecte d, as d escri be d i n 
Secti o n  8. 1 . Cli nical si g ns a n d s y m pt o ms of ac ute c ystitis will be rec or de d, as 
descri be d i n Secti o n  8. 1. 3. 1  a n d A p pe n di x  6.  
 
 
• Partici pa nts e x perie nci n g si g ns  a n d s y m pt o ms s u g gesti ve of i nfecti o n rec urre nce 
or rela pse will be assesse d a n d treate d p er t he i n v esti gat or’s j u d ge m e nt.  
8. 1.  Effi c a c y A s s e s s m e nt s  
8. 1. 1.  T h er a p e uti c R e s p o n s e E v al u ati o n  
T hera p e utic res p o nse (s u ccess/fail ure) is a me as ur e of t he o verall efficac y res p o nse. A 
t hera pe utic s u ccess r efers t o partici pa nts w h o ha ve bee n dee me d b ot h a “ mi cr o bi ol o gic al 
s uccess” (see Secti o n  8. 1. 2. 1 ) a n d a “cli nical s uc cess”  (see Secti o n  8. 1. 3. 1 ). All ot her 
c o m bi nati o ns ( ot her t ha n cli nical s uccess + micr o bi ol o gical s uc cess) will b e dee me d 
fail ures f or t h era p e utic res p o nse.  
T hera p e utic r es p o nse will be deter mi ne d b y statistical pr o gra m mi n g f or t h e T O C a n d 
F oll o w -u p Visits.  
T hera p e utic res p o nse at T O C is t he pri mar y effi cac y e n d p oi nt.  
8. 1. 2.  B a ct eri ol o g y S a m pl e s  
At t he Bas eli ne Visit, a pretreat me nt, clea n -cat c h mi dstrea m uri ne sa m ple m ust be 
o bt ai ne d fr o m all ra n d o miz e d partici pa nts f or Gra m stai n, q ua ntitati ve bacteri ol o gic al 
c ult ure, a n d i n vitr o a nti micr o bial s usce pti bilit y testi n g at a d esi g nate d ce ntral C CI 
C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 60 
 laboratory(ies). For inclusion in the micro -ITT Population, a baseline qualifying bacteri al 
uropathogen is required as defined in Appendix 4 ; for inclusion in the micro -ITT NTF -S 
Population, the baseline qualifying uropathogen must also be susceptible to 
nitrofurantoin . At the On -therapy, TOC, and Follow -up Visits, a clean -catch midstream 
urine sample will be obtained and sent to a designated central laboratory(ies) for Gram 
stain, quantitative bacteriological culture, and in vitro antimicro bial susceptibility testing. 
Identification and susceptibility testing of isolates recovered from urine specimens at all 
visits will also be conducted at a designated central laboratory(ies). Additional tests, as 
needed, to further characterize recovered i solates will also be performed by a designated 
central laboratory(ies). Instructions for sample collection, processing, and shipment are 
provided in the SRM and the laboratory manual. The study site should follow the 
Microbiology Procedures section of the laboratory manual to minimize potential 
contamination of the specimens.  
[IP_ADDRESS].  Microbiological Outcome and Response  
Only those participants who have a qualifying bacterial uropathogen (defined in 
Appendix 4 ) identified at Baseline will be evaluated for microbiological outcome and 
response by [CONTACT_760994]. The 
microbiological outcome and response to study treatment wil l be determined 
programatically for each participant/uropathogen prior to breaking of the study blind.  
The microbiological outcome by [CONTACT_760995] (see 
Table 2, Table 3, and Table 4 for baseline qualifying uropathogen outcomes). The 
corresponding microbiological response (success or failure) “by [CONTACT_126720]” is then 
assigned, as shown in Table 3 and Table 4. Participant -level microbiological response is a 
measure of the combined “by [CONTACT_126720]” res ponse(s). Participant -level microbiological 
success refers to participants who have been deemed a “microbiological success” for all 
of their “by [CONTACT_126720]” microbiological responses. All other combinations (other than 
all “microbiological successes”) are  deemed failures for participant -level microbiological 
response. The participant -level microbiological outcome and response definitions are 
provided in Table 5. 
Microbi ological outcome criteria for new qualifying uropathogens (i.e., uropathogens not 
identified at Baseline) are defined by [CONTACT_760996] 6, Table 7, and Table 8. 
TMF-13817737  CONFIDENTIAL   
  212390  
 61 
 Table 2 Microbiological Outcome by [CONTACT_760997]-Therapy Visit  
Defining Criteria  Outcome  
A quantitative urine culture taken at the 
On-therapy Visit  shows that the qualifying 
bacterial uropathogen recovered at Baseline is 
reduced to <103 CFU/mL, without the 
participant receiving other systemic 
antimicrobials before the On -therapy Visit  Microbiological eradication  
A quantitative urine culture taken at the 
On-therapy Visit  shows that the qualifying 
bacterial uropathogen recovered at Baseline 
grows 103 CFU/mL, without the participant 
receiving other systemic antimicrobials before 
the On -therapy Visit  Microbiological persistence  
1) The On -therapy urine culture result is 
missing, or  
2) The participant received other systemic 
antimicrobials before the On -therapy Visit  Unable to determine  
CFU=colony -forming units.  
 
TMF-[ADDRESS_1042198] -of-Cure Visit  
Defining Criteria  Outcome  Response  
Participants considered microbiological failures at the TOC Visit will also be considered 
microbiological failures at the Follow -up Visit.  
A quantitative urine culture taken at the TOC 
Visit shows reduction of the qualifying 
bacterial uropathogen recovered at Baseline 
to <103 CFU/mL, without the participant 
receiving other systemic antimicrobials 
before the TOC Visit  Microbiological 
eradication  Microbiological 
success  
A quantitative urine culture taken at the TOC 
Visit shows that the qualifying bacterial 
uropathogen recovered at Baseline, and 
which was also shown to persist or unable to 
determine at the On -therapy Visit, grows 
≥103 CFU/mL, without the participant 
receiving other systemic antimicrobials 
before the TOC Visit   Microbiological 
persistence  Microbiological failure  
A quantitative urine culture taken at the TOC 
Visit shows that the qualifying bacterial 
uropathogen recovered at Baseline, and 
which was also shown to be eradicated at 
the On -therapy Visit, grows ≥103 CFU/mL, 
without the participant receiving other 
systemic antimicrobials before the T OC Visit  Microbiological 
recurrence  Microbiological failure  
1) The TOC urine culture result is missing, 
or 
2) The participant received other systemic 
antimicrobials before the TOC Visit  Unable to determine  Microbiological failure  
CFU=colony -forming units; TOC= Test-of-Cure.  
 
TMF-13817737  CONFIDENTIAL   
  212390  
 63 
 Table 4 Microbiological Outcome and Response by [CONTACT_760998] -Up Visit  
Defining Criteria  Outcome  Response  
Participants considered microbiological failures at the TOC Visit will also be  considered 
microbiological failures at the Follow -up Visit.  
A quantitative urine culture taken at the 
Follow -up Visit  shows reduction of the qualifying 
bacterial uropathogen recovered at Baseline to 
<103 CFU/mL, following microbiological 
eradication at t he TOC Visit, without the 
participant receiving other systemic 
antimicrobials before the Follow -up Visit  Sustained 
microbiological 
eradication  Microbiological 
success  
A quantitative urine culture taken at the 
Follow -up Visit  shows that the qualifying 
bacterial uropathogen recovered at Baseline 
grows 103 CFU/mL, following microbiological 
eradication at the TOC Visit, without the 
participant receiving other systemic 
antimicrobials before the Follow -up Visit  Microbiological 
recurrence  Microbiological 
failure  
A quantitative urine culture taken at the 
Follow -up Visit  shows that the qualifying 
bacterial uropathogen recovered at Baseline 
grows 103 CFU/mL, and also did not achieve 
an outcome of microbiological eradication at the 
TOC Visit, without the participant receiving other 
systemic antimicrobials before the Follow -up 
Visit Microbiological 
persistence  Microbiological 
failure  
A quantitative urine culture taken at the 
Follow -up Visit  shows reduction of the qualifying 
bacterial u ropathogen recovered at Baseline to 
<103 CFU/mL, and also did not achieve an 
outcome of microbiological eradication at the 
TOC Visit, without the participant receiving other 
systemic antimicrobials before the Follow -up 
Visit Delayed 
microbiological 
eradication  Microbiological 
failure  
1) The Follow -up urine culture result is 
missing, or  
2) The participant received other systemic 
antimicrobials before the Follow -up Visit  Unable to determine  Microbiological 
failure  
CFU=colony -forming units; TOC=Test -of-Cure.  
 
TMF-[ADDRESS_1042199] an outcome 
of persistence or recurrence at Follow -up Delayed 
microbiological 
eradication  Microbiological 
failure  
All qualifying baseline uropathogen outcomes are unable to 
determine at Follow -up Unable to determine  Microbiological 
failure  
NA=Not applicable; TOC=Test -of-Cure.  
 
Table [ADDRESS_1042200]-of-Cure Visit  Colonization  
 
Table 8 Microbiological Outcome by [CONTACT_126725] -up Visit  
Defining Criteria  Outcome  
A new qualifying bacterial uropathogen , not 
identified at Baseline, is documented by 
[CONTACT_126726] -up Visit 
in a participant who did not achieve a clinical 
resolution at the Follow -up Visit  New infection  
A new qualifying bacterial uropathogen , not 
identified at Baseline, is documented by 
[CONTACT_126726] -up Visit 
in a participant who did a chieve a clinical 
resolution at the Follow -up Visit  Colonization  
 
8.1.3.  Clinical Evaluation  
[IP_ADDRESS].  Clinical Signs and Symptom Scores, Clinical Outcomes, and Clinical 
Response  
Clinical signs and symptoms of acute cystitis will be recorded based on participant 
interview per the SoA (Section  1.3) using the scoring system and instructions in 
Appendix  6. At Baseline, the participant must present with at least [ADDRESS_1042201] a total cumulative symptom score ≥2. At TOC, success is defined as normal 
presentation of signs an d symptoms with a total cumulative symptom score of zero and 
no new signs and symptoms of the infection under study.  
A study physician or otherwise appropriately medically trained staff will determine the 
individual clinical signs and symptoms scores for a cute cystitis ( Appendix  6) at the 
On-therapy, TOC, and Follow -up Visits. The same scorer will be used at all assessment 
TMF-13817737  CONFIDENTIAL   
  212390  
 66 
 time points for each participant, o n all occasions, whenever possible. The score will be 
used to programmatically determine the clinical outcome at the On -therapy Visit 
(Table  9) and the clinical outco me and response (success or failure) at the TOC Visit 
(Table 10) and the Follow -up Visit ( Table 11).  
Table  9 Clinical Outcome at the On -Therapy Visit  
Defining Criteria  Outcomea 
Resolution of signs and symptoms of acute 
cystitis present at Baseline (and no new signs 
and symptoms), without the participant 
receiving other systemic antimicrobials before 
the On -therapy Visit  Clinical resolution  
Improvement in total symptom scores from 
Baseline, but not complete resolution, without 
the participant receiving other systemic 
antimicrobials before the On -therapy V isit Clinical improvement  
Worsening or no change in total symptom 
scores from Baseline or the participant 
received other systemic antimicrobials for the 
current infection prior to or on the date of the 
On-therapy Visit  Clinical worsening  
1) The Baseline score is missing, or  
2) The On -therapy assessment is missing, or  
3) The participant received other systemic 
antimicrobials not for the current infection 
prior to the assessment (unless clinical 
worsening outcome criteria were met)  Unable to determine  
a. A study  physician or otherwise appropriately medically trained staff will determine the individual clinical signs 
and symptoms scores for acute cystitis ( Appendix  6), which will then be used to programmatically determine 
the clinical outcome. The same scorer will be used at all assessment time points for each participant, on all 
occasions, whenever possible.   
 
TMF-[ADDRESS_1042202] -of-Cure Visit  
Defining Criteria  Outcomea Response  
Resolution of signs and symptoms of 
acute cystitis present at Baseline (and no 
new signs or symptoms), without the 
participant receiving other systemic 
antimicrobi als before the TOC Visit  Clinical resolution  Clinical success  
Improvement in total symptom scores 
from Baseline, but not complete 
resolution, without the participant 
receiving other systemic antimicrobials 
before the TOC Visit  Clinical improvement  Clinical failure  
Worsening or no change in total symptom 
scores from Baseline or the participant 
received other systemic antimicrobials for 
the current infection before or on the date 
of the TOC Visit  Clinical worsening  Clinical failure  
1) The Baseline scor e is missing, or  
2) The TOC assessment is missing, or  
3) The participant received other 
systemic antimicrobials not for the 
current infection prior to the 
assessment (unless clinical 
worsening criteria were met)  Unable to determine  Clinical failure  
TOC = Test-of-Cure  
a. A study physician or otherwise appropriately medically trained staff will determine the individual clinical signs 
and symptoms scores for acute cystitis ( Appendix  6), which will then be used to programmatically determine 
the clinical outcome. The same scorer will be used at all assessment time points for each participant, on all 
occasions, whenever  possible.  
 
TMF-[ADDRESS_1042203] at the Follow -up Visit (and no  
new signs and symptoms), without the 
participant receiving other systemic 
antimicrobials before the Follow -up Visit  Sustained clinical resolution  Clinical success  
Resolution of signs and symptoms of 
acute cystitis present at Baseline (and no 
new signs or  symptoms), after clinical 
failure at TOC, without the participant 
receiving other systemic antimicrobials 
before the Follow -up Visit  Delayed clinical resolution  Clinical failure  
Improvement in total symptom scores 
from Baseline, but not complete 
resoluti on, without the participant 
receiving other systemic antimicrobials 
before the Follow -up Visit  Clinical improvement  Clinical failure  
Worsening or no change in total symptom 
scores at Follow -up compared to Baseline 
after clinical failure at TOC, or the 
participant received other systemic 
antimicrobials for the current infection 
before or on the date of the Follow -up 
Visit Clinical worsening  Clinical failure  
Signs and symptoms of acute cystitis 
reoccur at the Follow -up Visit after clinical 
success at TOC  Clinical recurrence  Clinical failure  
1) The Baseline score is missing, or  
2) The Follow -up assessment is missing, 
or 
3) The participant received other 
systemic antimicrobials not for the 
current infection prior to the 
assessment (unless the clinical 
worsening or recurrence outcome 
criteria were met)  Unable to determine  Clinical failure  
TOC = Test -of-Cure  
a. A study physician or otherwise appropriately medically trained staff will determine the individual clinical signs 
and symptoms scores for acute cystitis ( Appendix  6), which will then be used to programmatically determine 
the clinical outcome. The same scorer will be used at all assessment ti me points for each participant, on all 
occasions, whenever possible.  
 
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 6 9  
 8. 2.  S af et y A s s e s s m e nt s  
Pla n ne d ti me p oi nts f or all safet y assess me nts are pr o vi de d i n t he S o A ( Secti o n 1. 3 ).  
8. 2. 1.  P h y si c al E x a mi n ati o n s  
• A p h ysic al e x a mi nati o n will be perf or me d at t he ti me p oi nts i n dicate d i n t he 
S o A ( Secti o n  1. 3 ).  
• At Baseli ne, t h e e x a mi nati o n will i ncl u de assess me nts of t he res pir at or y, C V, 
a b d o mi nal, gastr oi ntesti nal, ne ur ol o gical, a n d ur o ge nital s yste ms. Hei g ht a n d 
wei g ht will o nl y be me as ure d a n d rec or de d at t he Baseli ne Visit ( bef ore 
d osi n g ).  
• At t he T O C Visit, t he p h ysical e x a mi nati o n ma y be s y m pt o m directe d a n d is 
o nl y re q uire d if i n dicat e d f or a s pecific partici pa nt.  
• I n v esti gat ors s h o ul d pa y s pecial atte nti o n t o cli nical si g ns r elate d t o pre vi o us 
seri o us ill nesses.  
• Cli nicall y si g nifica nt c ha n ges fr o m baseli ne or cli nicall y si g nifica nt ne w cli nical 
si g ns will be re p orte d as A Es.  
8. 2. 2.  Vit al Si g n s  
• Vital si g ns will be meas ure d at t he ti me p oi nts i n dicate d i n t he S o A 
( Secti o n  1. 3 ).  
• Vital si g ns will be meas ure d i n a se mi -s u pi [INVESTIGATOR_050] p ositi o n after [ADDRESS_1042204] olic bl o o d press ure, a n d p ulse rat e.  C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 70 
 • Vital sign measurements should  be obtained before any blood draws scheduled 
on the same assessment day.  
• Clinically significant changes from baseline will be reported as AEs.  
8.2.3.  Electrocardiograms  
• Electrocardiograms will be performed at the time points indicated in the SoA 
(Section  1.3). 
• Triplicate 12 -lead ECGs (over an approximate 5 - to 10 -minute period) will be 
performed using an ECG machine that automatically calculates the heart rate 
and measures PR, QRS, QT, and QTc intervals. Refer to Section 7.1.2  for QTc 
withdrawal criteria and additional QTc readings that may be necessary.  
• Ideally, ECGs will be obtained before any vital sign measurements or blood 
draws scheduled on the same assessment day; however, sites may perform 
procedures in an order per their standard of care, as long as participants return to 
a resting state prior to the start of the ECG collections.  
• Triplicate ECGs will be performed at Baseline.  
• For the first approximately 1200 participants enrolled, On -therapy Visit 
triplicate ECGs will also be obtained. The On -therapy ECGs will be collected 
approximately 2 hours postd ose (i.e., expected time of maximum concentration; 
ECG collection should ideally be within approximately 1.5 hours postdose to 
4 hours postdose). After the first approximately [ADDRESS_1042205] triplicate 
ECGs performed at On -therapy, the ECG collecti on at this visit is no longer a 
protocol requirement.  
• If any additional ECGs are performed during the study (if deemed necessary by 
[CONTACT_093]), those may be collected as a single ECG; however, if that initial 
single reading shows QTc prolongation, then triplicate ECGs should also be 
performed (see Sect ion 7.1.2 ). 
• If clinically significant changes occur during the study, they will be reported as 
AEs.  
• Electrocardiograms will be reviewed locally by [CONTACT_760999]. Electrocardiograms will be centrally overread for the data analysis.  
8.2.4.  Clinical Safety Laboratory Assessments  
• Refer to Appendix [ADDRESS_1042206] of clinical laboratory tests to be performed and 
to the SoA (Section  1.3) for the timing and frequency.  
• The investigator must review the laboratory repor t, document this review, and 
record any clinically relevant changes occurring during the study in the AE 
section of the eCRF. The laboratory reports must be filed with the source 
documents. Clinically significant abnormal laboratory findings are those whic h 
are not associated with the underlying disease, unless judged by [CONTACT_165781] ’s condition.  
TMF-13817737  CONFIDENTIAL   
  212390  
 71 
 • All laboratory tests with values considered clinically significantly abnormal 
during participation in the s tudy should be repeated until the values return to 
normal or baseline or are no longer considered significantly abnormal by [CONTACT_63200].  
• If such values do not return to normal/baseline within a period of time judged 
reasonable by t he investigator, the etiology should be identified and the sponsor 
notified.  
• All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_1042207] be 
conducted in acc ordance with the laboratory manual and the SoA.  
8.3. Adverse Events and Serious Adverse Events  
The definitions of an AE or SAE can be found in Appendix 11 . 
Adverse events  will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant’s legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, 
and reporting events that mee t the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study treatment or the study, 
or that caused the participant to discontinue the study treatment or from the study (see 
Section 7). 
8.3.1.  Time Period and Frequency for Collecting AE and SAE 
Information  
• All SAEs will be collected from the signing of the informed consent form until 
the Follow -up Visit  at the time points specified in the SoA (Section 1.3).  
• All AEs will be collected from the start of treatment until the Follow -up Visit at 
the time points specified in the SoA (Section 1.3). 
• Medical occurrences that begin before the start of study treatment but after 
obtaining informed c onsent will be recorded on the Medical History/Current 
Medical Conditions section of the eCRF and not the AE section.  
• All SAEs will be recorded and reported to the sponsor or designee immediately 
and under no circumstance should this exceed 24 hours,  as indicated in 
Appendix 11 . The investigator will submit any updated SAE data to the sponsor 
within 24  hours of it being available.  
• Investigators are not obligated to activel y seek AEs or SAEs after the conclusion 
of the study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has been discharged from the 
study, and he/she considers the event to be reasonably relat ed to the study 
treatment or study participation, the investigator must promptly notify the 
sponsor.  
TMF-13817737  CONFIDENTIAL   
  212390  
 72 
 8.3.2.  Method of Detecting AEs and SAEs  
• The method of recording, evaluating, and assessing causality of AEs and SAEs 
and the procedures for completing and transmi tting SAE reports are provided in 
Appendix 11 . 
• Care will be taken not to introduce bias when detecting AEs and/or SAEs. 
Open -ended and nonleading verbal questioning of the  participant is the preferred 
method to inquire about AE  occurrence.  
8.3.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs, and nonserious AEs of special interest 
(as defined in Section 8.3.7 ), will be followed until the event is resolved, stabilized, 
otherwise explained, or the participant is lost  to follow -up (as defined in Section 7.3). 
Further information on follow -up procedures is given in Appendix 11 . 
8.3.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_11012] a SAE is essential so 
that legal obligations and ethical responsibilities towards the safety of 
participa nts and the safety of a study treatment under clinical investigation are 
met. 
• The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study treatment 
under clinical investigat ion. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, 
IRB/IEC, and investigators.  
• For all studies except those utilizing medical devices, investigator  safety reports 
must be prepared for suspected unexpected serious adverse reactions according 
to local regulatory requirements and sponsor policy and forwarded to 
investigators as necessary.  
• An investigator who receives an investigator safety report descri bing a SAE or 
other specific safety information (e.g., summary or listing of SAEs) from the 
sponsor will review and then file it along with the IB and will notify the 
IRB/IEC, if appropriate according to local requirements.  
8.3.5.  Pregnancy  
• Details of all pregnan cies in female participants will be collected after the start of 
study treatment and through the Follow -up Visit.  
• If a pregnancy is reported, the investigator should inform [COMPANY_004] within 24 hours of 
learning of the pregnancy and should follow the procedures o utlined in Appendix 2 . 
• Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs.  
TMF-13817737  CONFIDENTIAL   
  212390  
 73 
 8.3.6.  Cardiovascular and Death Events  
For any CV events detailed in Appendix 11  and all deaths, whether or not they are 
considered SAEs, specific CV and Death sections of the eCRF will be required to be 
completed. These sections include questions regarding CV (including sudden cardiac 
death) and non -CV death.  
The CV eCRFs are presented as queries in response to reporting of certain CV Medical 
Dictionary for Regu latory Activities (MedDRA) terms. The CV information should be 
recorded in the specific CV section of the eCRF within [ADDRESS_1042208] for this study are CV events, gastrointestinal events , C. 
difficile  infection or colitis events, and AEs related to acetylcholinesterase inhibition (see 
Section  2.3.1 ), which will be identified by a prespecified list of coded terms or 
determined by [CONTACT_59637], as described in the reporting and analysis plan (RAP). 
Additional details are provided in Appendix 11 . 
8.4. Treatment of Overdose  
There is no specific antidote for overdose with a bacterial topoisomerase inhibitor. In the 
event of a suspected overdose, it is recommended that the appropriate supportive clinical 
care should be instituted, as dictated by [CONTACT_2299]’s clinical status.  
Occasional incidents of acute overdosage of nitrofurantoin have not resulted in any 
specific symptoms other than vomiting (refer to locally approved prescribing 
information). Induction of emesis is recommended. There is no specific antidote, but a 
high fluid intake should be maintained to promote urinary excretion of the drug.  
In the event of an overdose, the investigator should:  
1. Contact [CONTACT_10990].  
2. Closely monitor the participant for AEs/SAEs and laboratory abnormalities until 
study treat ment can no longer be detected systemically (at least 72  hours).  
3. Obtain a plasma sample for PK analysis within [ADDRESS_1042209] 
dose of study treatment if requested by [CONTACT_7195] (determined on a case -
by-case basis).  
4. Document the  quantity of the excess dose as well as the duration of the overdosing in 
the case report form (CRF).  
T M F -[ADDRESS_1042210] u d y will be pr o vi de d i n t he R A P.  C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 75 
 9.1. Statistical Hypotheses  
The study is designed to demonstrate that gepotidacin administered orally is noninferior 
compared to nitrofurantoin administered orally on the primary effic acy endpoint of 
therapeutic response (combined per -participant microbiological and clinical response) at 
the TOC Visit in participants with a qualifying bacterial uropathogen at Baseline that is 
susceptible to nitrofurantoin. Microbiological success is def ined as eradication (i.e., 
reduction of all qualifying bacterial uropathogens recovered at Baseline to <103 CFU/mL 
as observed on quantitative urine culture) without the participant receiving other systemic 
antimicrobials. Clinical success is defined as re solution of signs and symptoms of acute 
cystitis present at Baseline (and no new signs and symptoms) without the participant 
receiving other systemic antimicrobials.  
The following are null and alternative hypotheses for the primary analysis of the 
therape utic success rates at the prespecified noninferiority margin of -10.0%:  
H0: therapeutic success rate of gepotidacin 1500 mg BID – therapeutic success rate 
of nitrofurantoin 100 mg BID ≤ -10.0%  
H1: therapeutic success rate of gepotidacin 1500 mg BID – therap eutic success rate 
of nitrofurantoin 100 mg BID > -10.0%  
The use of a -10% noninferiority margin in the primary efficacy estimand is in 
accordance with current FDA guidance [ DHHS , 2019; EMA , 2013].  
If noninferiority is declared between gepotidacin and nitrofurantoin, superiority will be 
tested with the following null a nd alternative hypotheses:  
H0: therapeutic success rate of gepotidacin 1500 mg BID – therapeutic success rate 
of nitrofurantoin 100 mg BID ≤0%  
H1: therapeutic success rate of gepotidacin 1500 mg BID – therapeutic success rate 
of nitrofurantoin 100 mg BID >0%  
An IA is planned as described in Section 9.5. The study will utilize a group sequential 
design with 1 IA using Lan -DeMets spending function [Lan, 1983 ]. The timing of the IA 
is planned to occur when approximately 60% of the maximum planned participants in the 
micro -ITT NTF -S Population (N≈884) have achieved the  TOC Visit. The stoppi[INVESTIGATOR_760974] 
O’Brien -Flemming stoppi[INVESTIGATOR_126669]. At the time of the IA, the IDMC will 
perform an unblinded review to confirm that there are sufficie nt microbiological data for 
regulatory submission before proceeding to the IA for efficacy and futility. If in any case 
the microbiological data are not sufficient, the IDMC will instead conduct a futility -only 
IA. If futility is not declared, the sample s ize needed for the final analysis will be 
approximately 768  participants in the micro -ITT NTF -S Population. This will be based 
on the O’Brien -Flemming stoppi[INVESTIGATOR_126670] . Details on the timing and 
design selection process are described in Secti on 9.5. 
TMF-13817737  CONFIDENTIAL   
  212390  
 76 
 9.2. Sample Size Determination  
9.2.1.  Justification of Sample Size  
Participants will be randomized to gepotidacin and nitrofurantoin in a 1:1 ratio. 
Assuming a 76% thera peutic success rate for both nitrofurantoin and gepotidacin, a 
sample size of approximately 884 participants in the micro -ITT NTF -S Population is 
required, for a design with 1 IA allowing for stoppi[INVESTIGATOR_760975], to provide approximately  90% power to demonstrate noninferiority in the 
therapeutic response rate of gepotidacin to nitrofurantoin with a 0.0 25 one-sided alpha 
level and a -10.0% noninferiority margin. The minimal response rate difference that 
would meet the statistical  criterion for noninferiority is provided in Table  12. 
Table  12 Minimal Response Rate Difference for Efficacy  and Futility Interim 
Analysis  
Design   
Information 
Fraction  Micro -ITT NTF -S 
Sample Size  Minimal Response Rate Difference 
for Noninferiority  
Analysis for Efficacy  and Futility  60% 530 -2.2%  
100%  884 -3.6%  
Micro -ITT NTF -S=Microbiological Intent -to-Treat Nitrofurantoin -Susceptible.  
In case a futility -only IA is conducted, under the same assumption for response rate, 
significance level, and noninferiority margin, a sample size of 768 participants in the 
micro -ITT NTF -S Population will provide approximately  88% power to demonstrate 
nonin feriority. The minimal response rate difference that would meet the statistical 
criterion for noninferiority is -4.0% for the final analysis.  
The study is planned to enroll approximately 2500 participants to ensure a sufficient 
number of participants in th e primary analysis population (i.e., micro -ITT NTF -S 
Population). If the study proceeds to an efficacy and futility IA, the maximum target 
sample size (assuming there is a decision to continue the study at the IA) for the primary 
analysis population will b e around 884 participants. If the study proceeds to the 
futility -only IA, the maximum target sample size (assuming a decision to continue the 
study at the IA) for the primary analysis population will be approximately 
768 participants. The final number of r andomized participants may vary based on the 
evaluability rate and review of qualifying uropathogens by [CONTACT_126729] .  
Note : “Enrolled” means that a participant’s or their legally acceptable representative’s 
agreement to participate in the clinical st udy following completion of the informed 
consent process. Potential participants who are screened for the purpose of determining 
eligibility for the study, but do not participate in the study, are not considered enrolled, 
unless otherwise specified in the protocol.  
9.2.2.  Sample Size Sensitivity  
Sensitivity of the sample size has been explored considering various therapeutic success 
rates. Table 13 and Table 14 show the minimum power under various assumptions of 
TMF-13817737  CONFIDENTIAL   
  212390  
 77 
 “true” therapeutic success rates of gepotidacin and nitrofurantoin under 2 different IA 
designs, when the IA is conduc ted at approximately 60%  information fraction of the 
design allowing for efficacy  and futility stop at the IA. For all of these cases, the 1-sided 
type I error is 2.5%, the noninferiority margin is -10%.  
Table 13 Power of the Study Under Various Assumptions of the True 
Therapeutic Success Rates for Efficacy  and Futility Group 
Sequential Design  
Therapeutic 
Success Rate of 
Nitrofurantoin  Therapeutic 
Success Rate 
of Gepotidacin  Total Number of 
Participants in 
the Primary 
Analysis  Number  of 
Participants in the 
Primary Analysis in 
the Interim Analysis  Power  
76% 76% 884 530 90% 
72% 72% 884 530 87% 
68% 68% 884 530 84% 
64% 64% 884 530 81% 
60% 60% 884 530 79% 
 
Table 14 Power of the Study Under Various Assumptions of the True 
Therapeutic Success Rates for Futility Only Group Sequential 
Design  
Therapeutic 
Success Rate of 
Nitrofurantoin  Therapeutic 
Success Rate of 
Gepotidacin  Total Number of 
Participants in 
the Primary 
Analysis  Number of 
Participants in the 
Primary An alysis in 
the Interim Analysis  Power  
76% 76% 768 530 88% 
72% 72% 768 530 85% 
68% 68% 768 530 81% 
64% 64% 768 530 79% 
60% 60% 768 530 77% 
 
9.3. Populations for Analyses  
For purposes of analysis, the following populations are defined:  
Population  Description  
Intent -to-Treat (ITT) 
Population  All participants randomly assigned to study treatment. Participants 
will be analyzed according to their randomized study treatment.  
TMF-13817737  CONFIDENTIAL   
  212390  
 78 
 Population  Description  
Microbiological ITT 
(micro -ITT) Population  All participants randomly assigned to study treatment who receive 
at least [ADDRESS_1042211] a qualifying baseline 
uropathogen (defined in Appendix 4 ), from a quantitative 
bacteriological culture of a pretreatment clean -catch midstream 
urine specimen. Participants will be analyzed according to their 
randomized study treatment.  
Micro -ITT NTF -S 
Population  All participants in the micro -ITT Population whose baseline 
qualifying bacterial uropathogens all are susceptible to 
nitrofurantoin (NTF -S). Participants with missing MIC susceptibility 
results for any qualifying uropathogens will not be  included in the 
NTF-S subpopulation. Participants will be analyzed according to 
their randomized study treatment.  
This is the primary analysis population.  
Micro -ITT NTF -NS 
Population  All participants in the micro -ITT Population who have any 
qualifying ba seline bacterial uropathogens that are not susceptible 
to nitrofurantoin (NTF -NS), defined as resistant to nitrofurantoin, 
intermediate to nitrofurantoin, or have no interpretation to 
nitrofurantoin. Participants with missing MIC susceptibility results 
for all qualifying uropathogens will not be included in the NTF -NS 
subpopulation. Participants will be analyzed according to their 
randomized study treatment.  
Microbiologically Evaluable 
(ME) Population  Participants who meet the definition of the micro -ITT P opulation, 
follow important components of the study (as specified in the 
RAP) and have an interpretable quantitative urine culture at the 
specified visit. Note: Visit -specific ME populations will be defined 
in the RAP.  
ME NTF -S Population  All participants  in the ME visit -specific population whose baseline 
qualifying bacterial uropathogens all are susceptible to 
nitrofurantoin (NTF -S). Note: Visit -specific ME NTF -S populations 
will be defined in the RAP.  
ME NTF -NS Population  All participants in the ME visi t-specific population who have any 
baseline qualifying bacterial uropathogens that are not susceptible 
to nitrofurantoin (NTF -NS). Note: Visit -specific ME NTF -NS 
populations will be defined in the RAP.  
Clinically Evaluable (CE) 
Population  All participants  in the ITT Population who follow important 
components of the study as specified in the RAP. Note: 
Visit-specific CE populations will be defined in the RAP.  
TMF-[ADDRESS_1042212] to be estimated for primary and secondary estimands are clinical 
outcome/response, microbiological outcome/response, and therapeutic response at the 
designated visits in female participants with acute cystitis (clinical outcome/response) 
and female participants with acute cystitis with qualifying bacterial uropathogen(s)  at 
Baseline that all are susceptible to nitrofurantoin (clinical outcome/response, 
microbiological outcome/response, and therapeutic response). Intercurrent events include 
receiving other systemic antimicrobials and treatment discontinuation; a combinatio n of 
composite strategy and treatment policy strategy will be implemented to account for the 
2 ICEs, respectively. The ICE event strategies determine that (1) treatment effects will be 
estimated regardless of study treatment discontinuation when the analys is population is 
the ITT Population or its derivatives; and (2)  the definition of a successful response or a 
positive outcome (clinical resolution and microbiological eradication) precludes the use 
of other systemic antimicrobials.  
Any supplemental analyse s will be detailed in the RAP. Any additional analyses or 
outputs needed as a result of COVID -19 on the study will be detailed in the RAP.  
TMF-13817737  CONFIDENTIAL   
  212390  
 80 
 9.4.2.  Efficacy Analyses  
Estimands/Endpoints  Statistical Analysis Methods  
Primary  The primary analysis of the primary efficacy endpoint will be performed 
using the micro -ITT NTF -S Population.  
• The primary treatment effect to be estimated (estimand) is 
therapeutic response (combined per -participant microbiological 
and clinical response) at the TOC Visit in female participants with 
acute cystitis with a qualifying bacterial uropathogen(s) at Baseline 
that all are susceptible to nitrofurantoin. Microbiological success at 
the TOC Visit is defined as reduction of all qualifying bacterial 
uropathogens recovered at Baseline to <103 CFU/mL as observed 
on quantitative urine culture without the participant receiving other 
systemic antimicrobials; clinical success is defined as resolution of 
signs and symptoms of acute cystitis present at Baseline ( and no 
new signs and symptoms) without the participant receiving other 
systemic antimicrobials. Therapeutic success refers to participants 
who have been deemed both a microbiological success and a 
clinical success (i.e., responders). The primary treatment effect 
will be estimated regardless of treatment discontinuation, as per 
the treatment policy strategy. The ICE of use of other systemic 
antimicrobial therapy is captured through the definitions of 
microbiological and clinical response and will be counted as 
failures (composite strategy). If a participant experiences both 
ICEs of study treatment discontinuation and use of systemic 
antimicrobials, then a composite strategy (assigning therapeutic 
response as a failure) will be used from the point that the rel evant 
systemic antimicrobial was taken. Further details on the primary 
estimand are provided in Section  3. 
• The population -level effect will be estimated by [CONTACT_761000] 95% CI. For this analysis, 
participants who do not return for the TOC Visit or have missing 
data at the TOC Visit will be treated as failures.  
• The number and percentage of participants with therapeutic 
success will be su mmarized, along with the 95% CI, at the TOC 
Visit by [CONTACT_1570].  
TMF-13817737  CONFIDENTIAL   
  212390  
 81 
 Estimands/Endpoints  Statistical Analysis Methods  
• The testing procedure at the IA and the final analysis involves 
comparing the noninferiority test statistics with the stoppi[INVESTIGATOR_78971]. Test statistics of the therapeutic success rate d ifference 
between the 2 treatment groups for noninferiority ( -10% margin) 
will be calculated using the Miettinen and Nurminen method 
stratified by [CONTACT_67579] (<18  years, ≥18 to 50 years, or 
>50 years) and acute cystitis recurrence (nonrecurrent infection  or 
recurrent infection ) [Miettinen , 1985] and compared to the 
stoppi[INVESTIGATOR_74239]. If noninferiority is established, test statistics 
of the success rate difference be tween the 2 treatment groups for 
superiority will be calculated using the same method to compare 
with the stoppi[INVESTIGATOR_760976]. Details on the testing 
procedure and stoppi[INVESTIGATOR_760977].  
• In the event that  a participant is mis -stratified at randomization, the 
actual stratum will be used instead of the randomized stratum in 
the primary analysis.  
• Sensitivity analysis on the primary endpoint will be done with 
details provided in the RAP. In addition, a tippi[INVESTIGATOR_760978], if warranted by [CONTACT_761001].  
• Subgroup analysis and supplemental analysis on additional 
populations for the primary endpoint may be performed with 
details provided in the RAP.  
• Handlin g of protocol deviations will be described in the RAP.  
TMF-13817737  CONFIDENTIAL   
  212390  
 82 
 Estimands/Endpoints  Statistical Analysis Methods  
Secondary  Secondary efficacy endpoints for clinical outcome and response will 
be summarized using the ITT Population and micro -ITT NTF -S 
Population. Secondary efficacy endpoints for microbiological ou tcome 
and response, as well as therapeutic response, will be summarized 
using the micro -ITT NTF -S Population.  
• There will be no multiplicity adjustment for the testing of the 
secondary endpoints. No formal hypothesis testing will be 
performed.  
• The clinical outcome and response (number and percentage of 
participants with resolution of signs and symptoms) will be 
summarized by [CONTACT_761002] -up Visits. 
The ICE of use of other systemic antimicrobials is captured 
through the defining crite ria of clinical outcome and response 
(Section  [IP_ADDRESS] ). 
• The microbiological outcome and response (number and 
percentage of participants with microbiological success) will be 
summarized by [CONTACT_761002] -up Visits. 
The ICE of use of other systemic antimicrobials is captured 
through the defining criteria of microbiological outcome and 
response (Section  [IP_ADDRESS] ). 
• Therapeutic response (combined per -participant microbiological 
and clinical response) will be summarized by [CONTACT_761003] -up Visit.  
• Sensitivity analysis on the secondary endpoints, if war ranted, will 
be described in the RAP.  
• Subgroup analysis by [CONTACT_761004]. 
Additional subgroup analyses and supplemental analysis on 
additional populations may be car ried out. Details of these 
analyses will be provided in the RAP.  
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 8 3  
 E sti m a n d s/ E n d p oi nt s  St ati sti c al A n al ysi s M et h o d s  
 
9. 4. 3.  S a f et y A n al y s e s  
All safet y a nal yses will be perf or me d o n t he Safet y P o p ulati o n. T he se v erit y of A Es a n d 
S A Es will be deter mi ne d b y t he i n vesti gat or acc or di n g t o t he U S Nati o nal I nstit ute of 
Aller g y a n d I nfecti o us Diseases Di visi o n of Micr o bi ol o g y a n d I nfecti o us Diseases 
( D MI D) criteria f or a d ult t o xicit y assess me nt [ D MI D , 2 0 0 7a], wit h t he e x ce pti o n of 
ser u m creati ni ne a d oles ce nt la b orat or y d ata, w hic h will b e assesse d usi n g pe diatric 
t o xicit y criteri a [ D MI D , 2 0 0 7 b] ( A p pe n di x  1 3 ). All re p orte d A Es will be c o de d usi n g 
Me d D R A a n d s u m mariz e d b y s yste m or ga n class a n d preferre d ter ms.  
E sti m a n d s/ E n d p oi nt s  St ati sti c al A n al ysi s M et h o d s  
S ec o nd ary  • T h e s afety e n dp oi nt will us e a tr e at m e nt p olicy str ate gy f or t h e I C E 
of wit h dr a wal fr o m tr e at m e nt, as saf ety will b e assess e d at all 
p ost b as eli n e ass ess m ents irres p ectiv e of w h et h er t h e p artici p a nt 
c o m pl et ed t he tr eat m e nt.  C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 84 
 Estimands/Endpoints  Statistical Analysis Methods  
• The number and percentage of treatment -emergent AEs, study 
treatment -related AEs, deaths, SAEs, and AEs leading to study 
treatment or study withdrawal will be provided.  
• Treatment -emergent AEs will be summarized by [CONTACT_926].  
• Change from baseline over time in laboratory parameters, ECGs, 
and vital signs will b e summarized with descriptive statistics.  
Note:  Electrocardiograms will be centrally overread for the data 
analysis.  
• The frequency of laboratory abnormality events along with the shift 
from baseline to the worst -case postbaseline value will be 
provided. Abnormal liver chemistry results will be determined 
using increases above the upper limit of normal. Change from 
baseline values will be summarized with descriptive statistics.  
• The severity of specified AEs and laboratory abnormalities will be 
graded accor ding to the modified DMID toxicity grading system 
(Appendix  13). Data will be tabulated and reported by [CONTACT_761005] 3 and higher and shift table s, as appropriate.  
• Adverse events of special interest will include CV, gastrointestinal, 
and C. difficile infection or colitis  events. In addition, AEs 
associated with acetylcholinesterase inhibition are also considered 
special interest. As described in th e RAP, manual and 
programmatic reviews of AEs/preferred terms will be used to 
assess these events.  
 
9.5. Interim Analys is 
One IA is planned to assess either both efficacy  and futility or just futility by [CONTACT_31849]. 
The IDMC will meet when approximately 60% of participants in the micro -ITT NTF -S 
Population have achieved the TOC Visit to evaluate the primary endpoint, identify 
potential treatment benefit, and make recommendations for continuing or stoppi[INVESTIGATOR_90348], as per the IDMC charter. The IDMC members will  include at least [ADDRESS_1042213] for the unblinded gepotidacin treatment arm before 
deciding how to proceed.  
If the IDMC confirms there is sufficient microbiology data in the gepotidacin arm, an IA 
with stoppi[INVESTIGATOR_126675]. The nominal 
significance levels for the interim and final analyses will be determined by [CONTACT_126736]-DeMets spending functions approach [ Lan, 1983 ]. This will be based on the Pocock 
stoppi[INVESTIGATOR_760979] O’Brien -Flemming stoppi[INVESTIGATOR_126670]. 
The futility bounds of this study are no nbinding and are considered guidance rather than 
strict bounds.  
During the course of the IA, the accrual of the study will continue. If efficacy success is 
reached at the IA and the study is stopped early, data collected between the IA data cut 
and IA deci sion are considered overrun. Overrun data will be pooled with the IA data to 
repeat the primary efficacy analysis as sensitivity analysis.  
During the course of the IA, the accrual of the study will continue. If efficacy success 
(i.e., noninferiority) is re ached at the IA and the study is stopped early, the IA will be the 
primary analysis and data collected between the IA data cut and the time when the study 
is stopped will be considered overrun. Overrun data will be pooled with the IA data to 
repeat the pri mary efficacy analysis as sensitivity analysis. If efficacy success is not 
reached at the IA, the study will continue to the maximum target sample size for the 
micro -ITT NTF -S Population of approximately [ADDRESS_1042214] an IDMC as described in Section 9.5. In addition, there will be a 
[COMPANY_004] SRT and Microbiology Review Team. For details on these review teams, refer to 
Appendix 3 . 
TMF-13817737  CONFIDENTIAL   
  212390  
 86 
 10. SUPPORTING DOCUMENTA TION AND OPERATIONAL 
CONSIDERATIONS  
10.1.  Appendix 1: Clostridium Difficile  Testing Procedure and 
Algorithm  
 
CRA = clinical research associate ([COMPANY_003] site monitor); SRM = Study Reference Manual  
Note:  This algorithm is subject to investigator discretion when the clinical 
presentation and time course of diarrhea (e.g., during or within 12 hours immediately 
after dosing) do not fit the Clostridium difficile -associated diarrhea definition; 
consideration should be given to diarrhea occurring in this early time frame to be 
sugg estive of a cholinergic effect.  

TMF-13817737  CONFIDENTIAL   
  212390  
 87 
 10.2.  Appendix 2: Contraceptive Guidance and Collection of 
Pregnancy Information  
10.2.1.  Definitions:  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal 
unless perman ently sterile (see below).  
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study treatment, additional evaluation should be 
considered.  
Women in the following categories a re not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause oth er 
than the above, (e.g., mullerian agenesis, androgen insensitivity), investigator 
discretion should be applied to determining study entry.  
Note:  Documentation can come from the site personnel’s: review of the 
participant’s medical records, medical examin ation, or medical history interview.  
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confir m a postmenopausal state in women not 
using hormonal contraception or hormonal replacement therapy (HRT). 
However, in the absence of 12 months of amenorrhea, confirmation with 
more than one FSH measurement is required.  
• Females on HRT and whose menopausal status is in doubt will be required to 
use [ADDRESS_1042215] 
discontinue HRT to allow confirmation of postmenopausal status before  
study enrollment.  
• Refer to Appendix 8  for pregnancy testing requirements.  
TMF-13817737  CONFIDENTIAL   
  212390  
 88 
 10.2.2.  Contraception Guidance:  
Refer to Appendix 8  regarding pregnancy testing for female participants at 
Baseline  (Day  1) and associated pretreatment contraception and abstinence requirements. 
Female participants who enter the study using contraception must continue to do so 
throughout the study.  
As desc ribed in Section  5.3, participants will be requested to abstain from sexual activity 
from the Baseline Visit through the TOC Visit to prevent possible re -infection.  
• CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
• Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per 
year when used consistently and correctly  
• Implantable progestogen -only hormone contraception associated with inhibition of 
ovulationc 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)c 
• Bilateral tubal occlusion  
• Vasectomized partner  
• Note: Vasectomized partner is a highly effective contraceptive method provided that 
the partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. Spermatogenesis cycle is approximately 90 days.  
• Highly Effective Methodsb That Are User Depe ndent  Failure rate of <1% per year when 
used consistently and correctly  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated with 
inhibition of ovulationc 
• oral 
• intravaginal  
• transdermal  
• injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulationc 
• oral 
• injectable  
• Sexual abstinence  
• Note: Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associate d with 
the study treatment. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the 
participant.  
a. Contraceptive use by [CONTACT_103092].  
TMF-13817737  CONFIDENTIAL   
  212390  
 89 
 b. Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_17964].  
c. Male co ndoms must be used in addition to hormonal contraception. If locally required, in accordance with 
Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those 
which inhibit ovulation as the primary mode of acti on. 
 
Note: Periodic abstinence (calendar, sympto -thermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception. Male 
condom and female condom should  not be used together (due to risk of failure with friction ). 
 
10.2.3.  Collection of Pregnancy Information:  
Female participants who become pregnant  
• Investigator will collect pregnancy information on any female participant, who 
becomes pregnant while participating in this study.  
• The initial information will be recorded on the appropriate form and submitted to 
GlaxoSmithKline ([COMPANY_004])/[COMPANY_003] within 24 hours of learning of a participant’s 
pregnancy.  
• Participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on participant and neonate, which will 
be forwarded to [COMPANY_004]. Generally, follow -up will not  be required for longer than 6 to 
8 weeks beyond the estimated delivery date.  
• Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.  
• While pregnancy itself is not considere d to be an adverse event (AE) or serious AE 
(SAE), any pregnancy complication or elective termination of a pregnancy for 
medical reasons will be reported as an AE or SAE.  
• A spontaneous abortion (occurring at <22 weeks gestational age) or still birth 
(occurring at >22 weeks gestational age) is always considered to be an SAE and will 
be reported as such.  
• Any SAE occurring as a result of a poststudy pregnancy that is consider ed 
reasonably related to the study treatment by [CONTACT_093], will be reported to 
[COMPANY_004]/[COMPANY_003] as described in Appendix 11 . While the investigator is not obligated to 
activ ely seek this information in former study participants, he or she may learn of an 
SAE through spontaneous reporting.  
Any female participant who becomes pregnant while participating will discontinue study 
treatment.  
TMF-13817737  CONFIDENTIAL   
  212390  
 90 
 10.3.  Appendix 3: Regulatory, Ethical, and Stu dy Oversight 
Considerations  
10.3.1.  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
• Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council fo r International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines  
• Applicable International Council on Harmonisation (ICH) Good Clinical 
Practice (GCP) Guidelines  
• Applicable laws and regulations  
• The protocol, protocol amendments, in formed consent form (ICF)/assent 
form/eConsent (if applicable), investigator’s brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an institutional review 
board/independent ethics committee (IRB/IEC) by [CONTACT_1755] r eviewed 
and approved by [CONTACT_1201]/IEC before the study is initiated. * 
• Any amendments to the protocol will require IEC/IRB approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to stu dy participants.  
• The investigator will be responsible for the following:  
• Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, 
and procedures established by [CONTACT_1201] /EC* 
• Notifying the IRB/IEC of serious adverse events (SAEs) or other 
significant safety findings as required by [CONTACT_1744]/IEC procedures * 
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, 
the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations  
*Note :  In countries where the responsibility to perform these submissions and 
notifications resides with the sponsor rather than the investigator, [COMPANY_004] or their 
designee [COMPANY_003] (as described in the applicable powers of attorney) will take these 
responsibilities.  
10.3.2.  Financial Disclosure  
Investigators and subinvestigators will provide the sponsor with sufficient, accurate  
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial intere sts during the 
course of the study and for 1 year after completion of the study.  
TMF-13817737  CONFIDENTIAL   
  212390  
 91 
 10.3.3.  Informed Consent/Assent Process  
• The investigator or his/her representative will explain the nature of the study to 
the participant or her legally authorized representative and answer all questions 
regarding the study.  
• Participants must be informed that their participation is voluntary. Participants 
or their legally authorized representative will be required to sign a statement of 
informed consent and/or eConsent (if applicable) that meets the requirements of 
[ADDRESS_1042216] (HIPAA) requirements, where applicable, and the IRB/IEC 
or study site.  
• The medical record must include a statement that written informed consent 
and/or eConsent (if applicable) was obtained before the participant was enrolled 
in the stud y and the date informed consent was obtained. The authorized person 
obtaining the informed consent must also sign the ICF.  
• Participants must be re -consented to the most current version of the 
ICF(s)/eConsent during their participation in the study.  
• A copy  of the ICF(s)/eConsent must be provided to the participant or the 
participant’s legally authorized representative.  
• Adolescent participants should be asked for their written assent or eConsent (if 
applicable) to participate in the study.  
• As applicable, the IRB/IEC will be consulted before assent form development 
for guidance around age -appropriate groupi[INVESTIGATOR_126680]/IEC 
requirements or local laws for conducting and documenting assent.  
Participants who are rescreened are required to sign a new  ICF or provide eConsent (if 
applicable).  
[COMPANY_004] (alone or working with others) may use participant’s coded study data and samples 
and other information to carry out this study; understand the results of this study; learn 
more about gepotidacin or about the s tudy disease; publish the results of these research 
efforts; work with government agencies or insurers to have gepotidacin approved for 
medical use or approved for payment coverage.  
10.3.4.  Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any information which would make the participant 
identifiable will not be transferred.  
• The participant must be informed  that her personal study -related data will be 
used by [CONTACT_10999]. The level of 
disclosure must also be explained to the participant who will be required to give 
consent for their data to be used as described in  the informed consent.  
TMF-13817737  CONFIDENTIAL   
  212390  
 92 
 • The participant must be informed that her medical records may be examined by 
[CONTACT_103083], by [CONTACT_6667]/IEC members, and by [CONTACT_761006].  
10.3.5.  Committees Structure  
To protect the safety interests of participants, a GlaxoSmithKline ([COMPANY_004]) Safety Review 
Team will review blinded safety data instream on a regular basis throughout study 
conduct. Data reviewers will include but are not l imited to the following participants: 
medical monitor, safety team lead, statistician, clinical team lead, and data quality lead.  
A Microbiology Review Team will monitor blinded uropathogen identification and 
susceptibility data instream, including the en rollment rate of participants with a 
qualifying bacterial uropathogen at Baseline and the resistance profile of uropathogens.  
Procedures will be described in a separate microbiology sample monitoring plan.  
An Independent Data Monitoring Committee will man age the interim analysis, with 
details provided in a separate charter and analysis plan.  
Written documentation regarding key decisions made by [CONTACT_126739]/committee will 
be promptly distributed to participating investigators and IRB/IECs.  
10.3.6.  Disseminatio n of Clinical Study Data  
• Where required by [CONTACT_25435], an investigator signatory 
will be identified for the approval of the clinical study report. The investigator 
will be provided reasonable access to statistical tables, figures, a nd relevant 
reports and will have the opportunity to review the complete study results at a 
[COMPANY_004] site or other mutually agreeable location.  
• [COMPANY_004] will also provide the investigator with the full summary of the study 
results. The investigator is encouraged to share the summary results with the 
study participants, as appropriate.  
• [COMPANY_004] will provide the investigator with the randomization codes for their site 
only after completion of the full statistical analysis.  
• The procedures and timing for public disclosure of the protocol and results 
summary and for development of a manuscript for publication for this study will 
be in accordance with [COMPANY_004] policy.  
• [COMPANY_004] intends to make anonymized participant -level data from this trial available 
to external researchers for scientifi c analyses or to conduct further research that 
can help advance medical science or improve patient care. This helps ensure the 
data provided by [CONTACT_165793].  
TMF-13817737  CONFIDENTIAL   
  212390  
 93 
 10.3.7.  Data Quality Assur ance  
• All participant data relating to the study will be recorded on printed CRFs or 
electronic CRFs (eCRFs) unless transmitted to the sponsor or designee 
electronically (e.g., laboratory data). The investigator is responsible for 
verifying that data entrie s are accurate and correct by [CONTACT_56857].  
• The investigator must maintain accurate documentation (source data) that 
supports the information entered in the eCRF.  
• The investigator must permit study -related monitoring, aud its, IRB/IEC review, 
and regulatory agency inspections and provide direct access to source data 
documents.  
• Monitoring details describing strategy (e.g., risk -based initiatives in operations 
and quality such as Risk Management and Mitigation Strategies and  Analytical 
Risk-Based Monitoring), methods, responsibilities and requirements, including 
handling of noncompliance issues and monitoring techniques (central, remote, 
or on -site monitoring) are provided in the Monitoring Plan. In addition, refer to 
Appendix [ADDRESS_1042217] and/or 
monitoring due to COVID -19. 
• The sponsor or designee is responsible for the data management of th is study 
including quality checking of the data. Detailed information about study data 
collection and management process can be found in the Data Validation Manual.  
• The sponsor assumes accountability for actions delegated to other individuals 
(e.g., contract research organizations).  
• Study monitors will perform ongoing source data verification to confirm that 
data entered into the eCRF by [CONTACT_1191], complete, 
and verifiable from source documents; that the safety and rights of participants 
are being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements. In addition, refer to Appendix [ADDRESS_1042218] and/or monitoring due to 
COVID -19. 
• Records and documents, including signed ICF, pertaining to the conduct of this 
study must be retained by [CONTACT_1732] 25 years from the issue of the final 
clinical study report/ equivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the 
sponsor. No records may be transferred to another location or party without 
written notification to the sponsor.  
10.3.8.  Source Document s 
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
TMF-13817737  CONFIDENTIAL   
  212390  
 94 
 • Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may need to request previous 
medical records or transfer records, depending on the study. Also, current 
medical records must be available . 
• Definition of what constitutes source data can be found in the Study Reference 
Manual.  
10.3.9.  Study and Site Start and Closure  
[COMPANY_004] or its designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretio n of [COMPANY_004]. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site clo sure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_103086]:  
• Failure of the inve stigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor’s procedures, or GCP guidelines  
• Inadequate recruitment of participants by [CONTACT_093]  
• Discontinuation of further study treatment development  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform 
the investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, a s specified 
by [CONTACT_1214]. The investigator shall promptly inform the 
participant and should assure appropriate participant therapy and/or follow -up. 
10.3.10.  Publication Policy  
• The results of this study may be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary 
information and to provide comments.  
• The sponsor will comply with the  requirements for publication of study results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generally support publication of multicenter studies only in their entirety and not 
as individual site data. In this case, a coordi nating investigator will be 
designated by [CONTACT_11402].  
• Authorship will be determined by [CONTACT_43217].  
TMF-13817737  CONFIDENTIAL   
  212390  
 95 
 10.4.  Appendix 4: Algorithm for Determining Qualifying 
Urop athogens  
In addition to other criteria indicated in Section  9.3, to be included in the micro -ITT 
Population, participants must have a qualifying bacter ial uropathogen (defined in  
Figure  2) at Baseline from a quantitative bacteriology culture of a pretreatment 
clean -catch midstream urine specimen. For inclusion into the micro -ITT NTF -S 
Population, all baseline qualifying uropat hogen(s) must also be susceptible to 
nitrofurantoin . Qualifying uropathogen susceptibilities will be monitored instream to 
ensure sufficient and balanced enrollment of participants with uropathogens resistant to 
specific microbiological classes. Please ref er to the RAP for specific details.  
The algorithm for determining qualifying uropathogens based on microbiology laboratory 
quantitative culture results is provided in Figure  2, with additional algorithm details 
provided in the RAP.  
Figure  2 Baseline Algorithm for Determining Qualifying Uropathogens  
 
CFU=colony -forming units.  
Note:  Only the following uropathogen species/groups will be considere d for inclusion in the micro -ITT and other 
microbiological populations: Gram -negative bacilli (e.g., E. coli , K. pneumoniae , P. mirabilis ), S. saprophyticus , 
and Enterococcus  spp. Analysis details for the other uropathogens and uropathogen groups will be d escribed in 
the RAP, as applicable.  
 
References  
McCarter YS, Burd EM, Hall GS, Zervos M. Cumitech 2C, Laboratory diagnosis of 
urinary tract infections. Coordinating ed., Sharp SE. Washington, DC; ASM Press; 
2009.1 -26. 
Chan WW. Chapter 3.12: Urine cultures.  In: Leber AL, editor. Clinical microbiology 
procedures handbook, 4th ed. Vol 1 -3. Washington, DC; ASM Press; 2016.  
 

TMF-13817737  CONFIDENTIAL   
  212390  
 96 
 10.5.  Appendix 5: COVID -[ADDRESS_1042219] participants’ safety, welfare and rights, and promote data 
integrity. These measures are expected to be temporary and study sites will be notified of 
any change to these allowances as the COVID -[ADDRESS_1042220] of any travel restrictions 
implemented by [CONTACT_5737]/regional health authorities and local institut ions, and individual 
benefit/risk when making enrollment and treatment decisions for study participants.  
Every effort should be made to adhere to protocol -specified assessments for participants 
on study treatment, including follow -up assessments; however, when not possible, for the 
duration of these special circumstances, the following measures may be implemented:  
• Only where applicable country and local regulations and infrastructure allow, home 
healthcare (home visits and telemedicine visits) may be perfor med at the discretion 
of the investigator and following the participant signing of an informed 
consent/assent form specific for home healthcare. Specific details will be described 
in the Study Reference Manual. The participant should be informed of the hom e 
healthcare plan and any potential risks associated with home visits and telemedicine. 
The participant must sign an informed consent form specific to home healthcare.  
• For all study visits, to minimize the amount of time that participants spend at the 
clinic, eConsent may be utilized and remote collection of study -related data may be 
obtained as described in the Study Reference Manual. Thus, some visit data may be 
collected through a combination of telemedicine and on -site visits. Collection of 
information via telemedicine will be performed only where local regulations permit.  
• Clinical investigators should document in site/participant/source files how 
restrictions related to COVID -[ADDRESS_1042221], the duration of 
those changes, and indicat e which trial participants were impacted and how those 
trial participants were impacted (as per the current local COVID -19 related 
regulatory guidance).  
• Missing protocol -required data/visits due to COVID -19 should be noted in 
site/participant/source files  and recorded as a COVID -19 protocol deviation.  
TMF-13817737  CONFIDENTIAL   
  212390  
 97 
 Specifically for data management and monitoring the following will apply:  
• If on -site monitoring is no longer permitted, [COMPANY_004]/[COMPANY_003] will consider remote Source 
Data Verification/Source Document Review (SDV/SDR) where permitted by [CONTACT_42042]/institution. Remote SDV/SDR will be proposed to study sites to meet a 
participant and/or critical quality need, e.g., to assess participant safety or to ensure 
data integrity. In case of remote SDV/SDR, [COMPANY_004]/[COMPANY_003] will wor k with the site to 
ensure participant privacy.  
• eCRF/CRF Final or Interim Sign -Off Process: The principal investigator [INVESTIGATOR_760980] (ICH GCP 4.9.1 4.9.2). The 
principal investigator [INVESTIGATOR_126682]/re -sign the eCRF from any computer/location by 
[CONTACT_126741]/her unique eCRF log -in creden tials. The 
principal investigator [INVESTIGATOR_760981]. It is recommended that the principal investigator [INVESTIGATOR_31797] a 
subinvestigator as a back -up for eCRF signatures and that appropriate training on the 
protocol and eCRF requirements is provided and documented.  
• Essential Document Sign -Off Process: If an investigator is unable to print and sign 
essential documents such as Protocol/Amendment signature [CONTACT_680429] e -mail 
approval can be accepted by [CONTACT_126742] e -mail that is sent by [CONTACT_23983]/[COMPANY_003].  
 
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 9 8  
 1 0. 6.  A p p e n di x  6: Cli ni c al Si g n s a n d S y m pt o m s S c or e f or A c ut e 
C y stiti s  
Cli nical si g ns a n d s y m pt o ms of ac ute c ystitis will be rec or de d as f oll o ws:  
Cli ni c al Si g n s 
a n d S y m pt o m s  N o n e  
 Mil d  
Sy m pt o m is 
e asily t ol er at e d, 
c a usi n g mi ni m al 
disc o mf ort a n d 
n ot i nt erf eri n g 
wit h ev ery day 
activiti es  M o d er at e  
Sy m pt o m is 
s uffici e ntly 
disc o mf orti n g t o 
i nt erf er e with 
n or mal ev ery day 
activiti es  S e v er e  
Sy m pt o m 
pr ev e nts n or mal 
ev ery d ay 
activiti es  
 
S C O R E 0  S C O R E 1  S C O R E 2  S C O R E 3  
Dys uri a      
Fr e q u ency      
Ur g e ncy      
L o w er a b d o mi nal 
or s u pr ap u bic p ai n      
 
C CI 
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 9 9  
  C CI 
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 1 0 0  
 C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 101 
 10.8.  Appendix 8: Clinical Laboratory Tests  
• The tests detailed in Table 15 will be performed by [CONTACT_2237].  
• Local laboratory results are only required in the event that the central laboratory 
results are not available in time for a response evaluation. If a local sample is 
required, it is important that the sample f or central analysis is obtained at the 
same time.  
• Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.  
• Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
Pregnancy Testing  
• Refer to Section 5.1 Inclusion Criteria for screening pregnancy criteria.  
• Women of childbearing potential (WOCBP) should only be included after a 
confirmed menstrual period and a negative urine pregnancy test.  
• Pregnancy testing will be performed at Baseline (Day 1) before study 
treatment administration. The urine pregnancy test at Baseline will determine 
study contraception and abstinence requirements as follows:  
• Pregnancy testing at Baseline (Day 1) should be performed using the 
urine t est kit provided to the study site (FIRST RESPONSE Early Result 
Pregnancy Test with a high sensitivity of ≤6.3  mIU/mL). Participants 
with a negative urine pregnancy test result from this test kit may be 
included in the study with no pretreatment contracept ion or abstinence 
requirements. Women of childbearing protentional are not required to be 
using contraception or to have practiced abstinence within [ADDRESS_1042222] results are 
negative at Baseline (Day 1).  
Note:   ONLY  if the study -specific pregnancy kit provided to the study 
site is unavailable, a standard urine pregnancy test with a sensitivity of 
25 mIU/mL may be used as an exception. A participant with a negative 
urine pregnancy test result from the standard test may be included in the 
study only if the participant has used a highly effective contraception 
method as described in Section 10.2.2  or has practiced abstinence from 
penile/vaginal intercourse for at least 14 days before receiving study 
treatment.  
• After Dose [ADDRESS_1042223] kit provided to the study site (FIRST RESPONSE Early Result 
Pregnancy Test with a sensitivity of ≤6.3  mIU/mL) is required to be 
performed for WOCBP who have not used a highly effective contraception 
method (in Section 10.2.2 ) or have not practiced abstinence from 
penile/vaginal intercourse for at least [ADDRESS_1042224] to be performed at th e study 
site; however, for participants for whom this is not possible, the urine 
TMF-[ADDRESS_1042225] be immediately discontinued.  
• A pregnancy test will also be performed at the Test -of-Cure (Day 10 to 13) 
Visit, [ADDRESS_1042226] dose of study treatment.  
• Pregnancy testing will be performed whenever a menstrual cycle is missed or 
when p regnancy is otherwise suspected.  
• Additional serum or urine pregnancy tests may be performed, as determined 
necessary by [CONTACT_31837], to establish the 
absence of pregnancy at any time during the subject's participation i n the 
study.  
TMF-13817737  CONFIDENTIAL   
  212390  
 103 
 Table 15 Protocol -Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Platelet count   RBC Indices : 
MCV  
MCH  WBC Count With 
Differential : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  RBC count  
Hemoglobin  
Hematocrit  
Clinical 
Chemistrya Blood urea 
nitrogen  Potassium  AST/SGOT  Total and direct 
bilirubin  
Creatinine  Sodium  ALT/SGPT  Total protein  
Glucose 
nonfasting  Calcium  Alkaline 
phosphatase  Albumin  
Chloride  Magnesium  Phosphorus   
Routine 
Urinalysis  • Specific gravity  
• pH, glucose, protein, blood, ketones, nitrite, and leukocyte esterase by 
[CONTACT_5230]  
• Microscopic examination (if blood or protein is abnormal)  
Other 
Screening 
Tests  • Serum or urine alcohol and drug screen (to include at minimum: 
amphetamines, barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids, and 
benzodiazepi[INVESTIGATOR_1651])  
• Urine hCG pregnancy test (as needed for women of childbearing 
potential)b 
Note: See text earlier in this section for pregnancy test sensitivity 
requirements and additional pregnancy testing details.  
• Serology (HBsAg, hepatitis C virus antibody, and HIV). If serology testing 
was performed within [ADDRESS_1042227] dose of study treatment 
and results were positive, testing at Baseline is not  required. If testing 
was performed within 3  months and any result was negative, testing at 
Baseline is required.  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; HBsAg=hepatitis B surface antigen; hCG=human 
chorionic gonadotropin; HIV=human immunodeficiency virus; MCH=mean corpuscular hemoglobin; 
MCV=mean corpuscular volume; RBC=red blood cell; SGOT=serum glutamic -oxaloacetic transaminase; 
SGPT=serum glutamic -pyruvic transaminase; WBC=while blood cell.  
a. Details of liver chemistry stoppi[INVESTIGATOR_007] c riteria and required actions and follow -up assessments after liver stoppi[INVESTIGATOR_103031] 7.1 and Appendix 10 . All events of ALT 3 × upper limit of normal 
(ULN) and bilirubin 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and international normalized ratio (INR) 
>1.5, if INR measured, which may indicate severe liver injury (possible Hy’s Law), must be reported as a 
serious adverse event.  
b. Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_761007]/Independent Ethics Committee.  
 
Laboratory results that could unblind the study will not be reported to study sites or other 
blinded personnel until the study has been unblinded.  
TMF-13817737  CONFIDENTIAL   
  212390  
 104 
 10.9.  Appendix  9: Additional Guidance on Permitted and 
Prohibited Medications and Crediblemeds.org  
For quick reference, a list of some common concomitant medications that are permitted 
for participants to take during the study for nausea, vomiting, pain, diarrhea, etc. per 
investigator discretion is provided below. A list of some of  the commonly used 
medications that are prohibited is also provided in this appendix. Lastly, a topline 
overview of how to use crediblemeds.org is also provided.  
A further detailed list of medications will be provided in the Study Reference Manual.  
List of  Concomitant Medications Permitted During the Study:  
Generic Namea Common Therapeutic Use(s)  
Acetylsalicylic acid  Only  allowed for the prevention of cardiovascular disease events at 
a low dose of ≤100  mg/day  
Dolasetron  Nausea, vomiting  
Granisetron  Nausea, vomiting  
Metoclopramide  Nausea, vomiting  
Palonosetron  Nausea, vomiting  
Promethazine  Nausea, vomiting  
Acetaminophen or paracetamol  Pain, fever  
Tramadol  Pain 
Hydrocodone ER  Pain, severe  
Loperamide  Diarrhea  
Cetirizine  Antihistamine (H 1) 
Ebastine  Antihistamine (H 1) 
Fexofenadine  Antihistamine (H 1) 
Loratadine  Antihistamine (H 1) 
Clindamycin  Antibiotic – topi[INVESTIGATOR_2855], nonsystemic only  
Neomycin  Antibiotic – topi[INVESTIGATOR_2855], nonsystemic only  
Polymyxin  Antibiotic – topi[INVESTIGATOR_2855], nonsystemic only  
Clotrimazole  Antifungal – topi[INVESTIGATOR_2855], nonsystemic only  
Tolnaftate  Antifungal – topi[INVESTIGATOR_2855], nonsystemic only  
Ketoconazole  Antifungal – topi[INVESTIGATOR_2855], nonsystemic only  
ER=extended release.  
a. Check within each local country to assess if other generic names apply.  
Note: See also Section 6.5.[ADDRESS_1042228] of Prohibited Concomitant Medications:  
Generic Name [CONTACT_126749](s)  
Ondansetron  Nausea, vomiting  
Acetylsalicylic acid (doses >100 mg/day)  Pain, other  
Celecoxib  Pain 
Diclofenac  Pain 
Diflunisal  Pain 
Etodolac  Pain 
Ibuprofen  Pain, fever  
Indomethacin  Pain 
Ketoprofen  Pain 
Ketorolac  Pain 
Nabumetone  Pain 
Naproxen  Pain 
Oxaprozin  Pain 
Phenazopyridine  Pain (urinary tract)  
Pi[INVESTIGATOR_126684] (e.g., ciprofloxacin, amoxicillin/clavulanate, cephalexin, 
doxycycline)  Antibiotic – all systemic  
Systemic antifungals (e.g., itraconazole, fluconazole, terbinafine)  Antifungal – all systemic  
Prednisolone or equivalent (refer to Section 6.5.2  for details)  Immunosuppressive therapy  
Strong CYP3A4 inhibitors and strong CYP3A4 inducers  See Study Reference Manual  
St John’s wort  Herbal, various  
Uva ursi  Herbal, various  
D-mannose  Nutritional supplement, various  
Cranberry supplements  Nutritional supplement, various  
Probenecid  Uric acid reducer  
Sulfinpyrazone  Uric acid reducer  
Magnesium trisilicate  Antacid (common ingredient)  
Succinylcholine and other nondepolarizing paralytic agents  Muscle relaxation, muscle paralysis  
CYP3A4=cytochrome P450 enzyme 3A4; NSAIDS=nonsteroidal anti -inflammatory medications.  
a. Check within each local country to assess if other generic names apply.  
Note: See also Section  6.5.2  for other prohibited medications and details for the when these medications are 
prohibited. All NSAIDS are prohibited; this list may not be an exhaustive list of all NSAIDS available globally.  
TMF-13817737  CONFIDENTIAL   
  212390  
 106 
 Crediblemeds.org Instructions  
Instructions for accessing www.crediblemeds.org and searching for an exclusionary drug 
due to its “Known Risk of Torsades de Pointes (TdP)” category are summarized below.  
To access www.crediblemeds.org, copy and paste this l ink into the internet search bar: 
https://www.crediblemeds.org/  
On the main home page, there are [ADDRESS_1042229] option to 
search for 1 drug at a time, which does not require registration.  
 
Choosing that option brings you to a screen that allows for you to enter a generic or brand 
drug name [CONTACT_126750]. If it has a Known Risk of TdP (i.e., is a prohibited 
exclusionary medication), it will show a red triangle with an exclamation point as shown 
here:  
 
Always check the www .crediblemeds.org website for the most up -to-date information on 
drugs with a Known Risk of TdP for participant safety.  

TMF-13817737  CONFIDENTIAL   
  212390  
 107 
 10.10.  Appendix 10: Liver Safety: Required Actions and Follow -up 
Assessments  
Phase III liver chemistry stoppi[INVESTIGATOR_760982].  
Phase III liver chemistry stoppi[INVESTIGATOR_126686] -up assessments  
Liver Chemistry Stoppi[INVESTIGATOR_31789]-absolute  ALT 8xULN  
ALT Increase  ALT 5xULN but <[ADDRESS_1042230] persists for 2 weeks  
ALT 3xULN but <[ADDRESS_1042231] persists for 4 weeks  
Bilirubina,b ALT 3xULN and bilirubin [ADDRESS_1042232] (>35% direct bilirubin)  
INRb  ALT 3xULN and INR>1.5  
Cannot 
Monitor  ALT 5xULN but <[ADDRESS_1042233] and cannot be monitored weekly for 2 weeks  
ALT 3xULN but <[ADDRESS_1042234] and cannot be monitored weekly for 4 weeks  
Symptomaticc ALT [ADDRESS_1042235] associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity  
Required Actions and Follow -up Assessments  
Actions  Follow -up Assessments  
• Immediately discontinue study treatment  
• Report the event to [COMPANY_004]/[COMPANY_003]  within 
24 hours  
• Complete the liver event eCRF and 
complete an SAE data collection tool if the 
event also meets the criteria for an SAEb 
• Perform liver event follow -up assessments  
• Monitor the participant until liver chemistries 
resolve, stabilize, or return to within 
baseline (see MONITORING  below)  
• Do not restart/rechallenge  participant with 
study treatment  
• If rest art/rechallenge not allowed or not 
granted , permanently discontinue study 
treatment and continue participant in the • Viral hepatitis serologyd 
 Only in those with underlying chronic 
Hepatitis B at study entry (identified 
by [CONTACT_23977] B surface 
antigen) and quantitative hepatitis B 
DNA  
• Obtain INR and recheck with each liver  
chemistry assessment until the 
transaminases values show downward 
trend  
• Obtain blood sample for pharmacokinetic 
(PK) analysis, within [ADDRESS_1042236] 
dosee 
• Serum creatine phosphokinase and 
lactate dehydrogenase  
TMF-13817737  CONFIDENTIAL   
  212390  
 108 
 study for any protocol -specified follow -up 
assessments  
MONITORING:  
For bilirubin or INR criteria:   
• Repeat liver chemistries (include ALT, AS T, 
alkaline phosphatase, bilirubin, and INR)  
and perform liver event follow -up 
assessments within 24 hours  
• Monitor participant twice weekly until liver 
chemistries resolve, stabilize, or return to 
within baseline  
• A specialist or hepatology consultation is 
recommended  
For All other criteria:   
• Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin, and INR)  
and perform liver event follow -up 
assessments within 24 to 72 hours  
• Monitor participant weekly until liver 
chemistries resolve, stabilize, or return to 
within baseline  • Fractionate bilirubin, if total bilirubi n 
[ADDRESS_1042237] 
• Obtain complete blood count with 
differential to assess eosinophilia  
• Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form  
• Record use of concomitant medications 
on the concomitant med ications report 
form including acetaminophen, herbal 
remedies, other over -the-counter 
medications . 
• Record alcohol use on the liver event 
alcohol intake eCRF page  
 
For bilirubin or INR criteria:  
• Antinuclear antibody, antismooth muscle 
antibody, type 1 antil iver kidney 
microsomal antibodies, and quantitative 
total IgG or gamma globulins.  
• Serum acetaminophen adduct HPLC 
assay (quantifies potential 
acetaminophen contribution to liver injury 
in participants with definite or likely 
acetaminophen use in the preced ing 
week [ James , 2009]). NOTE: not 
required in China   
• Liver imaging (ultrasound, magnetic 
resonance, or computed tomography) 
and/or liver biopsy to evaluate  liver 
disease; complete liver imaging and/or 
liver biopsy eCRFs.  
AE=adverse event; ALT=alanine aminotransferase; AST=aspartate aminotransferase; eCRF=electronic case report 
form; [COMPANY_004]=GlaxoSmithKline; HPLC=high -performance liquid chromatography; IgG=immunoglobulin G; 
IgM=immunoglobulin M; INR=international normalized ratio; PCR=polymerase chain reaction; PK=pharmacokinetic; 
SAE=serious adverse event; ULN=upper limit of normal.  
a. Serum bilirubin fractionation should be performed if testing is availab le. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that participant if ALT [ADDRESS_1042238] and bilirubin [ADDRESS_1042239] bilirubin elevations and suggesting liver injury.  
b. All events of ALT [ADDRESS_1042240] and bilirubin [ADDRESS_1042241] (>35% direct bilirubin) or ALT [ADDRESS_1042242] and INR >1.5 which 
may indicate severe liver injury (possible ‘Hy ’s Law’), must be reported as an SAE (excluding studies of 
hepatic impairment or cirrhosis) ; the INR threshold value stated will not apply to participants receiving 
anticoagulants.  
TMF-13817737  CONFIDENTIAL   
  212390  
 109 
 c. New or worsening symptoms believed to be related to liver injury (such as f atigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia).  
d. Includes: hepatitis A IgM antibody; hepatitis B surface antigen and hepatitis B core antibo dy; hepatitis C RNA; 
cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, heterophile 
antibody or monospot testing); and hepatitis E IgM antibody. In those with underlying chronic hepatitis B at study 
entry (iden tified by [CONTACT_23977] B surface antigen) quantitative hepatitis B DNA and hepatitis delta antibody. 
If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].  
e. PK sample may not be required for participants known to be receiving placebo or noncomparator treatments. 
Record the date/time of the PK blood sample draw and the date/time of the las t dose of study treatment prior to 
the PK blood sample draw in the eCRF. If the date or time of the last dose is unclear, provide the participant’s 
best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collec ted 
in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_760983].  
 
Phase III liver chemistry increased monitoring criteria with continued therapy  
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event  
Criteria  Actions  
 
ALT [ADDRESS_1042243] and  <[ADDRESS_1042244] and 
bilirubin <[ADDRESS_1042245] without  symptoms 
believed to be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 2 weeks.  
OR 
ALT [ADDRESS_1042246] and <[ADDRESS_1042247] and 
bilirubin <[ADDRESS_1042248] without  symptoms 
believed to be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 4 weeks.  
 • Notify the [COMPANY_004]/[COMPANY_003] medical monitor within 
24 hours  of learning of the abnormality to discuss 
participant safety.  
• Participant can continue study treatment.  
• Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilize or return to 
within baseline.  
• If at any time participant meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above.  
• If ALT decreases from ALT [ADDRESS_1042249] and  
<[ADDRESS_1042250] to ≥[ADDRESS_1042251] but <[ADDRESS_1042252], continue to 
monitor liver chemistries weekly.  
• If, after 4 weeks of  monitoring, ALT <[ADDRESS_1042253] and 
bilirubin <[ADDRESS_1042254], monitor participants twice 
monthly until liver chemistries normalize or return 
to within baseline.  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; [COMPANY_004]=GlaxoSmithKline; ULN=upper limit of norm al. 
References  
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, et al. 
Pharmacokinetics of acetaminophen -adduct in adults with acetaminophen overdose and 
acute liver failure. Drug Metab Dispos 2009; 37:1779 -1784.  
Le Gal F, Gordien E, Af folabi D, Hanslik T, Alloui C, Dény P, et al. Quantification of 
hepatitis delta virus RNA in serum by [CONTACT_90644] -time PCR indicates different 
TMF-13817737  CONFIDENTIAL   
  212390  
 110 
 patterns of virological response to interferon therapy in chronically infected patients. J 
Clin Microbiol. 200 5;43(5):2363 -2369.  
TMF-13817737  CONFIDENTIAL   
  212390  
 111 
 10.11.  Appendix 11: Adverse Events: Definitions and Procedures 
for Recording, Evaluating, Follow -up, and Reporting  
10.11.1.  Definition of Adverse Event  
Adverse Event Definition  
• An adverse event (AE) is any untoward medical occurrence in a clinical study 
participant, temporally associated with the use of a study treatment, whether or not 
considered related to the study treatment.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or d isease (new or exacerbated) 
temporally associated with the use of a study treatment.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (e.g., electrocardiogr ams, radiological 
scans, vital signs measurements), including those that worsen from baseline, 
considered clinically significant in the medical and scientific judgment of the 
investigator (i.e., not related to progression of underlying disease).  
• Exacerbati on of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the st art of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/serious AE (SAE) unless it is an intentional overdose taken with possible 
suicidal/self -harming intent. Such overdoses should be reported regardless of 
sequelae.  
• “Lack of efficacy” or “failure of expected pharmacological action” per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting 
from lack of effic acy will be reported as AE or SAE if they fulfill the definition of 
an AE or SAE.  
 
TMF-13817737  CONFIDENTIAL   
  212390  
 112 
 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlyin g disease, unless judged by 
[CONTACT_19448]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expe cted for the 
participant’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
 
10.11.2.  Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study, 
death due to progression of disease).  
An SAE is defined as any untoward medical occurrence that, at any dose:  
o Results in death . 
o Is life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
Requ ires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_19949] 
(usually involving at least an overnight stay) at the hospi[INVESTIGATOR_53107]/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_42244]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious.  When in doubt as to whether 
“hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered 
serious.  
• Hospi[INVESTIGATOR_5187] a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
TMF-[ADDRESS_1042255] ent or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
Is a congenital anomaly/birth defect  
Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_184119] t 
may jeopardize the participant or may require medical or surgical treatment to 
prevent one of the other outcomes listed in the above definition. These events 
should usually be considered serious.  
• Examples of such events include invasive or malignant canc ers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency or drug abuse.  
 
10.11.3.  Cardiovascular Adverse Events of Special Interest and Cases of 
Clostridium Difficile  
Investigators will be required to fill out the specific event page of the electronic case 
report form (eCRF) for the following cardiovascular AEs and SAEs, and for cases of 
Clostridium difficile : 
Cardiovascular Events:  
• Myocardial infarction/unstable angina  
• Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
• Cerebrovascular events/stroke and transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
• Revascu larization  
TMF-13817737  CONFIDENTIAL   
  212390  
 114 
 10.11.4.  Recording and Follow -Up of AE and SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.  
• The investigator will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to GlaxoSmithKline ([COMPANY_004])/[COMPANY_003] in lieu of completion of the 
[COMPANY_004]/[COMPANY_003] AE/SA E eCRF page.  
• There may be instances when copi[INVESTIGATOR_31784]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_760984].  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
• The severity of AEs and SAEs will be determined by [CONTACT_126743] 
[DMID , 2007a], with the exception of serum creatinine adolescent laboratory data, 
which be assessed using pediatric toxicity criteria [ DMID , 2007b] ( Appendix  13).  
An event is defined as “ serious” when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment 
and each occurrence of each AE/SAE.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• The investigator will use clinical judgment t o determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be considered and investigated.  
• The inves tigator will also consult the investigator’s brochure and/or product 
information, for marketed products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an ass essment of causality.  
TMF-13817737  CONFIDENTIAL   
  212390  
 115 
 • There may be situations in which an SAE has occurred, and the investigator has 
minimal information to include in the initial report to [COMPANY_004]/[COMPANY_003]. However, it is 
very important that the investigator always make an assessment of causality  
for every event before the initial transmission of the SAE data to [COMPANY_004]/[COMPANY_003] . 
• The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Follow -up of AE and SAE  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_42383]/or causality of the AE or SAE as fully as possible. This 
may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_004] with a copy of any post -
mortem findings including histopathology.  
• New or updated information will be recorded in the originally completed eCRF.  
• The investigator will submit any updated SAE data to [COMPANY_004]/[COMPANY_003] within 24 hours 
of receipt of the information.  
 
10.11.5.  Reporting of SAE to [COMPANY_004]/[COMPANY_003]  
SAE Reporting to [COMPANY_004]/[COMPANY_003]  via Electronic Data Collection Tool  
• The primary mechanism for reporting SAE to [COMPANY_004]/[COMPANY_003] will be the electronic data 
collection tool.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• The investigator or medically qualified subinvestigator must show evidence within 
the eCRF (e.g., check rev iew box, signature, etc.) of review and verification of the 
relationship of each SAE to study treatment/study participation (causality) within 
72 hours of SAE entry into the eCRF.  
• After the study is completed at a given study site, the electronic data coll ection 
tool will be taken off -line to prevent the entry of new data or changes to existing 
data.  
• If a study site receives a report of a new SAE from a study participant or receives 
updated data on a previously reported SAE after the electronic data collect ion tool 
has been taken off -line, then the site can report this information to the medical 
monitor or SAE coordinator by [CONTACT_756].  
TMF-13817737  CONFIDENTIAL   
  212390  
 116 
 • Contacts for SAE reporting can be found in the Study Reference Manual.  
TMF-13817737  CONFIDENTIAL   
  212390  
 117 
 10.12.  Appendix 12: Genetics  
USE/ANALYSIS OF DNA  
• Genetic variation may impact a participant’s response to study treatment, 
susceptibility, severity and progression of disease. Variable response to study 
treatment may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excret ion; mechanism of action of the drug; disease 
etiology; and/or molecular subtype of the disease being treated. Therefore, where 
local regulations and institutional review board/independent ethics committee allow, 
a blood sample will be collected for DNA an alysis.  
• DNA samples will be used for research related to gepotidacin or uncomplicated 
urinary tract infections and related diseases. They may also be used to develop 
tests/assays (including diagnostic tests) related to gepotidacin and uncomplicated 
urinary  tract infections. Genetic research may consist of the analysis of one or more 
candidate genes or the analysis of genetic markers throughout the genome [or 
analysis of the entire genome] (as appropriate).  
• Additional analyses of DNA samples may be conducted  if it is hypothesized that this 
may help further understand the clinical data.  
• The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to gepotidacin or study treatments of this class. The results 
of ge netic analyses may be reported in the clinical study report or in a separate study 
summary.  
• The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
• The samples will be retained while research on gepotidacin (or study treatments of 
this class) or uncomplicated urinary tract infections continues but no longer than 
[ADDRESS_1042256] visit or other period as per local requirements.  
TMF-13817737  CONFIDENTIAL   
  212390  
 118 
 10.13.  Appendix  13: Division of Microbiology and Infec tious 
Diseases Adult Toxicity Tables for Adverse Event 
Assessment  
ESTIMATING SEVERITY GRADE:  For abnormalities NOT found elsewhere in the 
Toxicity Tables, use the scale below to estimate grade of severity:  
GRADE  1 Mild Transient or mild discomfort (<48 hou rs); no medical 
intervention/therapy required  
GRADE  2 Moderate  Mild to moderate limitation in activity – some assistance 
may be needed; no or minimal medical 
intervention/therapy required  
GRADE  3 Severe  Marked limitation in activity, some assistance usually 
required; medical intervention/therapy required, 
hospi[INVESTIGATOR_126691]  4 Life-threatening  Extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, 
hospi[INVESTIGATOR_760985] -THREATENING AEs:  ANY clinical event deemed by [CONTACT_126745] -threatening should be considered a Grade  4 event. 
Clinical events considered to be serious or life -threatening include, but are not limited to:  
seizures, coma, tetany, diabetic ketoacidosis, disseminated intravascular coagulation, 
diffuse petechiae, paralysis, acute psychosis, and severe depression.  
COMMENTS REGARDING THE USE OF THESE TABLES  
• Standardized and commonly used toxicity tables (Divisio n of AIDS, National Cancer 
Institute’s Common Toxicity Criteria, and World Health Organization) have been 
adapted for use by [CONTACT_71513] (DAIDS) 
and modified to better meet the needs of participants in Division of M icrobiology and 
Infectious Diseases (DMID) trials.  
• For parameters not included in the following Toxicity Tables, study sites should refer 
to the “Guide for Estimating Severity Grade” located above.  
• Criteria are generally grouped by [CONTACT_6764].  
Some protoc ols may have additional protocol -specific grading criteria, which will 
supersede the use of these tables for specified criteria.  
 
Note :  Adult DMID toxicity criteria will be applied for all laboratory parameters, with the 
exception of serum creatinine adol escent laboratory data, which will be assessed using 
pediatric DMID toxicity criteria. The DMID pediatric toxicity table may be accessed at 
https://www.niaid.nih.gov/sites/default/files/dmidpedtox.pdf.  
 
 
TMF-13817737  CONFIDENTIAL   
  212390  
 119 
 HEMATOLOGY  
 Grade  1 Grade  2 Grade  3 Grade  4 
Hemoglobin  9.5 to 10.5  gm/dL  8.0 to 9.4  gm/dL  6.5 to 7.9  gm/dL  <6.5 gm/dL  
Absolute Neutrophil Count  1000 to 1500  /mm3 750 to 999  /mm3` 500 to 749  /mm3 <500  /mm3 
Platelets  75,000 to 99,999  /mm3 50,000 to 74,999  /mm3 20,000 to 49,999  /mm3 <20,000  /mm3 
White Blood Cells  11,000 to 13,000  /mm3 13,000 to 15,000  /mm3 15,000 to 30,000  /mm3 >30,000 or <1000  /mm3 
% Polymorphonuclear Leukocytes + 
Band Cells  >80%  90 to 95%  >95%  N/A 
Abnormal Fibrinogen  Low: 100 to 200  mg/dL  
High: 400 to 600  mg/dL  Low: <100  mg/dL  
High: >600  mg/dL  Low: <50  mg/dL  
High: N/A  Fibrinogen associated with gross bleeding or 
with disseminated coagulation  
Fibrin Split Product  20 to 40  mcg/mL  41 to 50  mcg/mL  51 to 60 mcg/dL  >60 mcg/dL  
Prothrombin Time (PT)  1.01 to 1.25   ULN 1.26 to 1.5   ULN 1.51 to 3.0   ULN >3  ULN 
Activated Partial Thromboplastin (APTT)  1.01 to 1.66   ULN 1.67 to 2.33   ULN 2.34 to 3   ULN >3  ULN 
Methemoglobin  5.0 to 9.9%  10.0 to 14.9%  15.0 to 19.9%  >20%  
N/A=not applicable; ULN=upper limit of normal.  
TMF-13817737  CONFIDENTIAL   
  212390  
 120 
 CHEMISTRIES  
 Grade  1 Grade  2 Grade  3 Grade  4 
Hyponatremia  130 to 135  mEq/L  123 to 129  mEq/L  116 to 122 mEq/L  <116  mEq/L or abnormal sodium with 
mental status changes or seizures  
Hypernatremia  146 to 150  mEq/L  151 to 157  mEq/L  158 to 165  mEq/L  >165  mEq/L or abnormal sodium with 
mental status changes or seizures  
Hypokalemia  3.0 to 3.4  mEq/L  2.5 to 2.9 mEq/L  2.0 to 2.4  mEq/L or intensive 
replacement therapy of 
hospi[INVESTIGATOR_91536]  <2.0 mEq/L or abnormal potassium with 
paresis, ileus, or life -threatening arrhythmia  
Hyperkalemia  5.6 to 6.0  mEq/L  6.1 to 6.5  mEq/L  6.6 to 7.0  mEq/L  >7.0 mEq/L or abnormal potassium with 
life-threatening arrhythmia  
Hypoglycemia  55 to 64  mg/dL  40 to 54  mg/dL  30 to 39  mg/dL  <30 mg/dL or abnormal glucose with mental 
status changes or coma  
Hyperglycemia  
(nonfasting and no prior 
diabetes)  116 to 160  mg/dL  161 to 250  mg/dL  251 to 500  mg/dL  >500  mg/dL or abnormal glucose with 
ketoacidosis or seizures  
Hypocalcemia  
(corrected for albumin)  8.4 to 7.8  mg/dL  7.7 to 7.0  mg/dL  6.9 to 6.1  mg/dL  <6.1 mg/dL or abnormal calcium with 
life-threatening arrhythmia or tetany  
Hypercalcemia  
(corrected for albumin)  10.6 to 11.5  mg/dL  11.6 to 12.5  mg/dL  12.6 to 13.5  mg/dL  >13.5  mg/dL or abnormal calcium with 
life-threatening arrhythmia  
Hypomagnesemia  1.4 to 1.2  mEq/L  1.1 to 0.9  mEq/L  0.8 to 0.6  mEq/L  <0.6 mEq/L or abnormal magnesium with 
life-threatening arrhythmia  
Hypophosphatemia  2.0 to 2.4  mg/dL  1.5 to 1.9  mg/dL or 
replacement Rx required  1.0 to 1.4  mg/dL  
intensive therapy or hospi[INVESTIGATOR_126693]  <1.0 mg/dL or abnormal phosphate with 
life-threatening arrhythmia  
Hyperbilirubinemia (when 
accompanied by [CONTACT_126746])  1.1 to <1.25   ULN 1.25 to <1.5   ULN 1.5 to 1.75   ULN >1.75   ULN 
Hyperbilirubinemia (when other 
liver function tests are in the 
normal range)  1.1 to <1.5   ULN 1.5 to <2.0   ULN 2.0 to 3.0   ULN >3.0  ULN 
Blood urea nitrogen  1.25 to 2.5   ULN 2.6 to 5   ULN 5.1 to 10   ULN >10  ULN 
Hyperuricemia (uric acid)  7.5 to 10.0  mg/dL  10.1 to 12.0  mg/dL  12.1 to 15.0  mg/dL  >15.0  mg/dL  
Creatinine  1.1 to 1.5  ULN 1.6 to 3.0   ULN 3.1 to 6.0   ULN >6  ULN or dialysis required  
Rx=therapy; ULN=upper limit of normal.  
TMF-13817737  CONFIDENTIAL   
  212390  
 121 
 ENZYMES  
 Grade  1 Grade  2 Grade  3 Grade  4 
Aspartate aminotransferase (AST)  1.1 to <2.0   ULN 2.0 to <3.0   ULN 3.0 to 8.0   ULN >8.0  ULN 
Alanine aminotransferase (ALT)  1.1 to <2.0   ULN 2.0 to <3.0   ULN 3.0 to 8.0   ULN >8.0  ULN 
Gamma to glutamyl transferase (GGT)  1.1 to <2.0   ULN 2.0 to <3.0   ULN 3.0 to 8.0   ULN >8.0  ULN 
Alkaline Phosphatase  1.1 to <2.0   ULN 2.0 to <3.0   ULN 3.0 to 8.0   ULN >8.0  ULN 
Amylase  1.1 to 1.5   ULN 1.6 to 2.0   ULN 2.1 to 5.0   ULN >5.1  ULN 
Lipase  1.1 to 1.5   ULN 1.6 to 2.0   ULN 2.1 to 5.0   ULN >5.1  ULN 
ULN=upper limit of normal.  
URINALYSIS  
 Grade  1 Grade  2 Grade  3 Grade  4 
Proteinuria  1+ or  
200 mg to 1  gm loss/day  2 to 3+ or  
1 to 2  gm loss/day  4+ or  
2 to 3.5  gm loss/day  Nephrotic syndrome or  
>3.5 gm loss/day  
Hematuria  Microscopic only  
<10 RBC/HPF  Gross, no clots  
>10 RBC/HPF  Gross, with or without clots,  
or red blood cells casts  Obstructive or  
required transfusion  
HPF=high -power field; RBC=red blood cells.  
TMF-13817737  CONFIDENTIAL   
  212390  
 122 
 CARDIOVASCULAR  
 Grade  1 Grade  2 Grade  3 Grade  4 
Cardiac rhythm  N/A Asymptomatic, transient signs, no 
Rx required  Recurrent/persistent; symptomatic 
Rx required  Unstable dysrhythmia; 
hospi[INVESTIGATOR_126694] >20  mm/Hg;  
no treatment  Recurrent, chronic increase 
>20 mm/Hg;  
treatment required  Acute treatment required; 
outpatient treatment or 
hospi[INVESTIGATOR_126695] 
<20 beat/min or decreased by 
<10 mmHg systolic BP.  
No treatment required  Symptoms due to orthostatic 
hypotension or BP decreased by 
<20 mmHg systolic; correctable 
with oral fluid treatment  Requires IV fluids;  
no hospi[INVESTIGATOR_126696] <60  mmHg 
or end organ damage or shock;  
requires hospi[INVESTIGATOR_126697]/moderate asymptomatic 
effusion, no treatment  Symptomatic effusion; pain; EKG 
changes  Tamponade; pericardiocentesis or 
surgery required  
Hemorrhage, Blood Loss  Microscopic/occult  Mild, no transfusion  Gross blood loss;  
1 to 2  units transfused  Massive blood loss; >3  units 
transfused  
BP=blood pressure; IV=intravenous; EKG=electrocardiogram; N/A=not applicable; Rx=therapy.  
RESPI[INVESTIGATOR_7382]  1 Grade  2 Grade  3 Grade  4 
Cough  Transient; no treatment  Persistent cough; treatment 
responsive  Paroxysmal cough; uncontrolled 
with treatment  N/A 
Bronchospasm, Acute  Transient; no treatment; FEV 1 70 
to 80% of peak flow  Requires treatment; normalizes 
with bronchodilator; FEV 1 50 to 
70% of peak flow  No normalization with 
bronchodilator; FEV 1 25 to 50% of 
peak flow; or retractions present  Cyanosis: FEV 1 <25% of peak 
flow; or intubation necessary  
Dyspnea  Dyspnea on exertion  Dyspnea with normal activity  Dyspnea at rest  Dyspnea requiring oxygen therapy  
FEV 1=forced expi[INVESTIGATOR_3741] 1 second; N/A=not applicable.  
TMF-13817737  CONFIDENTIAL   
  212390  
   
 123 
 GASTROINTESTINAL  
 Grade  1 Grade  2 Grade  3 Grade  4 
Nausea  Mild or transient; maintains 
reasonable intake  Moderate discomfort; intake 
decreased significantly; some 
activity limited  No significant intake; requires IV fluids  Hospi[INVESTIGATOR_126698]  1 epi[INVESTIGATOR_85712] 24  hours  2 to 5 epi[INVESTIGATOR_11630] 24  hours  >6 epi[INVESTIGATOR_11630] 24  hours or needing IV 
fluids  Physiologic consequences requiring 
hospi[INVESTIGATOR_126699]; 3 to 
4 loose stools/day or mild 
diarrhea lasting <1  week  Moderate or persistent; 5 to 
7 loose stools/day or diarrhea 
lasting >1  week  >7 loose stools/day or bloody diarrhea; 
or orthostatic hypotension or electrolyte 
imbalance or >2L IV fluids required  Hypotensive shock or physiologic 
consequences requiring hospi[INVESTIGATOR_126700]/  
Dysphagia  Mild discomfort; no 
difficulty swallowing  Some limits on eating/drinking  Eating/talking very limited; unable to 
swallow solid foods  Unable to drink fluids; requires IV fluids  
IV=intravenous.  
NEUROLOGICAL  
 Grade  1 Grade  2 Grade  3 Grade  4 
Neuro -Cerebellar  Slight incoordination 
dysdiadochokinesis  Intention tremor, dysmetria, 
slurred speech; nystagmus  Locomotor ataxia  Incapacitated  
Psychiatric  Mild anxiety or depression  Moderate anxiety or depression; 
therapy required; change in 
normal routine  Severe mood changes requiring 
therapy; or suicidal ideation; or 
aggressive ideation  Acute psychosis requiring 
hospi[INVESTIGATOR_059]; or suicidal 
gesture/attempt or hallucinations  
Muscle strength  Subjective weakness; no 
objective symptoms/signs  Mild objective signs/symptoms; no 
decrease in function  Objective weakness; function limited  Paralysis  
Paresthesia  
(burning, tingling, etc.)  Mild discomfort; no treatment 
required  Moderate discomfort; non -narcotic 
analgesia required  Severe discomfort; or narcotic analgesia 
required with symptomatic improvement  Incapacitating; or not responsive 
to narcotic analgesia  
Neurosensory  Mild impairment  in sensation 
(decreased sensation, e.g., 
vibratory, pi[INVESTIGATOR_29107], hot/cold in 
great toes) in focal area or 
symmetrical distribution; or 
change in taste, smell, vision, 
and/or hearing  Moderate impairment (moderately 
decreased sensation, e.g., 
vibratory, pi[INVESTIGATOR_335500], hot/cold to 
ankles) and/or joint position or 
mild impairment that is not 
symmetrical  Severe impairment (decreased or loss of 
sensation to knees or wrists) or loss of 
sensation of at least moderate degree in 
multiple different body areas (i.e., upper 
and lower extremities)  Sensory loss involves limbs and 
trunk; paralysis; or seizures  
TMF-13817737  CONFIDENTIAL   
  212390  
   
 124 
 MUSCULOSKELETAL  
 Grade  1 Grade  2 Grade  3 Grade  4 
Arthralgia 
(joint pain)  Mild pain not interfering with function  Moderate pain, analgesics and/or pain 
interfering with function but not with ADL  Severe paid; pain and/or analgesics 
interfering with ADL  Disabling pain  
Arthritis  Mild pain with inflammation, erythema or 
joint swelling, but not interfering with 
function  Moderate pain with inflammation, erythema or 
joint swelling; interfering with function but not 
with ADL  Severe pain with inflammation, 
erythema or joint swelling, and 
interfering with ADL  Permanent and/or 
disabling joint 
destruction  
Myalgia  Myalgia with no limitation of activity  Muscle tenderness (at other than injection site) 
or with moderate impairment of activity  Severe muscle tenderness with marked 
impairment of activity  Frank myonecrosis  
ADL=activities of daily living.  
SKIN  
 Grade  1 Grade  2 Grade  3 Grade  4 
Mucocutaneous  Erythema; pruritus  Diffuse, maculo papular rash, dry 
desquamation  Vesiculation or moist 
desquamation or ulceration  Exfoliative dermatitis, mucous membrane 
involvement or erythema, multiforme or suspected 
Stevens -Johnson or necrosis requiring surgery  
Induration  <15 mm 15 to 30 mm >30 mm N/A 
Erythema  <15 mm 15 to 30  mm >30 mm N/A 
Edema  <15 mm 15 to 30  mm >30 mm N/A 
Rash at injection site  <15 mm 15 to 30  mm >30 mm N/A 
Pruritus  Slight itching at injection site  Moderate itching at injection extremity  Itching over entire body  N/A 
N/A=not applicable.  
 
 SYSTEMIC  
 Grade  1 Grade  2 Grade  3 Grade  4 
Allergic reaction  Pruritus without rash  Localized urticarial  Generalized urticarial; angioedema  Anaphylaxis  
Headache  Mild, no treatment required  Transient, moderate; treatment 
required  Severe; responds to initial narcotic 
therapy  Intractable; requires repeated 
narcotic therapy  
Fever: oral  37.7 to 38.5 C or 100.0 to 101.5 F 38.6 to 39.5 C or 101.6 to 102.9 F 39.6 to 40.5 C or 103 to 105 F >40C or >105F 
Fatigue  Normal activity reduced <48 hours  Normal activity decreased 25 to 50%; 
>48 hours  Normal activity decreased >50%; 
cannot work  Unable to care for self  
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 1 2 5  
 1 0. 1 4.  A p p e n di x 1 4: A b br e vi ati o n s a n d Tr a d e m ar k s  
A B S S SI  ac ute bacterial s ki n a n d s ki n str uct ure i nfecti o n  
A E  a d verse e ve nt  
A L T  ala ni ne a mi n otra nsf eras e  
A U C [ADDRESS_1042257] u g c o nce ntrati o n -ti me c ur ve o ver 2 4 
h o urs  
BI D  t wice dail y  
C D C  Ce nters f or Disease C o ntr ol a n d Pre ve nti o n  
C E  Cli nicall y E val ua ble  
C F U  c ol o n y -f or mi n g u nits  
CI  c o nfi de nce i nter val  
C O N S O R T  C o ns oli date d Sta n dar ds of Re p orti n g Trials  
C O VI D -1 9  c or o na vir us disease  
C R F  case re p ort f or m  
C V  car di o vas c ular  
C Y P 3 A 4  c yt o c hr o me P 4 5 0 e nz y m e 3 A 4  
D MI D  Di visi o n of Micr o bi ol o g y a n d I nfecti o us Diseases  
E A G L E  Efficac y of A nti bacterial Ge p oti daci n E val uat e d  
E C G  electr ocar di o gra m  
e C R F  electr o nic case re p ort f or m  
E M A  E ur o pea n Me dici nes A ge nc y  
E S B L  e xte n de d -s pectr u m -lacta mase  
F Fa hre n heit  
fA U C/ MI C  rati o of t he area u n d er t h e free -dr u g c o nce ntrati o n -ti me 
c ur ve t o mi ni m u m i n hi bit or y c o n ce ntr ati o n o ver [ADDRESS_1042258] u g A d mi nistrati o n  
G C P  G o o d Cli nical Practice  
G S K  Gla x o S mit h Kli ne  
H P F  hi g h -p o w er fi el d  
H R T  h or m o nal re pla ce me nt t h era p y  
I A  i nteri m a nal ysis  
I B  i n vesti gat or’s br oc h ure  
I C E  i nterc urre nt e ve nt  
I C F  i nf or me d c o nse nt f or m  
I C H  I nter nati o nal C o u ncil o n Har m o nisati o n  
I D M C  I n d e pe n de nt Data  M o nit ori n g C o m mittee  
I E C  i n de pe n de nt et hics c o m mittee  
I R B  i nstit uti o nal re vie w b oar d  
I R T  i nteracti ve res p o nse tec h n ol o g y  
I T T  I nte nt -t o -Treat  
I V  i ntra ve n o us  
k g  kil o gra m  C CI 
TMF-[ADDRESS_1042259]  multidrug -resistant  
ME Microbiologically Evaluable  
MedDRA  Medical Dictionary for Regulatory Activities  
mg milligram  
MIC  minimum inhibitory concentration  
micro -ITT Microbiological Intent -to-Treat  
min minute  
mL milliliter  
mm millimeter  
msec  millisecond  
NTF  nitrofurantoin  
NTF -NS not susceptible to NTF  
NTF -S susceptible to NTF  
PD pharmacodynamic  
PK pharmacokinetic  
QTc corrected QT interval  
QTcB  QT interval corrected for heart rate according to Bazett’s 
formula  
QTcF  QT interval corrected for heart rate according to 
Fridericia’s formula  
RAP  reporting and analysis plan  
SAE  serious adverse event  
SDAC  Statistical Data Analysis Center  
SoA Schedule of Activities  
SRM  Study Reference Manual  
SRT Safety Review Team  
ST sequence type  
TdP torsades de pointes  
TOC  Test-of-Cure  
TMP -SXT  trimethoprim -sulfamethoxazole  
µg microgram  
ULN  upper limit of normal  
UTI urinary tract infection  
WHO  World Health Organization  
WOCBP  woman of childbearing potential  
 
Trademark Information  
Trademarks of the GlaxoSmithKline 
group of companies   Trademarks not owned by [CONTACT_761008]  
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 1 2 7  
 1 0. 1 5.  A p p e n di x 1 5: Pr ot o c ol A m e n d m e nt Hi st or y  
T he Pr ot oc ol A me n d me nt S u m mar y of C ha n ges T a ble f or t he c urre nt a me n d me nt (i.e., 
Pr ot oc ol A me n d me nt 3) is l ocate d directl y b ef ore t he Ta ble of C o nte nts.  
A me n d me nt 2   1 4 -A P R -2 0 2 1  
T his gl o bal a me n d m e nt was c o nsi dere d t o be s u bsta ntial.  
O ver all R ati o n ale f or t he A me n d me nt:    
 
 
 i n dicat e d st u d y o p erati o nal all o wa nces wit h re gar d t o C O VI D -1 9; 
i nc or p orate d p ast a d mi nistrati ve letters t o t he si tes; clarifie d esti ma n d te xt; pr o vi de d 
mi n or statistical clarificati o ns t o t he a nal ysis p o p ul ati o ns, res p o nse a n d o utc o mes ta bles, 
a n d acc o u nte d f or s u p ple me ntar y a nal ysis, w hic h will be detaile d i n t he R A P; i ncrease d 
t he pla n ne d t otal e nr oll m e nt p o p ulati o n; clarifie d O n -t hera p y Visit electr ocar di o gra ms 
will be c ollecte d i n t he first a p pr o xi matel y 1 2 0 0 p artici pa nts; i nc or p orate d u p dates per 
t he m ost rece nt I B versi o n 0 7; a n d gl o ball y re place d “i nter ve nti o n” wit h “treat me nt.” T h e 
a me n d me nt als o i ncl u des a d di ti o nal mi n or a d mi nistrati ve a n d w or di n g e dits.  
S e cti o n # a n d N a me  D e s cri pti o n of C h a n g e  Bri ef R ati o n al e  
Sy n o psis  
3 O bj ectiv es a n d 
Esti m a n ds/ E n dp oi nts  
T a bl e 1 Esti m a nd for 
t h e S ec on d ary 
E n d poi nts  
9. 4.1 G en er al 
C o nsi d er atio ns  
9. 4.2 Efficacy 
A n alysis  S e p arat e d esti m an d text fr o m t h e 
e n dp oi nt t ext, r evis e d t h e 
esti m a n d la n gu ag e to i ncl ude t he 
5 c o m p on ents per r ec ent I C H 
g ui d eli nes o n esti m an ds, a dd e d 
esti m a n d d escri pti ons for t h e 
s ec o nd ary en d poi nts  T o pr ovi de ex pa nd e d d et ails o n 
t h e pri m ary a n d sec on d a ry 
esti m a n ds  
Sy n o psis  
3 O bj ectiv es a n d 
Esti m a n ds/ E n dp oi nts  F or t h e sec o nd ary ( up d at e d o nly 
i n t h e Sy no psis) a nd expl orat ory 
o bj ectiv es, a n a dditi o n al obj ectiv e 
a n d e nd p oi nt w er e a dd e d t o e ac h 
s ecti o n t o exa mi n e th e cli nic al 
r es p o nse i n fe m al e p artici pa nt s 
wit h ac ute cystitis wit h q ualifyi n g 
b act eri al ur o p at h og ens(s) at 
B as eli n e t hat all ar e s usce pti bl e t o 
nitr of ur ant oi n  C o nsist e ncy with t he pri m ary 
o bj ectiv e p op ul atio n  C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 128 
 Section # and Name  [CONTACT_42407]  
9.2.[ADDRESS_1042260] the expected number of 
participants for full enrollment to 
support the required number of 
evaluable participants for the 
primary analysis  
1.2 Schema  Revised On -therapy Visit to state 
Days 2 to 4  Protocol consistency  
2.3.1 Risk 
Assessment  
5.2 Exclusion Criteria 
#5 Added acute porphyria as an 
example of a risk for the 
nitrofurantoin comparator and 
excluded the medical condition for 
participant enrollment  Incorporation of the letter to sites 
dated 17 -DEC -2019  
Section 2.3.1 Risk 
Assessment  
5.2 Exclusion Criteria 
#[ADDRESS_1042261] current 
Version 07 of the investigator’s 
brochure  
5.2 Exclusion Criteria 
#10 Expanded text to include, “or 
preclude complete resolution of 
acute cystitis symptoms”  Clarification purposes  
6.[ADDRESS_1042262] on the efficacy 
evaluations  
TMF-13817737  CONFIDENTIAL   
  212390  
 129 
 Section # and Name  [CONTACT_11029]  
6.5.[ADDRESS_1042263]  
[IP_ADDRESS] 
Microbiological 
Outcome and 
Response  Minor text clarifications were 
added to the outcome and 
response tables, and a new table 
(Table 5)  was added to define 
participant -level microbiological 
outcomes and responses  To provide clarification to support 
the planned statistical analyses 
and programming details  
8.1.3 Clinical 
Evaluation  Subsections were added for the 
different clinical evaluat ions 
planned for primary and 
exploratory objectives, minor text 
clarifications were added to the 
outcome and response tables  To provide clarification to support 
the planned statistical analyses 
and programming details  
T M F -1 3 8 1 7 7 3 7  C O N FI D E N TI A L   
  2 1 2 3 9 0  
 1 3 0  
 S e cti o n # a n d N a me  D e s cri pti o n of C h a n g e  Bri ef R ati o n al e  
Sy n o psis  
Sc h e dul e of Activiti es  
8. 1.3. [ADDRESS_1042264] atistic al an alysis a n d r eq uir e d 
o ut p uts  C CI 
TMF-13817737  CONFIDENTIAL   
  212390  
 131 
 Section # and Name  [CONTACT_11029]  
9.4.[ADDRESS_1042265] on 
the study  Consis tency with the planned 
statistical analysis and required 
outputs  
9.4.2 Efficacy 
Analyses  
9.4.3 Safety Analyses  Minor clarifications to the plans for 
analysis  Consistency with the planned 
statistical analysis and required 
outputs  
2.3.1 Risk 
Assessment  
Throughout  Updates to protocol text, including 
risk/benefit and dose justification 
rationale text (i.e., added topline 
PK and safety results from a study 
in healthy adult and adolescent 
participants) per the most current 
investigator’s brochure; no new 
safety signals were identified or 
added  Consistency with the most current 
Version 07 of the investigator’s 
brochure  
Appendix 4 Algorithm 
for Determining 
Qualifying 
Uropathogens  Minor clarifications per the current 
plans for analysis  Consistency with regul atory 
authority feedback and statistical 
analysis plans  
Throughout  Where applicable, globally 
replaced “intervention” with 
“treatment”  Consistency with the planned 
statistical analysis and required 
outputs  
Throughout  Revised the in -text definitions of 
microbiological and clinical 
success to remove “specific to the 
disease under study” regarding 
the use of other systemic 
antimicrobials  Corrected text to align with the 
original definitions of success in 
the endpoint definition tables  
Throughout  Updated te xt to state Clostridium 
difficile  and acetylcholinesterase 
inhibition events are considered 
adverse events of special interest  To support the planned safety 
analysis  
Throughout  Minor editorial and document 
formatting revisions  Minor, therefore, have not b een 
summarized  
 
 
TMF-13817737  CONFIDENTIAL   
  212390  
 132 
 Amendment 1  14-NOV -2019  
Overall Rationale for the Amendment:   This global amendment provided clarification 
on Inclusion Criteria 3 and 4, including no requirement for contraception use or 
abstinence within 14  days of study entry in women of childbearing potential (WOCBP) 
with a negative high sensitivity urine pregn ancy test result at Baseline (Day  1), expanded 
the On -therapy Visit window, allowed flexible options for pregnancy testing and dose 
administration for the On -therapy Visit, and further defined the optimum window for 
pregnancy testing while participants wer e receiving study treatment. The amendment also 
included additional minor administrative edits.  
Section # and Name  [CONTACT_11029]  
5.1 Inclusion Criteria  
Schedule of Activities  Criterion 3, edited terminology to 
“large” for the prese nce of 
3+ leukocyte esterase  To correct terminology for 
laboratory results  
5.[ADDRESS_1042266] 
result at Baseline (Day 1)  To provide clarification on female 
participant requirements at study 
entry  
Synopsis  
Schedule  of Activities  
4.1 Overall Design  
8 Study Assessments 
and Proce dures  Revised the study day range for 
the On -therapy Visit from “Day  2 
to 3” to “Day 2 to 4” and noted that 
each treatment day will be 
assessed over [ADDRESS_1042267]  
Schedule of Activ ities 
8 Study Assessments 
and Procedures  Updated the definition of the 
On-therapy Visit to be “1 to 
3 days” postrandomization  Protocol consistency  
Schedule of Activities  
6.[ADDRESS_1042268] for 
WOCBP during study treatment to 
be performed “after Dose  4 and 
before Dose  8” To ensure the pregnancy test is 
performed within an optimum 
safety window and to support 
TMF-13817737  CONFIDENTIAL   
  212390  
 133 
 Section # and Name  [CONTACT_155885] 6  testing to preferably occur at the 
study site  
9.4.2 Efficacy 
Analyses  Moved the microbiological 
outcome for new qualifying 
uropathogens from secondary to 
exploratory  Correction to the planned data 
analyses  
Throughout  Expanded the definitions of 
microbiological and clinical 
success to include “specific to the 
disease under study” regarding 
the use of other systemic 
antimicrobials  To further clarify which 
antimicrobials will affect success 
or failure in the analysis  
Throughout  Minor editorial and document 
formatting revisions  Minor, therefore, have not been 
summarized  
 
TMF-13817737  CONFIDENTIAL   
  212390  
 134 
 11. REFERENCES  
Abreu AG, Marques SG, Monteiro -Neto V, Gonçalves AG. Extended -spectrum 
-lactamase -producing enterobacteriaceae in community -acquired urinary tract infections 
in Sãn Luís, Brazil. Braz J Microbiol. 2013;44(2):469 -71. 
Centers for Disease Control and Preven tion (CDC). Antibiotic resistance threats in the 
[LOCATION_002], 2019. https://www.cdc.gov/drugresistance/pdf/threats -report/2019 -ar-
threats -report -508.pdf. Accessed 20 -Mar-2021.  
European Association of Urology (EAU). EAU guidelines. Edn. presented at the E AU 
Annual Congress Barcelona 2019. ISBN 978 -94-[ZIP_CODE] -04-2. 
https://uroweb.org/guideline/urological -infections/. Accessed 26 -Jul-2019.  
European Medicines Agency (EMA). Addendum to the guideline on the evaluation of 
medicinal products indicated for treatment  of bacterial infections. CPMP/EWP/558/[ADDRESS_1042269] infection in women. 
N Engl J Med. 2003;349(3):[ADDRESS_1042270] isolates from a global surveillance program (2011). 
Diagn Microbiol Infect Dis. 2014;80(3):233 -8. 
Foxman B, Barlow R, D’Arcy H, Gillespie B, Sobel JD. Urinary tract infection: 
self-reported incidence and associated costs . Ann Epi[INVESTIGATOR_5541]. 2000;10(8):[ADDRESS_1042271] infections: incidence, morbidity, and economic 
costs. Am J Med. 2002;113(Suppl 1A):5S -13S. 
Foxman B. The epi[INVESTIGATOR_126679]. Nat Rev Urol. 
2010;7(12):653 -60. 
Gupta K, Hooton TM, Miller L; Uncomplicated UTI IDSA Guideline Committee. 
Managing uncomplicated urinary tract infection −making sense out of resistance data. 
Clin Infect Dis. 2011a;53(10):1041 -2. 
Gupta  K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International 
clinical practice guidelines for the treatment of acute uncomplicated cystitis and 
pyelonephritis in women: a [ADDRESS_1042272] Dis. 
2011b;52(5):e103 -20. 
Gupta K, Hooton TM, Roberts PL, Stamm WE. Short -course nitrofurantoin for the 
treatment of acute uncomplicated cystitis in women. Arch Intern Med. 
2007;167(20):[ADDRESS_1042273], Poon WW, Loke SL, Leung MS, Chow KH, Wong RC, et al; COMBAT study 
group. Community emergence of CTX -M type extended -spectrum -lactamases among 
urinary Escherichia coli  from women. J Antimicrob Chemother. 2007;60(1):[ADDRESS_1042274] infection. N Engl J Med. 
2012;366(11):[ADDRESS_1042275] Dis. 2012;18(4):598 -607. 
Lan KK, DeMets D. Discrete sequential boundaries for clinical trials. Biometrika. 1983; 
70:[ADDRESS_1042276] Dis. 2016;85(4):459 -65. 
Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 
1985;4(2):213 -26. 
National Institute for Health Care Excellence (NICE). Public Health England. Summary 
of antimicrobial prescribing guidance – managing common infections. Feb 2019. 
https://www.nice.org.uk/Media/Default/About/what -we-do/NICE -
guidance/antimicrobial%20guidance/summary -antimicrobial -prescribing -
guidance.pdf?UNLID=3157626232019111861. Accessed 19 -Jun-2019.  
Nicolas -Chanoine MH, Bertrand X, Madec JY. Escherichia coli  ST131, an intriguing 
clonal group. Clin Microbiol Rev. 2014;27(3):543 -74. 
Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S,  et al; Spanish 
ESBL -EARS -Net Study Group. Parallel increase in community use of fosfomycin and 
resistance to fosfomycin in extended -spectrum beta -lactamase (ESBL) -producing 
Escherichia coli . J Antimicrob Chemother. 2010;65(11):2459 -63. 
Peirano G, Richards on D, Nigrin J, McGreer A, Loo V, Toye B, et al. High prevalence of 
ST131 isolates producing CTX -M-15 and CTX -M-14 among extended -spectrum -beta-
lactamase -producing Escherichia coli  isolates from Canada. Antimicrob Agents 
Chemother. 2010;54(3):1327 -30.  
Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J. Antibiotic resistance 
among urinary isolates from female outpatients in the [LOCATION_002] in 2003 and 2012. 
Antimicrob Agents Chemother. 2016;60(5):2680 -3. 
Sanchez GV, Master RN, Karlowsky JA, Bordo n JM. In vitro antimicrobial resistance of 
urinary Escherichia coli  isolates among US outpatients from 2000 to 2010. Antimicrob 
Agents Chemother. 2012;56(4):[ADDRESS_1042277] u d y: 
a n i nter nati o nal s ur ve y o n t he a nti micr o bial resista nce of pat h o ge ns i n v ol v e d i n 
u nc o m plicate d uri nar y tr act i nfecti o ns. I nt J A nti micr o b A ge nts. 2 0 0 9; 3 4( 5): [ADDRESS_1042278] i nfecti o ns i n a d ults. N E n gl J 
Me d. 1 9 9 3; 3 2 9( 1 8): 1 3 2 8 -3 4.  
Tala n D A, Sta m m W E, H o ot o n T M, M ora n GJ, B ur ke T, Ira v a ni A, et al. C o m paris o n of 
ci pr ofl o x aci n ( 7 da ys) a n d tri met h o pri m -s ulfa met h o x az ole ( 1 4 da ys) f or ac ute 
u nc o m plicate d p yel o ne p hritis i n w o me n: a ra n d o mize d trial. J A M A. 
2 0 0 0; 2 8 3( 1 2): [ADDRESS_1042279] u g E val uati o n a n d Researc h, Cli nical/ A nti micr o bial. Draft g ui da nce f or 
i n d ustr y. U nc o m plic ate d uri nar y tract i nfecti o ns: d e vel o pi n g dr u gs f or tr eat me nt. 
htt ps:// w w w. f da. g o v/ me dia/ 1 2 9 5 3 1/ d o w nl oa d. Last u p date d A u g ust [ADDRESS_1042280] u g E val uati o n a n d Researc h, Cli nical/ A nti micr o bial. G ui da nce f or i n d ustr y. 
C o m plicat e d uri nar y tract i nfecti o ns: de vel o pi n g dr u gs f or treat me nt. 
htt ps:// w w w.f da. g o v/ me dia/ 7 1 3 1 3/ d o w nl oa d. Last u p date d J u ne 2 0 1 8. Accesse d 
2 9 -J ul -2 0 2 1.  
U S Nati o nal I nstit ute f or Aller g y a n d I nfecti o us Disease Di visi o n of Micr o bi ol o g y a n d 
I nfecti o us Dise ases. Di visi o n of Micr o bi ol o g y a n d I nfecti o us Dise ases ( D MI D) Pe diatric 
T o xicit y Ta bl e. Draft. htt ps:// w w w. niai d. ni h. g o v/sites/ defa ult/files/ d mi d pe dt o x. p df. Last 
u p date d N o ve m ber 2 0 0 7 b. Access e d 2 9 -J ul -2 0 1 9.  
U S Nati o nal I nstit ute f or Aller g y a n d I nfecti o us Disea ses, Di visi o n of Micr o bi ol o g y a n d 
I nfecti o us Dise ases. Di visi o n of Micr o bi ol o g y a n d I nfecti o us Dise ases ( D MI D) A d ult 
T o xicit y Ta bl e. Draft. htt ps:// w w w. niai d. ni h. g o v/sites/ defa ult/files/ d mi da d ultt o x. p df. 
Last u p d ate d N o ve m b er 2 0 0 7a. Accesse d 2 9 -J ul -2 0 1 9.  
W orl d Healt h Or ga niz ati o n ( W H O). A nti micr o bial resista nce gl o bal re p ort o n 
s ur veilla nce, 2 0 1 4. 
htt p://a p ps. w h o.i nt/iris/ bitstrea m/ 1 0 6 6 5/ 1 1 2 6 4 2/ 1/ 9 7 8 9 2 4 1 5 6 4 7 4 8 _e n g. p df. Access e d 
1 9 -J u n -2 0 1 9.  
W orl d Healt h Or ga niz ati o n ( W H O). Gl o bal pri orit y l ist of a nti bi otic -resista nt bacteri a t o 
g ui de researc h, disc o v er y, a n d de vel o p me nt of n e w a nti bi otics. 2 0 1 7. 
htt p:// w w w. w h o.i nt/ me dici nes/ p u blicati o ns/ W H O -P P L -S h ort _ S u m mar y _ 2 5 Fe b -
E T _ N M _ W H O. p df? ua = 1. Access e d 1 9 -J u n -2 0 1 9.  C CI 